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EPIDEMIOLOGy Of SkIN CaNCER
Skin cancer is the most common type of cancer worldwide among Caucasians and its 
incidence is still rising.1-3 The two most common subtypes of skin cancer are basal cell 
carcinoma (BCC) and squamous cell carcinoma (SCC), both commonly referred to as 
keratinocyte carcinoma (KC).2 KC is usually not deadly, however, they could cause con-
siderable functional and cosmetic morbidity as KC is typically found on sun-exposed 
areas such as the face.1,4 In 2017, over 48,000 Dutch inhabitants received the diagnosis 
BCC and over 12,000 were diagnosed with SCC.5 Melanoma is the third most common 
subtype of skin cancer with an incidence of nearly 6,200 in that same year.6 Addition-
ally, these high incidence numbers only include the first diagnosed tumour per type of 
skin cancer. Considering that more than one-third of KC patients develops at least one 
subsequent KC,7 it is no surprise that the economic burden of KC is substantial.8-11
IMPaCT Of SkIN CaNCER ON ThE (DuTCh) hEaLThCaRE SySTEM
A national skin cancer expenditure analysis in the US showed that in 2013 $2.5 billion 
was spent on skin cancer-related diagnoses in Medicare patients alone (i.e. $7,60 per 
capita). Half of this spending was attributed to KC.9 KC ranked as 5th most expensive 
cancer to treat among Medicare patients,9 among the highest per head in Australia8 
and among the five most costly cancers in the Netherlands.11 As KC puts pressure on 
healthcare systems, it is advocated to evaluate current KC care to identify opportunities 
to improve efficiency of care.
In 2013 the Dutch National Health Care Institute launched a project called ‘appropri-
ate care’.12 The rationale of this project is that every citizen must be able to count on 
receiving good health care. No more and no less than necessary, while also avoiding un-
necessary costs. Therefore, healthcare was assessed systematically to evaluate whether 
diagnostics and (therapeutic) interventions are being deployed in a patient-oriented, 
effective and cost-effective manner. Due to the before mentioned high economic bur-
den, skin cancer care was also evaluated as part of this project.
In order to interpret the results of this evaluation, one should first understand the 
Dutch healthcare system. Since 2005, all hospital visits and admissions are categorised 
in diagnosis-related groups (DRGs).13 Each DRG includes all hospital activities and ser-
vices associated with a patient’s care. Regarding the enlistment of medical specialists, 
currently about half are employed (i.e. on salary) and the other half are paid per DRG 
(i.e. fee-for-service).14
Dutch inhabitants however do not have direct access to a medical specialist. They 
need a referral from a general practitioner (GP). This so-called ‘gatekeeper’ function 
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is also the case in other countries such as the UK and Australia.15-17 The two main argu-
ments for having a healthcare system with a gatekeeper are that it reduces costs and 
that care is being provided more efficiently.18 However, the evidence regarding the 
effect of a gatekeeper system on healthcare and patients remains ambiguous and is 
complicated by the heterogeneity of systems and studies.19
EvaLuaTING kERaTINOCyTE CaNCER CaRE IN PRIMaRy CaRE
To identify areas of improvement in KC care, daily practices of both GPs and derma-
tologists were invesigated.20 The Integrated Primary Care Information database allowed 
us to study the GPs’ policy with respect to care of patients with (suspected) KCs.21 A 
random selection was made of 1597 patients suspicious for- or confirmed KC in primary 
care. All patients were diagnosed between 2009 and 2013 and followed up until 2016. 
Details on diagnosis, treatment and care during follow-up were described.
GPs’ skin cancer policy
GPs reported a skin malignancy in their initial differential diagnosis in approximately 
half of all confirmed KC cases. The specific diagnosis was correctly predicted for half of 
all BCCs, but only in 15% of all SCCs. This may also explain the relatively high propor-
tion of direct excisions by the GP without prior biopsy of SCCs (27%) compared to BCCs 
(10%). Furthermore, the relatively fast, often exophytic growth of SCCs may also urge a 
GP to take more immediate action compared to BCCs.
Ideally, the role of the GP as gatekeepers in the management of suspicious skin le-
sions is to control the referral rate and treat low-risk tumours, such as low-risk BCC. The 
newly introduced (June 2017) clinical guidelines for GPs regarding suspicious cutane-
ous lesions are based on this principle.22 Thus, during the investigated period, GPs could 
not rely on guidelines. If the GP suspected KC, the majority of patients were referred to 
a dermatologist. However, one-third of suspected KC lesions were skin malignancies, 
leading to unnecessary referrals.
Overall, GPs treated almost a third of all suspected KC lesions, but one-third of those 
treatments were not primarily directed at KC (e.g. antibacterial and/or antimycotic 
ointments). This observation does not necessarily suggest ‘mistreatment’ but that GPs 
first pragmatically treated the most likely diagnosis and kept an open mind that the 
skin lesion might be malignant. The new Dutch primary care and the UK guidelines 
recommend to directly refer when having a strong suspicion of high-risk KC (including 
all SCCs) and to take a biopsy from other suspected KC.15,16 If the guideline is imple-
mented successfully, the increased use of histology will improve appropriate care. In 
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1addition, clear agreements on referral indications will decrease the surgical treatments 
in primary care.
keratinocyte cancer follow-up in primary care
Variable patterns of follow-up visits in primary care for suspicious cutaneous (pre)
malignancies suggest that patients initiate GP visits. A single visit to evaluate treatment 
and provide instructions for self-examination should be sufficient. UK guidelines on KC 
also recommend self-examination or follow-up in primary care for primary adequately 
treated BCCs.16
EvaLuaTING kERaTINOCyTE CaNCER CaRE IN SECONDaRy CaRE
To identify areas of improvement in secondary KC care, the Netherlands Cancer Reg-
istry was used.20,23 A random selection was made of 1,569 histologically confirmed KC 
patients in secondary care. All patients were diagnosed between 2009 and 2013 and 
followed up was included until 2016. Details on diagnosis, treatment and care during 
follow-up were described. For medical specialists, clinical guidelines for BCC and SCC 
were implemented in 2002 and 2012 respectively.24,25
Dermatologists’ skin cancer policy
For BCC, a biopsy is recommended because histological growth patterns guide treat-
ment decisions, unless it concerns low-risk or multiple BCCs. These guidelines seem to 
be followed (i.e. no excisions of high risk-BCCs without biopsy) because the biopsy rate 
among BCC (59-66%) was much higher than the proportion of high-risk BCC (17-36%).
The histological clearance rate of excisions was higher for BCC (97%) compared to 
SCC (95%) and similar to other studies.26-28 The discrepancy between BCC and SCC 
might be explained by suboptimal clinical preoperative margins for SCC, less guidelines 
adherence concerning excision margins, more diagnostic excisions for SCC that are not 
followed by curative excisions and/or limited use of micrographic Mohs’ micrographic 
surgery for SCC compared to BCC.
keratinocyte cancer follow-up in secondary care
Comparable to a preliminary study, 83% of patients with BCC received more follow-up 
than recommended.20,29 In surprising contrast to BCC, patients with SCC received less 
follow-up than recommended. Although more than 80% of patients with SCC have stage 
I tumours of which only a very small fraction will develop metastasis.30 The Dutch and 
European guidelines recommend five years of follow-up for all patients with SCC.31,32 
The UK guidelines are less stringent and recommend to discharge low-risk patients 
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with SCC after a single postoperative visit, where instructions for self-examination and 
prevention are provided.
Low-risk BCC follow-up visits in hospital care is considered to be of low-value, as the 
current Dutch BCC guideline states to only monitor high-risk patients (e.g. patients with 
long-term immunosuppressants) or patients with a high-risk BCC.33 There is no evidence 
that earlier detection leads to improved health outcomes, while evidence exists that 
significant delay to treatment (up to 12 months) is not relevant to the outcome of the 
intended operation due to the slow growth rate.34 This low-value follow-up care seems 
a feasible option to de-adopt (i.e. the process of reducing or removing low-value clinical 
practices).35
REDuCING ThE buRDEN Of kERaTINOCyTE CaNCER ON ThE hEaLThCaRE 
SySTEM
Substitution of care to primary care is often mentioned as a suggestion to reduce the 
burden of KC on the healthcare system. However, substitution is not only suggested for 
dermatology, but also for many other diseases like cardiovascular diseases, diabetes 
mellitus and psychological disorders, which will substantially affect the workload of a 
GP.36 In addition to feasibility with respect to the workload for GPs, the question remains 
whether quality of care is preserved. Without proper training, clinical guidelines are 
insufficient to preserve patient care.37 Although skin-related complaints and referrals 
to dermatologists are high in primary care,38-40 it is worrisome that dermatology is not 
required at both the undergraduate and postgraduate training programs of GPs in the 
Netherlands and many other European countries.39,41,42 While in Australia, GPs play a 
larger role in skin cancer management after receiving extra training and accreditation. 
In the UK, services for the management of low-risk BCCs can be commissioned from 
accredited GPs with specialist dermatology training who participate in a regular histo-
logical accuracy audit.43 GPs can play a pivotal role in the early detection, diagnosis and 
management of many skin cancers considering they have had sufficient formal training, 
time and resources available.44
In 2016 the SKINCATCH (i.e. SKIN Cancer And Tumour Health Care) trial was initiated 
to assess whether low-risk BCC treatments could be substituted to primary care without 
loss of quality.45 GPs participating in this trial received a 2-day training in skin cancer 
management including skin cancer surgery. Unfortunately, the inclusion and excision 
rate of participating GPs was low. Some of the barriers reported by participating GPs 
were trial related, such as administrative challenges and patient recruitment issues. 
However, they also indicated other barriers, such as high workload, low volume of 
low-risk BCC patients and patients requesting a referral. Important vectors that are also 
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1applicable outside this trial setting. The trial demonstrated that substitution of low-risk 
BCC treatments was still a bridge too far, which means that it is necessary to explore 
other solutions to keep our healthcare systems sustainable for skin cancer.
Other initiatives focussing on GPs have been attempted to reduce the skin cancer 
burden, such as dermatologists working in GP clinics to reduce referrals and to educate 
GPs. However, this did not make it into national practice, mostly due to problems with 
the current financial structure of the healthcare system.46 This financial system is also a 
barrier for teledermatology to be successful.47 Artificial intelligence in the form of mo-
bile applications (mHealth) with skin cancer recognition software may be used as a tool 
for GPs to increase their diagnostic accuracy and reduce the number of improper refer-
rals to secondary care.48 However, currently, the technology is not advanced enough, 
and the current landscape is still too divided for successful implementation.49
De-adoption of low-value follow-up visits in secondary care
Initiatives focussing on primary care seem unfeasible at the moment, so opportunities 
to reduce the skin cancer burden in secondary care were reviewed. The evaluation of 
daily practice of dermatologists revealed that low-risk BCC patients received more 
follow-up than recommended in the current guidelines, which is considered a low-value 
service. The high volume of BCC makes this a suitable option for de-adoption.
De-adoption of low-value care is a fairly new concept, with little research conducted 
on this subject compared to implementation of care. Some may think that de-adoption 
is the reverse process of implementation. However, the processes of implementation 
and de-adoption are likely to be different and work in different ways. Traditional imple-
mentation methods based on increasing awareness and knowledge are unlikely to be 
effective for de-adoption.50
Multifaceted strategies are required to address the three levels of barriers, which are 
barriers related to patients, physicians and the system.51 There are additional barriers 
on all three of these levels, which include (among others) anxiety of no longer receiv-
ing an intervention among patients, fear of medical malpractice among physicians and 
economic and political factors such as cost-benefit considerations among organisa-
tions.52,53 Researchers often fail to include all relevant stakeholders as partners in the 
design, testing, and dissemination of interventions.54
Apart from the stakeholders’ factors, other factors of de-adoption differ from imple-
mentation as well. Such as the types of action (i.e. remove, replace, reduce or restrict), 
types of strategies (e.g. more affective based interventions to reduce anxiety) and 




aIMS Of ThIS ThESIS
The main aim of this thesis was to stimulate the de-adoption of low-value BCC follow-up 
care. Although de-adoption of care differentiates from implementation of care concern-
ing the aforementioned contextual factors, the ‘Grol and Wensing Implementation of 
Change Model’ can still be used to develop and evaluate a strategy for de-adoption of 
care.55 The aims of this thesis align with this model of change (figure 1).
The first step was to determine a concrete and feasible proposal for desired improve-
ment in existing practice. This proposal for change was developed in Chapter 1 by 
describing daily skin cancer practise of GPs and dermatologists. By comparing daily 
practice to guidelines, areas for improvement were found.
In order to assess actual performance, indicators to measure performance in a valid 
and reliable way are needed. This is preferably employed by a systematic method. In 
Chapter 2 a nationwide claims database was used to define quality indicators of skin 
cancer care, benchmark performance and reveal practice variation.
Development of proposal for 
changeChapter 1
Analysis of actual performance, 
targets for changeChapter 2
Problem analysis of target 
group and settingChapter 3
Development and selection of 
strategies and measures to 
change practice
Chapter 4
Development, testing and 




figure 1. Implementation of change model by Grol and Wensing55, which was used as guiding prin-
ciple for the de-adoption of low-value basal cell carcinoma follow-up care.
15
General introduction
1Before a de-adoption strategy can be developed, the target groups (i.e. stakeholders) 
must be analysed. This includes determining the barriers and facilitators to changing 
practice from each target group’s viewpoint. A qualitative approach was used in Chapter 
3 to determine the thoughts and believes of skin cancer patients and dermatologists.
The aim of Chapter 4 was to select a de-adoption strategy. The relative importance 
of the needs and preferences expressed by patients and dermatologists were quanti-
fied. The most important factors were integrated in a discrete choice experiment, 
which learned us which trade-offs they are willing to make in order to accept fewer BCC 
follow-up visits.
Finally, in Chapter 5, a de-adoption strategy based on the previous work was tested 
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background: Quality indicators are used to benchmark and subsequently improve qual-
ity of healthcare. However, defining good quality indicators and applying them to high 
volume care such as skin cancer is not always feasible.
Objectives: To determine whether claims data could be used to benchmark high-volume 
skin cancer care and to assess clinical practice variation.
Methods: All skin cancer care related claims in dermatology in 2016 were extracted 
from a nationwide claims database (Vektis) in The Netherlands.
Results: For over 220.000 patients a skin cancer diagnosis-related group (DRG) was re-
imbursed in 124 healthcare centres. Conventional excision reflected 75% of treatments 
for skin cancer, but showed large variation between practices. Large practice variation 
was also found for 5-fluorouracil and imiquimod creams. The practice variation of Mohs 
micrographic surgery and photodynamic therapy was low under the 75th percentile, 
but outliers at the 100th percentile were detected, which indicates that few centres 
performed these therapies far more often than average. On average, patients received 
1.8 follow-up visits in 2016.
Conclusions: Claims data demonstrated large practice variation in treatments and 
follow-up visits of skin cancer and may be a valid and feasible dataset to extract quality 
indicators. The next step is to investigate whether detected practice variation is unwar-
ranted and if a reduction improves quality and efficiency of care.
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2
INTRODuCTION
The high incidence of skin cancer, the low mortality rate, the long lag time to recur-
rence and/or low rate of severe treatment related complications make it difficult to 
monitor quality of skin cancer care.1 Benchmarking is a monitoring method which 
originated within commercial industry and has found its way into healthcare. Originally, 
benchmarking was used to improve organizational issues (e.g., staffing ratios), but soon 
after to improve clinical outcomes by benchmarking clinical practice.2 Benchmarking 
is a management approach which can be used to create a spirit of competition and to 
stimulate best practices at best cost.3 A way to translate benchmarking into medical 
care is often by using quality-indicators. These quality-indicators are thought to reflect 
quality of delivered care and can include items related to volume, complications and 
mortality rates.4
Analyses of quality-indicators can be used to reveal clinical practice variation, reflect-
ing differences in care policy or outcomes between healthcare providers.5 In only 15 
percent of medical interventions the choice of treatment is clear and the differences 
in provider judgment are negligible (e.g., hospital admission rates for hip fractures), 
making practice variation very common.6 To a certain degree practice variation is ac-
ceptable, but too much variation can be unwarranted and may be the result of under- or 
overtreatment.7,8 In the event of undertreatment, patients may not receive the care they 
actually need, which reduces their chance of receiving optimal care. When overtreat-
ment occurs, patients may be exposed to unnecessary side effects and/or costs caused 
by intervening more than is medically justified.9 For example, an identical skin cancer 
patient may be treated by Mohs micrographic surgery (MMS) in one healthcare centre 
and by conventional excision in another centre.
There are sets of quality-indicators which are mandatory to be registered for certain 
types of cancer in the Netherlands. Such as complications and survival rates after 
resection of pancreas carcinoma and the number of incomplete resections of ovarian 
carcinoma.10 However, for high-volume cancer such as skin cancer it is not feasible for 
healthcare providers to register quality-indicators for each patient.11 Therefore, quality-
indicators for skin cancer are currently only registered for stage 3C or higher melanoma 
in specialised melanoma centres.10 To obtain a complete overview of skin cancer care, 
routine data may be a promising data tool.12
The aim of the current study is to determine whether claims data can be used to 
benchmark high-volume care and to assess whether there is clinical practice variation 





Since 2005, all hospital visits and admissions in the Netherlands are categorised in 
diagnosis-related groups (DRGs). Each DRG includes all hospital activities and services 
associated with the patient care provided for a certain diagnosis. All activities related 
to diagnosis, treatment and follow-up are registered by the healthcare provider and 
included in a DRG, resulting in one reimbursement claim (Figure 1).13 These claims are 
collected by healthcare insurers and subsequently sent to a national information centre 
(Vektis B.V., Zeist) in the Netherlands. This nationwide claims database was used for 
the current study. As all Dutch inhabitants are obliged to have a healthcare insurance, 
the coverage is over 99% and a recent study determined this database to be over 95% 
accurate when compared to local patient records.14
Data extraction and analysis
All patients with a DRG reimbursed for a cutaneous malignancy within dermatology 
care in the most recent available calendar year (2016) were included. This includes 
patients who were diagnosed before 2016, but only had a follow-up visit in 2016. The 
data sets only included cutaneous malignancies (i.e. basal cell carcinoma, squamous cell 
carcinoma, melanoma and rare types of skin cancer). Pre-malignancies, such as Bowen’s 
disease and actinic keratosis were not included. It is not possible for patients to have 
diagnosis codes for both a cutaneous malignancy and a pre-malignancy (e.g. squamous 
cell carcinoma and actinic keratosis). Unfortunately, there were no specific diagnosis 
codes for each subtype of skin cancer. The ICD-10 codes were introduced from 2016 
which differentiates between different subtypes of skin cancer (except for basal cell 
 
figure 1. Example of a Diagnosis-Related Groups (DRGs) for a skin cancer patient. In this schematic 
example, a patient received a biopsy during the first visit, during the second visit the skin cancer 
was removed by conventional excision, then the sutures were removed and thereafter the patient 
received two follow-up visits. The conventional excision was included in the analyses of practice 
variation of treatments. The last two outpatient clinic visits, without any other registered activity 
on the same day, were considered follow-up visits and included in practice variation analysis of 
follow-up visits.
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carcinoma and squamous cell carcinoma), but the saturation of this data was too poor to 
use for the current study. Two data sets were extracted from Vektis’ nationwide claims 
database, based on health care activities (Figure 1):
- One dataset contained types of treatment indicated for skin cancer: conventional 
excision, MMS, photodynamic therapy (PDT), 5-fluorouracil and imiquimod cream. 
Destructive therapies, such as cryotherapy, were not included, because patients 
could be treated this way for their actinic keratosis during follow-up for their skin 
malignancy. If a patient received multiple treatments, for example topical treatment 
and excision, both treatments were registered. The number of treatments were 
stratified per healthcare centre.
- The second dataset contained the number of follow-up visits and was also stratified 
per healthcare centre. A follow-up visit was defined as a visit at the dermatology 
outpatient clinic after a skin cancer treatment, without any other activity registered 
on that day (e.g., removing sutures).
The maximum timeframe of an initial DRG is 90 days and 120 days for a subsequent 
DRG. When this time limit has passed and a new care activity is registered for this 
patient for the same diagnosis, a subsequent DRG will be opened. The eligible DRG 
codes are listed in Table S1. The number of referrals from other healthcare centres was 
determined by searching for a skin cancer DRG at another healthcare centre up to 90 
days before prior to the DRG in the main analysis (i.e., tertiary care). The healthcare 
centres were categorised as university hospital, general hospital or independent sector 
treatment centre (ISTC) and anonymised for the researchers.
The analyses were performed by using SAS software (version 9.3; SAS Institute Inc, Cary, 
NC) and Microsoft Excel (Microsoft, Redmont, WA, USA). Charts were created of the distri-
bution of treatment types and average number of follow-up visits per centre. Finally, after 
the healthcare centres were ranked on the proportion of type of treatment or follow-up 
visits, percentiles (p0, p25, p50, p75, p100) and the differences between percentiles (p25-
p75 and p0-p100) were determined to reveal practice variation. To determine whether 
results are skewed by small healthcare centres, a sensitivity analysis was performed by 
excluding the centres with the lowest quartile in terms of number of patients.
RESuLTS
In total, 124 healthcare centres in the Netherlands reimbursed at least one DRG for 
a skin malignancy within dermatology care in 2016 for over 220,000 unique patients 
(Table 1). The total number of patients is higher than the total number of treatments, 
as patients who solely received follow-up care in 2016 were included as well. Nearly 




An overview of the type of treatment quality indicator scores per healthcare centre are 
displayed in Figure 2. In 2016, general hospitals were the most consistent in treating 
their skin cancer patients by conventional excision, of which the hospitals with the least 
conventional excisions were performing more MMS. The two independent sector treat-
ment centres with the highest percentage of MMS (30% and 24%) had a substantial 
proportion of their patients referred from other healthcare centres (24% and 17%). The 
university hospital with 33% MMS had 35% of their patients referred from other health-
care centres, compared to 2% to 13% referred patients of the other university hospitals.
Table 1. Total number and distribution of treatments and follow-up visits for a skin malignancy per 
type of treatment centre in 2016








ISTCs 46 (37.1%) 24,857 (11.2%) 55,462 (14.1%) 17,125 (12.6%)
General hospitals 74 (59.7%) 180,525 (81.4%) 304,980 (77.4%) 108,758 (80.2%)
University hospitals 8 (6.5%) 16,498 (7.4%) 33,530 (8.5%) 9,715 (7.2%)
Total 124 221,880 393,972 135,598
aHealthcare centres with at least one patient with a follow-up visit for a skin malignancy
bPatients with at least one follow-up visit for a skin malignancy in 2016
cConventional excision, Mohs micrographic surgery, Photodynamic therapy, 5-fluorouracil and im-
iquimod cream
Abbreviation: ISTCs, Independent sector treatment centres.
 
figure 2. Distribution of Quality Indicator (QI) scores of the treatments indicated for skin cancer in 
2016. Each bar represents one healthcare centre. Abbreviations: University, University hospitals; 
ISTCs, Independent sector treatment centres
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Patients in university hospitals were treated with 5-fluorouracil or imiquimod cream 
in 22% of the cases, compared to 15% and 12% of patients in general hospitals and 
independent sector treatment centres respectively (online suppl. Fig. S1). In indepen-
dent sector treatment centres, 6% of skin cancer patients were treated with PDT, while 
in university and general hospitals 1% and 3% of patients were treated with PDT.
On average (taking the 50th percentile), 77.0% of all malignancies were treated by 
conventional excision in 2016 (Table 2). This proportion was reasonably comparable 
with the application of conventional excision in the 25th (71.3%) and 75th percentile 
(82.4%). The outliers however also showed healthcare centres with only 33.3% (p0) 
or more than 90% (p100) use of conventional excision. Most practice variation is 
revealed for topical treatment for skin cancer (5-fluorouracil and imiquimod), as the 
p0-p100 ranges from 0% to 66.7%. The low percentages of MMS and PDT until the 75th 
percentile (<7%) and the high percentage at p100 (>32%) indicate that few healthcare 
centres provided that care more often in 2016.
follow-up visits
Figure 3 provides an overview of the number of follow-up visits per healthcare centre. 
The average number of follow-up visits per patient was 2.0 for university hospitals, 1.7 
for general hospitals and 2.0 for independent sector treatment centres. The fourteen 
healthcare centres with the highest number of follow-up visits per patient were all 
independent sector treatment centres with an average of 2.4-6.6 follow-up visits per 
patient.
The difference in the average number of follow-up visits between healthcare centres 
from the 25th percentile and the 75th percentile was 0.53 follow-up visits per patient 
(Table 2). The number of follow-up visits per patient at these percentiles (1.48 – 2.01) 
did not differ much from the 50th percentile (1.75). However, the p100 showing an 
average number of follow-up visits of 6.61 per patient reveals that there were some 
healthcare centres on the higher end contributing to practice variation.
Table 2. Percentiles of the distribution of Quality Indicator (QI) scores of different types of skin 
malignancy treatments and follow-up visits between healthcare centres in 2016.




Conventional excision 33.3% 71.3% 77.0% 82.4% 90.6% 11.1% 57.2%
Mohs micrographic surgery 0% 0.9% 3.0% 6.7% 32.8% 5.8% 32.8%
5-fluorouracil or imiquimod 0% 10.5% 14.6% 18.5% 66.7% 7.9% 66.7%
Photodynamic therapy 0% 0.6% 1.8% 6.1% 39.5% 5.5% 39.5%
Average number of follow-up visits per patient 0.44 1.48 1.75 2.01 6.61 0.53 6.17
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The sensitivity analysis, which was used to detect if results were skewed by small 
healthcare centres, did not differ from the main analysis concerning the interquartile 
range (p25-p75). The results of the sensitivity analysis were different from the main 
analysis on the p0-p100 range of topical treatments (25.2%) and follow-up visits (2.1). 
This means that healthcare centres with a relative small amount of skin cancer patients, 
deviate more from the 50th percentile and caused more practice variation than larger 
healthcare centres regarding these quality indicators.
DISCuSSION
This study shows that claims data is able to detect relevant clinical practice variation 
in terms of skin cancer treatment and follow-up care. Proportion of specific treatments 
and follow-up could be valid quality indicators and routinely collected claims data may 
be a good data source for benchmarking.
The amount of clinical practice variation was highest for conventional excision, fol-
lowed by topical creams. This variation could be explained by referral rate of derma-
tologists to plastic surgeons depending on his/her surgical experience and skills, or the 
available facilities of the healthcare centre to provide high numbers of excisions. The 
practice variation in MMS and PDT was low under the 75th percentile, but outliers at the 
100th percentile were detected. MMS and PDT are treatments which were (and are) not 
provided in all healthcare centres, which means that there has to be practice variation. 
As shown by Arits et al., PDT is both more expensive and less effective than 5-fluo-
 
figure 3. Average number of follow-up visits per patient per healthcare centre in 2016. Each bar 
represents one healthcare centre. Abbreviation: ISTCs, Independent sector treatment centres.
*The Y-axis was cut off at 4.0 for clarity; this healthcare centre’s value was 6.6.
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rouracil and imiquimod cream, which led to guideline changes in 2014.15,16 The high 
amount of PDT in some healthcare centres might be explained by lack of knowledge of 
the guideline change. The near 100% compliance rate of conventional PDT might be 
a rationale to prefer this treatment for a subset of patients of whom is to be expected 
that they will not comply with creams at home (e.g. stopping treatment too early due 
to side-effects). However, it may also have been stimulated by a financial incentive, as 
PDT was more profitable for healthcare centres than conventional excision and topical 
treatments.
The average amount of follow-up visits per skin cancer patient was 1.8 in 2016. 
Considering skin cancer patients comprises 24% of all dermatology patients, these 
follow-up visits account for a large part of dermatology care.17 Comparing the 25th 
percentile to the 75th percentile indicates little practice variation between healthcare 
centres regarding the number of follow-up visits per skin cancer patient. However, it is 
remarkable that the fourteen healthcare centres with the highest number of follow-up 
visits per patient were all independent sector treatment centres.
Making use of claims data has some limitations. As the information was aggregated, 
it should be interpreted carefully. It does not allow analyses on absolute frequencies, 
but rather a comparison of relative frequencies between healthcare providers. No 
conclusions regarding under- or overtreatment can be drawn on the basis of practice 
variation found in the current study, because centres could treat different patient 
populations. For instance, due to lack of detailed information on the patient level (e.g. 
age, type of tumour), the case mix of each centre could not be determined. For this 
reason, it was not possible for the authors to determine whether the high percentage 
of MMS and high number of follow-up visits are due to specialisation in complex skin 
cancer care. Although the number of referrals provides an indication, no causality can 
be established. Strengths of claims databases are that it is routinely registered data, it 
is virtually complete due to obligatory registration and that the summaries of quality 
indicators of claims data match summaries of quality indicators of the actual medical 
records.18
The next step is to determine whether the practice variation found in our study is 
warranted. Institutions such as the Ministry of Health or health insurers (in collabora-
tion with clinical experts) could request healthcare centres to retrieve their own quality 
indicator scores from Vektis and investigate why certain centres deviate from the aver-
age. This process of audit and feedback might already effectively reduce possible un-
warranted practice variation.19 There are several other options to reduce the variation, 
such as the development and implementation of guidelines (most common strategy), 
improving shared decision-making and introduction of financial incentives.20-25 Multi-




In conclusion, claims data can be used to benchmark high-volume care and to reveal 
clinical practice variation on routinely collected quality indicators. The current study 
revealed that there might be under- and/or overtreatment in the case of conventional 
excisions and topical creams. In addition, it showed that there is little practice variation 
regarding follow-up visits, but it was surprising to see that the fourteen healthcare cen-
tres with the highest number of follow-up visits per patient were all independent sector 
treatment centres. It should be explored if the variation found in the current study is 
warranted and if further actions should be undertaken to reduce the practice variation.
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Needs and preferences of patients regarding 
basal cell carcinoma and cutaneous squamous cell 













background: Despite the high and rising incidence rate of keratinocyte cancer (KC) and 
the importance of incorporating patient values into evidence-based care, few studies 
have focused on the perspectives of patients with KC.
Objectives: To identify the needs and preferences of patients with basal cell carcinoma 
(BCC) and squamous cell carcinoma (SCC) regarding care.
Methods: A qualitative study was conducted consisting of three focus groups with 
patients with BCC and three focus groups with patients with SCC. In total 42 patients 
participated. In each focus group, the patients’ needs and preferences regarding treat-
ment and follow-up were discussed, using a predefined topic list. All sessions were 
transcribed verbatim and analysed by two researchers.
Results: The following needs and preferences were identified: (i) the need to receive 
all relevant, tailored information; (ii) a physician who takes you seriously and commu-
nicates well; (iii) a short waiting period and the best treatment with direct results; (iv) 
to be seen by the same physician; a preference for a dermatologist during (v) treatment 
and (vi) follow-up; (vii) a general need for structured follow-up care and (viii) a full-body 
skin examination during follow-up. Patients with BCC additionally expressed the need 
for openness and transparency and wanting to participate in shared decision making.
Conclusions: It is advocated to organize skin cancer care that is better tailored to the 
needs of patients with KC, providing patient-centred care. This should include investing 
in the patient–physician relationship, and personalizing the type and form of informa-
tion and the follow-up schedules. Adding the patient’s perspective to current guidelines 
could facilitate this process.
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INTRODuCTION
Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are among the most 
common cancers with increasing incidences worldwide.1,2 Due to their keratinocyte 
origin, they are nowadays commonly referred to as keratinocyte carcinoma (KC).3 The 
estimated global prevalence of KC was 5.529.600 in 2013.4 Although the costs per case 
are low, this high prevalence drives the costs of KC up to 600 million, 350 million, 150 
million and 100 million in the U.S.A., Australia, Germany and the U.K. respectively.5 KC 
therefore poses a considerable burden on health care systems.
To wisely manage finite sources, a strong initiative has spread over all medical societ-
ies over the past five years which aims to reduce low-value care,6-10 i.e. healthcare that it 
is of little or no value to the patient and consequently should not be provided routinely, 
or not at all.11 Providing follow-up care to low-risk BCC patients has been defined as 
an example of low-value care. Although the risk of a subsequent BCC is high (29% in 
five years)1, evidence is lacking that regular follow-up visits translate into improved 
patient outcomes.12 In addition, another trend aimed to reduce costs has been care sub-
stitution, which aims to shift skin cancer care from medical specialists towards general 
practitioners (GP) or nurse practitioners (NP) and physician assistants (PA) specialised 
in dermatology.13-15 It is of paramount importance that these GPs, NPs and PAs have had 
sufficient dermatological training.
Evidence based medicine includes three components: research-based evidence, 
professional expertise, and patient values.16 Given that patient values are a core com-
ponent of evidence based medicine,16 it is surprising that the experiences, needs and 
preferences of KC patients have received limited attention and were mainly focused 
on melanoma patients.17-34 A recently conducted qualitative review35 on the needs 
and experiences of skin cancer patients found that only three out of sixteen studies 
included KC patients.29,36,37 These qualitative KC studies focused mainly on experiences, 
psychological impact of hearing the diagnosis and quality of life and all identified the 
need for information among patients. An in-depth evaluation of preferences and needs 
regarding treatment and follow-up care is however lacking for this large patient group.35
The aim of the current qualitative study is therefore to identify the needs and prefer-
ences of BCC and SCC patients regarding KC care. The results of this study can be used 
as input to organise skin cancer care that is better tailored to the needs of patients 





Study design and methodological considerations
A qualitative study consisting of six focus groups was conducted. Qualitative research 
is ideally suited to provide an in-depth picture of patients’ needs and preferences.38,39 
Furthermore, the interactive component of the focus groups enables people to ponder, 
reflect and listen to experiences and opinions of others. This interaction helps partici-
pants compare their own personal realities to those of others.40
This focus group study has been designed and is reported in accordance with the 
SRQR (Standards for Reporting Qualitative Research) recommendations.41
Study setting and selection of participants
We selected participants for the BCC and SCC focus groups from the three types of 
health centres providing dermatologic care: academic hospitals (Erasmus MC), pe-
ripheral hospitals (Elisabeth-TweeSteden hospital) and independent sector treatment 
centres (DermaPark and Mohs Klinieken). One focus group for each diagnosis was 
organised at each type of health centre, where electronic patient files were screened to 
select patients with a history of exclusively BCC or SCC. Additional information about 
the selection procedure can be found in Appendix A.
Data collection
Three focus group sessions were held with BCC patients and three with SCC patients. 
A total of 42 patients participated, varying from 4-8 per group. The patients had a 
semi-structured discussion about their needs and preferences regarding treatment and 
follow-up care. A topic guide was used to structure the discussion (see Appendix B). The 
topic guide originated from earlier experiences of the investigators and from theoreti-
cal grounds derived from the literature.17,42-45
The sessions were moderated by an experienced moderator of focus groups (M.L., 
M.D. or Y.M.) and co-chaired by an independent dermatology-trained physician or 
dermatologist. The moderator explicitly stated that no consensus had to be reached 
and made sure that everyone was able to share their opinion, to prevent less confident 
participants from being constrained. All sessions were audio-taped and transcribed 
verbatim.
Data analysis
Two researchers (S.v.E. and M.L.) independently openly-coded the first two transcripts 
using the qualitative software program ATLAS.ti 8.0. The codes were discussed and 
adjusted when needed, which resulted in a preliminary coding scheme. The remaining 
four transcripts were coded by one researcher, then checked by the other. Different 
39
Needs and preferences of BCC and SCC patients
3.1
interpretations of codes were discussed and refined until agreement was reached. Data 
saturation was reached when no new codes (groups) were created in the third focus 
group of each diagnosis.
The analysis proceeded by the iterative and interpretive process of constant com-
parison, in which different codes were compared and the relationship between codes 
was explored to detect emerging themes. Separate code lists were created for BCC and 
SCC patients to be able to identify differences and similarities between the groups. In 
case comparable themes emerged in the different focus groups, the same theme titles 
were used to enhance visibility of similarities and differences between the groups of 
patients. The overall analysis process resulted in the identification of core themes and 
sub-themes concerning BCC and SCC patients’ needs and preferences regarding KC care.
Ethical considerations
The Medical Ethics Committee of the Erasmus University Medical Center declared that 
the Medical Research Involving Human Subjects Act was not applicable to this study and 
approved the study protocol (MEC-2016-204). Participation was on a voluntary basis 
and all patients participating in the study provided written informed consent.
RESuLTS
Needs and preferences of bCC and SCC patients regarding treatment and 
follow-up
The characteristics of the 42 participants are described in Table 1. Eight sub-themes 
emerged from the data on the needs and preferences of both BCC and SCC patients, 
two additional sub-themes were only relevant for BCC patients. The findings and sub-
themes are described in detail below. Additional quotations illustrating each sub-theme 
are presented in Appendix C.
Need for all relevant, tailored information and comprehensible explanation
Both BCC and SCC patients mentioned the importance of receiving all information 
relevant to their treatment and follow-up, including a clear and comprehensible expla-
nation. In this way they know what to expect and prepare for. BCC patients indicated an 
additional need for information on the disease background, preventative measures and 
all available treatments. SCC patients did not express this need. With respect to follow-
up care, both patient groups mentioned that clear information on self-inspection would 
reduce the need for follow-up visits. They wish to receive information that is specifically 
tailored to their diagnosis and needs, preferably on paper.
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“But I want to know what the background of that story is and I still don’t know that. The 
only thing he keeps saying at the end of a discussion is it won’t kill you. Yeah, okay.”
(Patient BCC group 1)
Need for openness and transparency
BCC patients want openness and transparency from their physicians with respect to 
their prognosis, treatment options and follow-up policy. Not hearing about their pros-
pects from their physician makes them feel insecure. They do not want their physician 
to withhold views or ideas about their situation and want their physician to express 
when he/she is uncertain. SCC patients did not report this need.
“I would like to have more openness, that he tells what the possibilities are that we 
have further, and now that’s still an open question, in two months we’ll see again, 
think yes, don’t you yourself have a vision that it’s gone, or that something must hap-
pen again, the uncertainty remains.”
(Patient BCC group 2)
Need for shared decision making
BCC patients want to contribute in the decisions regarding the management of their 
disease, for example in treatment decisions or in being treated by the type of physician 
of their preference. In contrast, some SCC patients indicated explicitly, they do not want 
to be involved in shared decision making and rather have their physician to decide for 
them.








bCC total 20 13 (65) 68.0 (60-78)
- Group 1 8 4 (50) 67.5 (54-74) Academic hospital
- Group 2 4 3 (75) 71.5 (60-82) Peripheral hospital
- Group 3 8 6 (75) 68.5 (67-77) ISTC
SCC total 22 12 (55) 76.5 (70-82)
- Group 1 7 5 (71) 73.0 (70-82) Academic hospital
- Group 2 8 4 (50) 80.5 (76-85) Peripheral hospital
- Group 3 7 3 (43) 75.0 (69-80) ISTC
IQR, interquartile range; BCC, basal cell carcinoma; SCC, squamous cell carcinoma; ISTC, Indepen-
dent sector treatment centre.
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“The same as if at a given moment a physician says what do you think yourself, damn, 
and I answered, sir, you studied for that and maybe even at my expense, so should you 
ask me what it is, huh?”
(Patient SCC group 2)
Need for a physician that listens, takes you seriously and communicates well
Patients from both groups reported the need for a physician that listens, takes you seri-
ously and communicates well. Patients find it important to be able to tell their story to 
a new physician, even though it is well documented in their medical file. They prefer a 
personal approach from the physician as this creates trust.
“Yes, a doctor can be very skilled but not get along with people, that’s a real shame, 
actually, because you have to trust, uh, that doctor.”
(Patient BCC group 3)
Need for short waiting period and to receive best treatment with direct results
BCC and SCC patients mentioned the importance of being treated fast and to receive the 
best treatment with direct results. Patients want to have a short waiting period because 
they do not want to be in uncertainty for too long. They rather have more skin removed 
than necessary in order to be tumour free in one session. SCC patients specifically pre-
ferred to be treated by Mohs’ micrographic surgery, as this has the highest likelihood of 
being tumour free by the end of the day.
“If the biopsy was taken and they have confirmed it is SCC, okay, treatment within 14 
days. That is what I think.”
(Patient SCC group 3)
Need for continuity of care, to be seen by same physician
Both patient groups expressed a need for continuity of care, i.e. to be treated by the 
same physician every time, so he or she will make the patient’s problem his or her 
problem instead of passing the problem to another physician. Another reason is that 
they do not need to tell the same story every time. In addition, they want a physician 
they can trust based on prior experiences. With respect to follow-up, some BCC patients 
indicated that the physician who treated them should also be the one who performs 
the follow-up visits, because they gained trust in this physician. SCC patients did not 
express this need.
“Yes sure, I also return to the same dentist every time, to name a thing”.
(Patient SCC group 3)
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Preference for dermatologist as a treating physician compared to GP, NP or PA
Overall, both BCC and SCC patients prefer to be treated by dermatologists, as they are 
the experts specialised in skin care, as opposed to GPs who are generalists. Furthermore, 
dermatologists have better equipment than GPs and have the option to ask support 
from nurses or colleagues when needed.
“I indeed have more trust in specialised people, certainly if we’re thinking in the direc-
tion that it is perhaps cancer, then I want to be where the specialist is.”
(Patient BCC group 2)
Some BCC and SCC patients, however, indicated that GPs might be involved in their 
treatment under certain conditions. According to some BCC patients, GPs may perform 
certain tasks such as excising small tumours, especially because of the short waiting 
period for GPs, but only when they have received proper training. Some SCC patients 
would let the GP perform the excision if it is superficial and the GP reassures them he 
or she is confident enough to do it. In addition, some BCC patients would allow being 
treated by an NP or PA, but only under the conditions of sufficient training and expe-
rience and under supervision of a dermatologist. SCC patients reported not to allow 
having their tumour excised by an NP or PA. They think their tasks should be limited to 
superficial treatments such as changing stitches or cleaning wounds.
“Basically, they are now being trained by the dermatologists, with a supervisor. So yes 
I would not have any problems with that I think, no.”
(Patient BCC group 1)
Need for structured follow-up care
In general, both BCC and SCC patients prefer periodic follow-up visits, with a possibility 
to come in-between visits when they discover new suspicious lesions. They believe it is 
too hard for them to distinguish age-related skin lesions from cancer and cannot com-
plete full-body self-inspection themselves. Periodic follow-up visits create a feeling 
of being taken seriously and provides certainty. Some BCC patients, however, believe 
periodic follow-up visits are not necessary, as long as they have easy and quick access 
to a dermatologist whenever they detect new suspicious lesions.
“I find another problem, that is that I can’t see half my body, and the dermatologist 
nice lamp, under a good lamp, with good eyes, an assistant next to him, and there free 
and worked out back and forth, what do you think in a manner of speaking and then 
I say the frequency if you in my case then once every half year then I’d like to see him 
even if I have no problems myself.
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(Patient SCC group 3)
Preference for dermatologist for follow-up visits as compared to GP, NP or PA.
With regard to follow-up visits, both groups prefer to be seen by dermatologists, rather 
than by GPs, NPs or PAs, especially for the first visit after treatment. They believe derma-
tologists are the experts, whereas they have insufficient confidence in the knowledge 
and expertise of GPs.
“No, not by the general practitioner, he is still not the specialist, even if he acknowl-
edged it, still a pat on the back for him but he is still not a specialist in that area.”
(Patient SCC group 3)
However, some BCC patients indicated that they would accept follow-up visits being 
performed by NPs or PAs, under the conditions that he or she is qualified and that 
the dermatologist feels confident enough to refer the patient to them. SCC patients 
reported that they do not to want the GP being involved in follow-up care. Some SCC 
patients indicated that they see a possibility for going to the GP when they have a suspi-
cious lesion in between the periodic follow-up visits at the dermatologist.
“I mean that I come back to the dermatologist every half year myself but in the interim 
I might dare to leave it to my general practitioner, something like that.”
(Patient SCC group 3)
Need for full body skin examination during follow-up visits
Both BCC and SCC patients expressed the need for a full body skin examination. They 
want to have their whole skin checked during follow-up visits, as they cannot check 
their whole body themselves. SCC patients emphasised the importance of full body skin 
examination because of their fear that the tumour can metastasize.
“...She (dermatologist) only looked at my face, and I thought that was very strange 
because you can get metastases in your whole body, and she really only really looked 
at my face and really no further, but did feel the glands because... she says because as 
soon as there was something there we can also feel it in the thickened glands.”




This first in-depth exploration on the needs and preferences of KC patients identified a 
range of themes, which could be used to organise skin cancer care that is more tailored 
to the needs and preferences of this large patient group.
The need for information has already been identified in previous qualitative KC stud-
ies.29,36,37 However, we found that both BCC and SCC patients emphasised the importance 
of receiving this information tailored to their specific situation and explained compre-
hensibly. Additionally, BCC patients indicated a need for more extensive information 
with respect to their diagnosis, treatment and prognosis in order to actively participate 
in the decision making process, whereas SCC patients explicitly stated not to want to be 
involved. This difference may be explained by the fact that BCC patients are generally 
younger and probably in an overall better condition than SCC patients,1,46,47 which is 
consistent with previous studies stating that older patients and patients with a lower 
level of perceived health are less likely to participate in shared decision making.48-51
Both patient groups also expressed the need for a physician that listens, takes you 
seriously and communicates well. This makes patients feel valued, increase their self-
worth and gives them a sense of control.52 Related to this was the need of patients to be 
seen by the same physician, at least for the treatment and first follow-up visit, because 
this increases patients’ trust in their physician.53 The need of patients to receive tai-
lored information, in some cases participate in decision making and to have a physician 
they can trust, suggests that care should be more patient-centred and more time should 
be invested in the patient-physician relationship.53 Research has shown that patient-
centred care leads to improved health outcomes.54,55
It should be stressed that there were far more similarities than differences in pref-
erences and needs between the BCC and SCC patient groups. In addition, qualitative 
studies with melanoma patients and even other types of cancers patients have dem-
onstrated many similar themes (e.g. the need for more information and lack of trust 
in the GP).35,56,57 Whereas some needs and preferences may be relevant to all types 
of patients (e.g. a general need for information), others may be more disease-specific 
(e.g. the need for full-body skin examination) or related to personal characteristics of 
patients rather than the diseases themselves. Several studies have indeed shown that 
patient characteristics such as demographic variables, comorbidities, perceived health 
status and patients’ attitude towards involvement of care are associated with patient 
preferences.58-60 Future (skin) cancer related qualitative research could take this into ac-
count by including subgroups like older patients or patients with certain comorbidities.
A limitation of our study is that we only included patients who were treated by 
dermatologists. This may have led to a selection bias in patients’ preference for a 
dermatologist as a healthcare provider. Since the role of GPs in BCC care is currently 
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expanding,13-15 future focus groups may also be organised in a primary care setting. 
By organising six focus groups in different medical specialist settings, we were able to 
create a representative sample of KC patients treated by dermatologists. However, the 
qualitative design does not allow us to draw conclusions on differences in the needs 
and preferences between patients from different medical settings.
Obviously, it is not possible in most health care systems to accommodate all the 
wishes of the patients, for example the preference to always be seen by a dermatolo-
gist. A recent discrete choice experiment among low- and high risk BCC patients found 
that patients accept fewer follow-up visits and have them performed by a GP, if the first 
treatment evaluation is performed by the initial health care professional and if they 
receive a personalised information hand-out.61 An intervention study among melanoma 
patients also showed that providing personalised information is more effective in 
increasing adherence to advice compared to generic information.62 Melanoma patients 
were also found to accept fewer follow-up visits from a non-specialist under certain 
conditions, such as increased continuity of care and rapid clinical review of anything 
causing concern.31,32 These trade-offs should be taken into account when developing 
future policies.
In conclusion, KC patients expressed a set of specific needs and preferences regarding 
KC care. The new insights from our focus group study could be used to tailor skin cancer 
care according to the needs and preferences of these patients. This could be achieved 
by enhancing patient-centred care, e.g. by investing in the patient-physician relation-
ship and by personalising the type and form of information, the way of explanation, and 
the follow-up schedules. In continuation of this study, an initiative has already started 
to investigate the effects of providing BCC patients with a personalised hand-out on 
paper.63 With this hand-out we hope to reduce the pressure on the current health care 
system by reducing the need for low-value BCC follow-up visits, while increasing pa-
tient satisfaction. Adding the patient’s perspective to current guidelines on BCC and 
SCC could further improve the quality of skin cancer care.
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background: Providing follow-up to patients with low-risk basal cell carcinoma (BCC) 
can be considered as low-value care. However, dermatologists still provide substantial 
follow-up care to this patient group, for reasons not well understood.
Objectives: To identify factors influencing current BCC follow-up practices among der-
matologists and suggested strategies to de-adopt this low-value care. In addition, views 
of patients regarding follow-up care were explored.
Methods: A qualitative study was conducted consisting of 18 semi-structured interviews 
with dermatologists and three focus groups with a total of 17 patients with low-risk BCC 
who had received dermatological care. The interviews focused on current follow-up 
practices, influencing factors and suggested strategies to de-adopt the follow-up care. 
The focus groups discussed preferred follow-up schedules and providers, as well as the 
content of follow-up. All (group) interviews were transcribed verbatim and analysed by 
two researchers using ATLAS.ti software.
Results: Factors influencing current follow-up care practices among dermatologists 
included complying with patients’ preferences, lack of trust in general practitioners 
(GPs), financial incentives and force of habit. Patients reported varying needs regard-
ing periodic follow-up visits, preferred to be seen by a dermatologist and indicated a 
need for improved information provision. Suggested strategies by dermatologists to 
de-adopt the low-value care encompassed educating patients with improved informa-
tion, educating GPs to increase trust of dermatologists, realizing appropriate financial 
reimbursement and informing dermatologists about the low value of care.
Conclusions: A mixture of factors appear to contribute to current follow-up practices 
after low-risk BCC. In order to de-adopt this low-value care, strategies should be aimed 
at dermatologists and GPs, and also patients.
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INTRODuCTION
Basal cell carcinoma (BCC) is the most common cancer in Caucasian people, and inci-
dence rates are increasing worldwide.1 It is a slow growing tumour which seldom me-
tastasises and is mostly treated by a conventional excision.2,3,4 Although BCC patients 
have an increased risk of getting a subsequent BCC,1 several European BCC guidelines 
try to identify high-risk patients for follow-up depending on patient and tumour char-
acteristics.5-7 As evidence that providing follow-up care to (low-risk) BCC patients leads 
to improved patient outcomes is lacking, BCC guidelines increasingly advise against 
annual follow-up after treatment of a single ‘low-risk’ BCC (i.e. primary BCC, smaller 
than 2 cm, located outside the H-zone and has a nodular or superficial subtype).5-7
Due to rising healthcare costs and finite recourses, policymakers focus more on de-
adopting low-value care, which concerns healthcare that is of little or no value to the 
patient and consequently should not be provided routinely.8-11 Several initiatives on 
de-adoption of care have been initiated resulting in lists of low-value services, such as 
the ‘Choosing Wisely’ lists, identifying potential candidates for de-adoption. 8,12-14 Since 
follow-up for low-risk BCC patients can be considered as low-value care, it was included 
in the Dutch list of low-value services (Manuscript in preparation).
Despite several European guidelines not recommending it, dermatologists seem to 
provide follow-up care to this large patient group. The number of newly diagnosed BCCs 
in the Netherlands is estimated to exceed 50.000 in 2020,1 and almost 50 percent of 
these can be considered low-risk.4 A Dutch study showed that low-risk BCC patients 
receive, on average, a total of 3.8 follow-up visits in three years.4 A study from the UK 
showed that after complete excision of a BCC outside the central ‘T’ area of the face, a 
quarter of the dermatologists reviewed it more than once.15 The underlying reasons of 
dermatologists for providing follow-up care to this patient group are thus far poorly 
understood.
We conducted present qualitative study as important first step of an intervention 
study, which aims to reduce the number of low-value follow-up visits of low-risk BCC 
patients by Dutch dermatologists. The aim of this study is to identify factors influencing 
current low-value BCC follow-up practices among dermatologists and suggested strate-
gies for de-adoption. In addition, views and preferences of patients regarding follow-up 





In the Netherlands, medical specialists can work either in a partnership within a hospital 
paid under fee-per-service (54% of specialists in 2015) or on salary (46% in 2015, 
mostly in academic hospitals). A small minority of physicians also work in an indepen-
dent sector treatment centre (ISTC).16 These different payment systems could lead to 
different financial incentives for physicians.17 The average price of a follow-up visit at 
the dermatologist in the Netherlands in 2018 was 100 Euro.18
Study design and methodological considerations
A qualitative study was conducted consisting of 18 individual semi-structured inter-
views with dermatologists and three focus groups with a total of 17 low-risk BCC pa-
tients (varying from five to six per session). This qualitative design was chosen because 
it enabled us to obtain information about behaviour, underlying motivation, and needs 
and preferences of all stakeholders.19
Selection of participants
Interviews
To select participants, a purposeful sampling method was used,20 in which information-
rich dermatologists known by the authors were invited to participate in an interview. 
Using this method, we strived for maximum variation in terms of the following relevant 
characteristics of the target group: types of medical centres in which dermatologic care 
is provided in the Netherlands (ISTCs, peripheral hospitals and academic hospitals), 
gender, knowledge of skin cancer and years of working experience. Initially, five der-
matologists were interviewed as part of a pilot. This was ultimately extended to 18 
dermatologists in total. Potential participants received an invitation by email, contain-
ing an information leaflet about the study. Potential participants could register for an 
individual interview by contacting the researchers.
Focus groups
One focus group was organised at each of the three types of medical service centres. 
To select participants, electronic patient records from an ISTC (Mohs Klinieken), a pe-
ripheral hospital (Elisabeth-TweeSteden hospital) and an academic hospital (Erasmus 
MC) were screened. Patients were selected if being treated for a low-risk BCC (i.e. non-
aggressive subtype, outside the ‘H-zone’, smaller than 2cm and primary tumor21) in the 
past year. Patients with previous skin malignancies and non-Dutch speakers were not 
invited, as were patients who did not seem fit enough to join a focus group based on 
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their age and comorbidities. Invitation letters were sent to their home address, contain-
ing an invitation and information leaflet. They were offered a gift voucher of 40 Euro to 
compensate for participating, as stated in the information leaflet. Patients could sign up 
for the focus group by contacting the researchers.
Data collection
Interviews
All interviews were conducted by an experienced qualitative researcher (ML): eleven 
were held face to face at the healthcare provider’s working place and seven were con-
ducted by phone.
A predefined topic list was used to structure the interview, consisting of the following 
main themes: current practices regarding BCC follow-up care, factors influencing pro-
viding follow-up care, and suggested strategies to de-adopt low-risk BCC follow-up care 
(See Appendix A). The original topic list also included management of actinic keratosis 
and squamous cell carcinoma, however, this part falls outside the scope of the current 
study.
Focus groups
The three focus groups were held at the centres where the patients were treated 
(Erasmus MC, Elisabeth-TweeSteden hospital and Mohs Klinieken). The sessions were 
moderated by experienced moderators of focus groups (ML and SD) and co-chaired by a 
physician independent of the hospitals (SvE).
In each focus group session, patients had a semi-structured discussion about needs 
and preferences regarding BCC treatment and needs and preferences regarding BCC 
follow-up care. In this study, we only focused on BCC follow-up care. A predefined topic 
list was used (See Appendix A) to structure the discussion, which included the follow-
ing main themes: general needs and preferences regarding follow-up care, preferred 
follow-up schedules, preferred types of healthcare providers and areas for improve-
ment of care. To prevent the less confident participants from withholding their opinion, 
the moderator made sure that everyone was able to say something and explicitly stated 
that opinions are never right or wrong.
Both the dermatologists and patients provided written informed consent and gave 
permission to audio-tape the session. In addition, they filled out a small questionnaire 
to collect socio-demographic information (e.g. age, gender).
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Data processing and analysis
All interviews (n=18) and focus groups (n=3) were transcribed verbatim. Next, all iden-
tifying characteristics were removed from the transcripts and they were imported into 
AtlasTi 8.0, a professional tool designed for qualitative data analysis.
Two researchers (ML and SD or SvE) independently studied and coded the first three 
transcripts (two dermatologist interviews and one patient focus group). Different inter-
pretations of codes were discussed and redefined until agreement was reached, which 
resulted in a preliminary coding scheme. The remaining 18 transcripts were coded by 
ML or SvE and checked by either SD, SvE or ML. Disagreements were discussed until 
consensus was reached. After 18 interviews with dermatologists and three focus groups 
with patients, thematic saturation, defined as when little or no changes to the codes 
were made, was reached for all covered research areas.
After the initial coding process the analyses proceeded by the iterative and inter-
pretive process of constant comparison. The final codes were discussed and emerging 
themes were grouped. The information in each category of factors was reflected on 
and interpreted jointly. Inter-observer reliability was tested by group discussions (on 
meaning) of codes and relationships between codes. This resulted in the identification 
of core categories of factors influencing current low-risk BCC care and strategies to de-
adopt it. In addition, core themes of patients regarding their needs and preferences on 
follow-up care emerged.
Ethical considerations
Ethical approval for this study was obtained from the Medical Ethical committee of the 
Erasmus MC (MEC-2016-204).
The current study has been designed and reported in accordance with SRQR (Stan-
dards for Reporting Qualitative Research) recommendations.22
RESuLTS
Description of participants
The characteristics of the participating dermatologists and low-risk BCC patients are 
displayed in Table 1.
Factors influencing current low-value BCC follow-up practices among 
dermatologists
Five types of factors emerged as influencing current low-value follow-up care among 
dermatologists.
57
Factors influencing low-value BCC care and strategies for de-adoption
3.2
Complying with patient preferences and needs
According to the dermatologists, patients visiting their practices often prefer follow-up 
visits as this is reassuring to them after their skin cancer diagnosis. Another reason, 
according to dermatologists, is the lack of trust by patients in their GP, as he or she will 
be the first person of contact for the patient after being discharged from follow-up. Der-
matologist indicated to comply with these preferences, for example by seeing patients 
once a year, or to provide follow-up visits to the patients until they are confident enough 
to do it on their own. In addition, dermatologists indicated that their predecessor often 
provided annual follow-up visits to the patients creating an unnecessary habit. This 
makes it hard for them to explain to patients that they do not need follow-up visits 
anymore and they rather avoid these discussions (Box 1).
Lack of trust in GPs to recognise suspicious lesions
Another factor contributing to providing low-value follow-up practices to patients is 
the lack of trust among dermatologists in GPs to adequately recognise suspicious skin 
lesions. They believe that GPs lack knowledge of skin cancer and do not see enough 
skin cancer to establish sufficient experience. The dermatologists indicated that they 











10 (56) 1 (20) 2 (33) 3 (50)
age
Median, years (IQR)
45 (38-54) 56 (47-63) 67 (56-68) 72 (62-78)
Setting Academic Peripheral ISTC
- academic 2 (11) 
- Peripheral 9 (50) 
- ISTC 3 (17) 




IQR, interquartile range; ISTC, Independent sector treatment centre
box 1. Illustrative quotes on complying with patient preferences and needs
“There are also people who just think the idea of skin cancer is frightening, and even if you explain it they keep 
thinking so anyway, and if they then get the choice or propose so themselves, may I come back again, then I say 
well I would like to see you once a year, and they are completely relieved, I think that’s a good thing.”
- Dermatologist 12
“Yes. And certainly when your predecessors have all said that you have to come back annually. It would be 
strange if I’d then go and say all right, no, you are now discharged. So I do that with some, but some of them 




often receive referrals suggesting poor diagnostic skills of the GPs. As a result, der-
matologists indicated to sometimes prefer continuing providing follow-up to low-risk 
BCC patients themselves, rather than making the GP the first person of contact for the 
patient. However, some dermatologists reported that discharging the patient depends 
on the expertise of the particular GP of the patient (Box 2).
Believes in the usefulness of follow-up visits
As patients have a high chance of a subsequent BCC, follow-up visits are useful, ac-
cording to some dermatologists. In addition, the usefulness of providing follow-up 
care to patients was reported for patients who, they believe, are not capable enough to 
self-examine their skin. Follow-up visits are sometimes provided by dermatologists as a 
means to educate patients, until they are believed to be capable of performing checks 
themselves (Box 3).
Financial incentives to perform follow-up visits
Generally, dermatologists reported not to be influenced by the financial incentives 
themselves, but indicated to know other dermatologists that are. Reasons reported 
were the need to reach certain targets within hospital partnerships and personal gain. 
Particularly, dermatologists indicated that their predecessors were influenced by finan-
cial incentives, but these incentives were thought to be still present today (Box 4).
box 2. Illustrative quotes on the lack of trust in GPs to recognise suspicious lesions
“Yes, we just know the neighbourhood and we know who’s a good general practitioner is and who isn’t, and 
those who have a good general practitioner [we discharge] and others we keep ourselves for follow-ups.”
- Dermatologist 5
box 3. Illustrative quotes on the believes in the usefulness of follow-up visits
“The reason for me is of course that they have a higher chance of a second basal cell carcinoma in the first two 
years, that’s one reason.”
- Dermatologist 2
“Yes, it’s someone who won’t notice it himself as easily, those you’ll see sooner than someone that you can 
instruct well.”
- Dermatologist 12
box 4. Illustrative quotes on the financial incentives to perform follow-up visits
“Because look, in a lot of hospitals with partnerships and things like that, certain targets have to be met, and if 
those targets all get dropped, then, ehm, it can all lead to financial problems of a club.”
- Dermatologist 9
“Those are the perverse financial incentives (laughs) that, eh, that are not beneficial for a lot of colleagues, it 
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Force of habit
Providing follow-up care to low-risk BCC patients used to be standard care, and der-
matologists reported that when a guideline changes it is hard to subsequently change 
common daily practice. They believe this is particularly true for older dermatologists, 
whereas younger dermatologists generally adhere better to current guidelines (Box 5).
Patient views and preferences regarding bCC follow-up care
Three main themes emerged from the focus groups with low-risk BCC patients concern-
ing follow-up care.
Varying needs with regard to regularity of follow-up care and skin examination
Some low-risk BCC patients, who were all treated by a dermatologist in secondary care, 
reported a preference for yearly follow-up visits. They indicated that – after being 
shocked to hear their diagnosis – a yearly check-up would reduce their anxiety. They 
prefer appointments to be pre-scheduled, to reduce the threshold to contact their 
dermatologist. In addition, initiating an appointment makes some patients feel like a 
nag. In terms of content of the follow-up visits, these patients indicated they would 
like to receive a full body skin examination (FBSE) during the follow-up visit. They find 
it hard to self-examine their skin and FBSEs performed by dermatologists gives them 
more confidence about their skin.
However, some patients indicated they find follow-up care not necessary. As a result 
of the very low chance of a BCC to metastasize, they believe self-examination of their 
skin is sufficient. They stated that regular follow-up visits should not be imposed to 
patients and are not worth the associated costs (box 6).
box 5. Illustrative quote on the force of habit
“And that’s not unwillingness, but it’s just that it’s the same when you have been eating broccoli on your 
birthday for years and then if you suddenly can’t eat broccoli you are deeply sad. That’s just in your system.”
- Dermatologist 13
box 6. Illustrative quotes on varying needs with regard to regularity of follow-up care and skin 
examination
“They have indeed said that whenever there’s something please come back, but yes, when is there something? I 
feel like there is always something, so then what’s... then you could say once a year, yes, well, then rather once 
every six months, but maybe even once a month actually. You know, for me it’s never often enough.”
- Patient focus group 1
“That eh skin cancer really is something that doesn’t proliferate so much, so then I think, I think yeah (...) then 
[follow-up] is not really necessary I think. Then I’ll keep a bit of a close eye on it myself.”
- Patient focus group 2
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Overall preference for a dermatologist to perform the follow-up visits
Patients in a secondary care setting overall prefer a dermatologist to perform follow-up 
visits because of their specialisation, whereas they consider the GP to be a general-
ist. As a result, patients have more confidence in dermatologists and also believe that 
dermatologists take them more seriously than GPs.
However, some patients stated that follow-up visits may also be performed by GPs 
as long as they have received appropriate skin cancer education, know their limits and 
refer to dermatologists when needed. In addition, some patients reported to prefer the 
GP to perform the follow-up visits. They mentioned that GPs are closer to home and 
more accessible than dermatologists (Box 7).
Need for improved written information provision
In general, patients reported to be satisfied with the information on skin cancer and 
self-examination as received - mostly orally - from the dermatologist. However, patients 
indicated a need to receive more written hand-outs information about skin cancer and 
self-examination, as they find it hard to remember everything the dermatologist has 
said during consultation. They also indicated that it may be useful to provide pictures of 
skin cancer on hand-outs to improve the instructions on self-examination. They prefer 
to receive specific information from dermatologists rather than having to search the 
internet themselves for more information, as this often scares them (box 8).
box 7. Illustrative quotes on the overall preference for the dermatologist to perform the follow-up 
visits
“I really don’t question the qualities of my general practitioner, but I think it’s a bit safer here, more professional 
as well of course. With a general practitioner, yes, if he’d had a refresher course it would be different.”
- Patient focus group 3
“What I just said, that they see me coming at dermatology every time like there she is again with her spots, but 
then the general practitioner is a bit more accessible”
- Patient focus group 1
box 8. Illustrative quotes on the improvements for information provision
“That there are also pictures included, that there are several of them. Looking at what it looks like when it’s calm 
and when it eh, yeah, gets malicious, what, what, what are the differences? The skin around it, does it get red, 
does it get white, does it contract, how does that that birthmark develop, that, that, that kind of stuff. You read it 
sometimes but then you think oh, you know, I don’t have it so, eh, don’t look at it any more. But if you do have it 
that you can check back and then you think God, have to be alert eh...”
- Patient focus group 2
“You’re also going to Google for yourself like is it, eh, yeah, and whether you run a risk that it can spread for 
example. Well that has been confirmed hasn’t it, that it’s rare in any case, but even that has lingered somewhat 
with me; is it never or is it rarely? It has been a bit of a thing.”
- Patient focus group 1
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Suggested strategies to de-adopt low-value follow-up care by 
dermatologists
Four types of strategies suggested by dermatologists emerged from the data to de-
adopt low-value follow-up care.
Educating patients with improved information
According to dermatologists, explaining to patients that follow-up care is not needed 
and explaining how to self-examine their skin, will reduce their anxiety and need for 
follow-up care. Dermatologists suggested that this could be achieved by expanding 
information and explanation to patients during consultation. Improved hand-outs for 
patients with more information about skin cancer and self-examination was reported to 
make it easier for them to discharge patients from follow-up (Box 9).
Educating GPs to increase trust of dermatologists and patients
Educating GPs in skin cancer care was also suggested as a strategy by dermatologists 
to facilitate the de-adoption of low-value follow-up care. Increasing the trust of both 
dermatologists and patients in GPs will ease discharging patients from follow-up. 
Dermatologists reported that, in particular, the diagnostic accuracy of the GPs should 
be improved. For example, by taking more biopsies in order to learn from the histology 
report. They also mentioned that GPs should work more like a dermatologist, by always 
performing a FBSE and by using dermoscopy (Box 10).
box 9. Illustrative quotes on educating patients with improved information
“Well, here also I think make more, eh, patients aware of eh, ehm, of what a basal cell carcinoma can look like, so 
that they can recognise it faster, say. Then you have, so that you don’t need to check too often out of fear.”
- Dermatologist 14
“I think a nice hand-out would be handy because I think that many people, if you just have a good hand-out with 
which people can be discharged, then it is also much easier to discharge people.”
- Dermatologist 9
box 10. Illustrative quotes on educating GPs to increase trust of dermatologists
“I think that GPs should have a lower threshold to perform biopsies, because when you perform a biopsy you 
also learn from that, right, you have a suspicion of a spot and you get a result so then you know am I okay or not, 
so I think that, I think that that’s one of the most important, maybe even more than skills.”
- Dermatologist 4
“Well there’s a lot of discussion about dermatoscopy in primary healthcare, eh, I think that, say, dermatoscopy, 
say, not so much for melanoma, but for skin cancers is helping the GP. I also think that the GP, eh, well, ehm, 





Realising appropriate financial compensation and consult times
Realising appropriate financial compensation and consult times was also suggested 
as a strategy to de-adopt follow-up care. One way to realise this, as indicated by der-
matologists, is to increase the time of the consult for high-risk oncology patients in 
dermatology. Currently, dermatologists generally have ten minutes per patient, without 
discriminating between low-risk and complex oncology patients. As a result, they cur-
rently use the leftover time of low-risk oncology patients for more complex patents. 
By increasing planned consultation time for complex oncology patients, the quality of 
care for complex patients can be maintained, making it more attractive to de-adopt the 
low-risk low-value care.
Dermatologists also mentioned to tackle financial incentives by penalising derma-
tologists who provide low-value care, for example by only reimbursing high-value care 
and not covering for the low-value follow-up visits. In addition, using a macro budget 
(i.e. budget restriction on national healthcare expenditure23) was suggested as an op-
tion to overcome this problem (Box 11).
Informing dermatologists on the low-value of follow-up care
Providing dermatologists with adequate information and convincing them about the 
low-value of follow-up visits, was also suggested as a strategy to de-adopt this care. 
This way unfounded fears regarding the risks of discharging patients from follow-up 
could be eliminated. According to dermatologists, this could be achieved by increasing 
awareness among dermatologists about the current BCC guidelines, which restricts 
follow-up care to high-risk patients. It was also proposed to visualise the (low) risks of 
de-adopting this care for patients on a piece of paper. In addition, the costs associated 
with providing this care on a yearly basis could be added (Box 12).
A complete overview of all illustrative quotations for each theme, including additional 
quotations, can be found in Appendix B.
box 11. Illustrative quotes on realising appropriate financial compensation and consult times
“If for example patients go to the GP more often, perhaps the time for the complex dermato-oncological patient 
should, perhaps they should also get more time, so that they are better looked at, and that it in any case doesn’t 
lead to losses...”
- Dermatologist 9
“It is like if you run a red light and you don’t get a ticket you keep running red lights, and if you are not punished 
for it, you just keep doing your own thing.”
- Dermatologist 13
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DISCuSSION
The current study has identified factors contributing to low-value follow-up care by 
dermatologists after low-risk BCC and suggested strategies for de-adoption. In addition, 
the views of patients regarding follow-up care were explored.
Consistent with previous studies, complying with patient preferences was reported 
as a main reason to provide low-value follow-up care.24-26 In an US study, 51% of physi-
cians reported to order unnecessary tests to keep the patient happy or because the 
patient insists on getting it.27 As for patients in our study, we found that part of them 
indeed preferred receiving periodic follow-up care, mainly to reduce their anxiety. 
Some patients, however, indicated to find periodic follow-up care unnecessary. Educat-
ing patients has been proven to be useful,28 as it may reduce patients’ anxiety, and, as 
a consequence, their need for periodic follow-up.29,30 A recent review on BCC care em-
phasises the importance of counselling patients about self-screening.31 Providing more, 
and preferably written, information to patients therefore seems a useful and feasible 
strategy to de-adopt low-value follow-up care. Since this strategy was suggested by 
both dermatologists and BCC patients, the likelihood of success of such an intervention 
increases.32,33
A lack of trust in GPs to adequately identify suspicious lesions was also identified by 
dermatologists as a reason to provide low-value follow-up care to BCC patients. Even 
though follow-up care is to be de-adopted and not to be substituted by GPs, a lack of 
trust in GPs of both dermatologists and patients plays an important role, as the GP will 
be the first healthcare provider of contact for the patient after being discharged. Trust 
has been found to be an important factor not only between patients and physicians, 
but also between GPs and specialists, as higher trustworthiness improves the commu-
nication between physicians.34-36 Improving GPs’ education in skin cancer may increase 
the level of trust between physicians, and that of patients, and may therefore reduce 
the perceived need to keep patients under dermatological follow-up.37 A first step to 
box 12. Illustrative quotes on informing dermatologists on the low-value of follow-up care
“Yes, then they just have to follow the guideline better, more familiarity with the guidelines, so they follow the 
guideline, in principle yes.”
- Dermatologist 14
“Yes, they should actually know that, of course. Look, every dermatologist always wrestles with yes, thirty, forty 
percent chance that a second one develops, but yes, also a sixty, seventy percent chance of it not. And baso is not 
generally a serious tumour, and usually very easy to see.”
- Dermatologist 18
“Do you know what also really works, very simple, give them a paper and show them what it means for the costs 
of the healthcare if you see someone every three months and make it visual with a little pie chart or with a, you 




improve skin cancer knowledge of GPs is to improve the exposure to dermatology in 
the medical curriculum, as this is currently underexposed in the Netherlands, but also 
internationally.38-41 However, it is also important to note that specialists and patients 
in secondary care are more likely to be negatively biased towards GPs due to selection 
bias. In addition, it could be argued that dermatologists should support the position of 
GPs towards patients to increase the level of trust between patients and their GPs.
The Dutch BCC guideline changed its recommendation in 2007; from providing follow-
up care to all BCC patients for at least five years, to restricting follow-up to high-risk BCC 
patients.42,43 Although over ten years have passed since this adjustment, dermatologists 
still indicated providing follow-up care to be a force of habit, particularly for older 
dermatologists. In line with this, physicians who have been in practise longer are found 
to be at risk for decreased guideline adherence and providing lower-quality care.44,45 
Also, it is known that implementation of changes in practise can take many years, and 
de-adoption processes take even longer.46-49 Merely giving the care time to change 
may therefore by itself be effective in diminishing this low-value care, particularly as 
new dermatology residents are adopting current guidelines. To accelerate this process, 
interventions such as new funding models which promote behavioural change could be 
useful.50,51
Finally, in accordance with previous studies, dermatologists also stated to be influ-
enced by reimbursements.52-54 In order to reduce ineffective care, macro-level financial 
strategies enacted by the government or national institutes may be appropriate.55 A 
particular effective option could be to increase compensation for the first consult after 
treatment while lowering compensation for additional follow-up visits. The benefits 
of this differential compensation are: (1) dermatologists have more time in the initial 
consult after treatment to provide patients with adequate information; (2) financial 
incentives to provide low-value follow-up care are removed and; (3) do not negatively 
influence the financial state of the partnership or department. This financial interven-
tion is worth considering because changes to policy and/or funding models are among 
the most successful interventions in de-adoption.32,52,56
A strength of this study is that we explored factors influencing current low-value BCC 
follow-up care as well as strategies to de-adopt this care from the perspectives of the 
stakeholders. Interventions are commonly created on the basis of theory and evidence, 
and in practise often depend on the experiences and preferences of researchers.57,58 As 
acceptance of the target group is an essential step for initiating change,32,33 integrating 
the preferences of the stakeholders in an intervention is likely to improve the success of 
an intervention.58 In addition, by conducting a comprehensive qualitative study which 
also includes the perspective of patients, we were able to gain a more complete over-
view of both contributing factors and strategies which have the highest potential to be 
effective in the de-adoption process. The used methodology can be used as an example 
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for studies aimed at reducing low-value care concerning other medical conditions. 
Moreover, the results of this study may be used in other countries dealing with a high 
incidence of BCCs and pressure on their healthcare system. This may particularly apply 
to countries with a GP gatekeeper system or fee-for-service reimbursement systems, 
such as most western countries.59,60
A limitation of this study is that we only invited patients treated by dermatologists to 
participate in our focus groups. Although the focus of our study was on the key stake-
holders in the de-adoption process (i.e. the dermatologists and the patients treated 
by dermatologists), future studies could also include the views of GPs and of patients 
solely treated by GPs. In contrast to a previous study with high-risk BCC patients,61 some 
low-risk BCC patients in the current study actually preferred the GP as opposed to the 
dermatologist as the GP is closer to home and easier accessible. Gaining insight in this 
subgroup of patients who trusts the GP could provide valuable information to further 
facilitate the de-adoption process.
In conclusion, this study provides insight into current practices regarding low-risk BCC 
follow-up regimens through the eyes of dermatologists and patients, and offers sugges-
tions to de-adopt this low-value care. It shows that the needs of patients and complying 
with them, a lack of trust in GPs and financial incentives are mainly responsible and that 
educating patients and GPs as well as realising appropriate financial compensation are 
suggested to be particularly effective in de-adopting the low value follow-up care. The 
effect of one strategy, educating low-risk BCC patients with improved patient informa-
tion containing personalised information, is currently being tested.62 This and the other 
proposed strategies may be implemented at a larger scale in the future to stimulate the 
de-adoption of low-value follow-up care after low-risk BCC.
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Introduction To provide patient-centered care, it is essential to explore what patients 
consider important and to adjust care accordingly. This may specifically be relevant for 
patients with complex skin cancer, for whom the care process is often more complicated 
and psychological and social problems may play a larger role.
Objectives to explore the experiences and needs of patients who had undergone 
surgical treatment by a dermatologist for a complex skin cancer with a subsequent 
reconstruction by a plastic surgeon.
Methods An interview study was conducted among 16 patients who had undergone 
surgical treatment by a dermatologist and reconstruction by a plastic surgeon for basal 
cell carcinoma, cutaneous squamous cell carcinoma, or lentigo maligna. The interviews 
focused on patients’ experiences and needs regarding care using a predefined topic list. 
All interviews were audio-taped, transcribed verbatim and inductively analyzed using 
Atlas.ti.
Results Patients reported a need for a skilled and friendly physician who tailors infor-
mation and communication to their individual situation. A need for continuity of care 
and improved collaboration between healthcare providers was also emphasized. Fur-
thermore, patients experienced complications and unmet expectations and expressed 
a need for shared decision-making at various steps throughout the treatment process 
(depending on age). Patients also considered completeness of tumor removal, follow-
up visits with multiple specialists to be planned the same day and recognition of the 
psychological impact of the disease on the partner important.
Conclusions To improve patient-centered care for complex skin cancer patients, more 
efforts should be directed towards improving continuity of care and collaboration. 
Furthermore, it is advocated for physicians to be sensitive to the individual needs of 
patients and their partner and adjust information, communication and (supportive) care 
accordingly.
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INTRODuCTION
Basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (cSCC) and lentigo 
maligna (LM) are among the most frequent (pre)malignancies of the skin, with increas-
ing incidence worldwide.1-3 BCC and cSCC are subtypes of non-melanoma skin cancer 
and LM is considered a precursor of LM melanoma.3,4 The main treatment modality of 
loco(regional) skin cancer is surgery, which in most cases is performed by dermatolo-
gists.5-8
In patients with complex skin cancer, the lesion is usually located at the scalp or face, 
making it challenging to remove and reconstruct due to size, location and/or depth.9,10 
This group predominantly consists of elderly patients with large tumors, but also in-
cludes younger patients with smaller tumors, located at areas where cosmetic outcome 
is an important factor, such as the nose. Irregularities or disfigurements after skin cancer 
treatment may therefore lead to social and psychologic problems.11,12
Aside from being more prone to social and psychologic problems, complex skin 
cancer patients are usually treated by a multidisciplinary team of dermatologists, plas-
tic surgeons, and radiation oncologists as part of a step-by-step process. The patient 
(preferences) and the lesion must first be assessed to assure that surgery is the best 
treatment.13 If surgery is the preferred option, the specific method is chosen depending 
on the type and size of the lesion.13 Usually, dermatologists remove the tumor with 
Mohs micrographic surgery (MMS) in case of BCC or cSSC or by means of a staged micro-
graphic surgery technique (Breuninger) in case of LM.13-17 Subsequent reconstructions 
may be more challenging, requiring the expertise of a plastic surgeon.13 In addition, 
some patients require adjuvant radiotherapy. This step-by-step process, involving 
multiple healthcare providers, may complicate the care process for this patient group.
High-quality care should ideally be tailored to the needs of individual patients (i.e. 
patient-centered care).18,19 A qualitative systematic review focusing on the needs 
and experiences of skin cancer patients revealed the scarcity of qualitative studies 
regarding this subject.20 Existing literature on patients with complex skin cancer has 
predominantly focused on surgical techniques.21,22 Knowledge about complex skin 
cancer patients’ experiences and needs regarding their care is currently lacking.
The aim of the current study was to explore the experiences and needs of patients 
who had undergone surgical treatment by a dermatologist for BCC, cSCC or LM with a 
subsequent reconstruction by a plastic surgeon. The results of this study can be used 
as input to facilitate patient-centered care for complex skin cancer patients by tailoring 





A qualitative interview study among complex skin cancer patients was conducted. 
Qualitative research is most suitable for gaining an in-depth understanding of patients’ 
experiences and needs.23,24 Individual interviews rather than focus groups were used 
because the average age of complex skin cancer patients is high and some of them were 
affected by disabling hearing impairment. In addition, for some patients skin cancer is 
a sensitive subject, which might prevent them from speaking freely about their disease 
in focus groups.25
Study setting
The study took place at Erasmus MC in Rotterdam, the Netherlands. This is an academic 
tertiary referral center for skin cancer patients and among the largest MMS centers in 
Europe with approximately 1,700 MMS procedures annually. Approximately 10% of 
patients treated with MMS require reconstruction by a plastic surgeon, usually under 
general anesthesia. Therefore, a special outpatient clinic is present at this center for 
patients who need to be evaluated by both a dermatologist and plastic surgeon.
Study sample
Electronic patient files were screened to select patients older than 18 years who had 
been to the special outpatient clinic mentioned above. We consecutively included pa-
tients who underwent surgical treatment within the preceding year by a dermatologist, 
followed by a reconstruction by a plastic surgeon for a BCC, cSCC or LM. Patients were 
excluded if they had other types of skin malignancies or if they were not able to speak 
Dutch. Data regarding gender, age, skin cancer type and location, type of treatment and 
method of reconstruction were collected from the electronic patient files.
Eligible patients were sent a letter containing study information and an invitation 
to participate in a 30-minute interview directly before or after their already planned 
follow-up consultation. If there was no more consultation planned, patients were asked 
to be interviewed by phone. After two weeks, a reminder was sent. If another person 
was present during the consultation (e.g. caretaker or partner), this person was also 
invited to join the interview to include their perspective.
We used purposive sampling, i.e. we explicitly selected information-rich cases to 
answer our research question by including a variable sample of patients in terms of sex, 
age and diagnosis.26 Participant recruitment ended after data saturation was reached, 
which was the case when there were no new code (groups) created.
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Data collection
Sixteen interviews were held; 13 were conducted face-to-face and three by telephone. 
A topic guide, based on previous research of the authors, expert opinion and information 
derived from the literature, was used to structure the interviews (see appendix A).27-30
The first three interviews were conducted by two researchers (M.H. and S.v.E), the 
remaining interviews were held by one (M.H.). The interviewers were not involved in 
the medical care of the interviewed patients. Interviews started with the explanation 
that everything would be analyzed anonymously and stimulated free expression of 
opinions. All sessions were audiotaped, transcribed verbatim and anonymized.
Data analysis
An inductive approach to data analysis was used allowing meaning to emerge from 
the data, rather than from pre-determined categories.31 Two researchers (S.v.E. and 
M.H.) independently openly coded the first four transcripts, by using the qualitative 
data analysis software ATLAS.ti (Version 8).32 These codes were discussed with a third 
researcher (M.L.) and adjusted if necessary, which resulted in a preliminary coding 
scheme. Next, all transcripts were coded using this coding scheme by one researcher 
(M.H. or S.v.E), then checked by the other.
Interpretive and iterative constant comparison followed the initial coding phase, in 
which different codes were compared and the relationship between codes was explored 
to detect emerging themes. The overall analytical process resulted in the identification 
of main themes and sub-themes regarding the experiences and needs of patients with 
complex skin cancer.
Ethical considerations
The medical ethics committee of Erasmus MC declared that the Medical Research In-
volving Human Subjects Act did not apply to the present study (MEC-2018-1677). All 
participants provided written informed consent and participation was voluntarily. This 
study has been designed and is reported in accordance with the SRQR (Standards for 
Reporting Qualitative Research) recommendations. 33
RESuLTS
Patient characteristics
The median age of the participants (7 women and 9 men) was 71.5 years (range 47-87). 
Six patients were diagnosed with BCC, five with cSCC and five with LM. Further tumor 
and treatment details are described in Table 1.
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Complex skin cancer patients’ experiences and needs
Based on the patient interviews, twelve sub-themes were identified on the experiences 
and needs of complex skin cancer patients (Figure 1).
1. Patients’ experiences and needs regarding healthcare providers
1.1  Need for a skilled and friendly physician who provides clear and honest 
information
Patients emphasized the importance of a physician who communicates clearly and 
provides honest information throughout the entire process of care (Table 2). In this way, 
they fully know where they stand and what to expect. They need to trust their physician 
and the provided information. In addition, they reported the importance of physicians 
to be skilled, but also to show compassion and to be friendly.
1.2  Need for a physician who tailors information and communication to individual 
patients
Patients expressed the importance of information and communication to be tailored 
to individual patients’ needs (Table 3). They suggested that physicians should ask each 
patient whether he/she needs more information and adjust the information provision 
Table 1. Characteristics of participating patients
Patient Age Sex Diagnosis Location Treatment Method of reconstruction Interview
1 87 Male LM Cheek Staged excision FTSG from supraclavicular Individual
2 71 Male cSCC Forehead Re-excision and ART Free skin grafted muscle flap With partner
3 87 Male cSCC Scalp Re-excision and ART Free skin grafted muscle flap With partner
4 65 Female BCC Nose MMS FTSG from preauricular Individual
5 78 Male cSCC Scalp MMS and ART Free skin grafted muscle flap Individual
6 73 Female cSCC Lower leg Staged excision SSG from upper leg Individual
7 47 Female cSCC Lower leg Staged excision SSG from upper leg Individual
8 67 Male LM Fifth digit of hand Staged excision FTSG from groin With partner
9 51 Female LM Nose Staged excision Local bilobed flap Individual
10 80 Male LM Vertex Staged excision Secondary intention* Individual
11 52 Male BCC Nose MMS FTSG from preauricular Individual
12 72 Male BCC Nose MMS Local hatchet flap With partner
13 64 Female BCC Nose MMS Paramedian Forehead Flap Individual
14 78 Female BCC Nose MMS FTSG from groin Individual
15 55 Female LM Nose Staged excision FTSG from preauricular Individual
16 72 Male BCC Cheek MMS Local advancement flap With partner
ART, adjuvant radiotherapy; MMS, Mohs micrographic surgery; LM, lentigo maligna; cSCC, cutane-
ous squamous cell carcinoma; BCC, basal cell carcinoma; FTSG, Full-thickness skin graft; SSG, Split-
thickness Skin Graft
*Was initially planned for SSG and tissue expander, but reconstruction was postponed.
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accordingly. Furthermore, patients indicated that physicians should adjust their expla-
nation to the particular patient to make sure every patient understands.
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figure 1. Overview of identified themes and sub-themes on the experiences and needs of complex 
skin cancer patient
Table 2. Illustrative quotes on need for a skilled and friendly physician who provides clear and 
honest information
“And be honest, don’t make it worse, don’t make it less serious. Just say it as it is.”
– Patient 11 (52-year-old male)
“The kindness of the people, of the physicians [is most important]. And their expertise”
– Patient 14 (78-year-old female)
Table 3: Illustrative quotes on need for a physician who tailors information and communication to 
individual patients
“But I wasn’t asked whether I needed more information. (...) It’s never a bad thing to hear that”
 – Patient 15 (55-year-old female)
“That they explain things in a clear, understandable way to the patient. Sometimes they are talking to clinicians 
and other occasions, with all due respect, they are talking to pavers. They must explain things clearly to both of 
them and that is a matter of choosing the right words.”
 – Patient 11 (52-year-old male)
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1.3  Need for continuity of care and preference for a specialist
Patients generally expressed the need to be seen by the same physician during diagno-
sis, treatment and follow-up visits (Table 4). This ensures them that their physician has 
all relevant information and also strengthens the bond with their physician. In addition, 
patients reported to prefer to be treated by a specialist instead of a physician assistant 
(PA), because they feel he/she is the expert. Patients particularly wished to be treated 
by a skilled expert, as their skin cancer is often located in the face and they wanted it to 
be done neatly. Nevertheless, patients generally stated it to be acceptable if PAs would 
provide information and explain things about the treatment process.
1.4  Need for improved collaboration between healthcare providers
Patients expressed the need for improved collaboration between healthcare providers 
and between hospitals (Table 5). They noticed that healthcare providers sometimes 
communicate past each other and are not aware of important information. They indi-
cated to sometimes receive wrong information due to miscommunication, such as a 
wrong dismissal date. A national electronic patient file for all hospitals was suggested 
to improve communication.
2. Patients’ experiences and needs regarding the care process
2.1  Varying needs on improved information provision
Whereas many patients indicated to be satisfied with the information they received, 
a need for improved information was also often reported (Table 6). This applied to all 
phases of the care process. Some patients indicated that they received hand-outs in ad-
dition to oral information and some patients were also shown pictures of other complex 
skin cancer patients. These pictures were regarded as informative by some patients, 
Table 4. Illustrative quotes on need for continuity of care and preference for a specialist
“You know what also disappointed me, it suddenly comes to mind, I think we drove to Rotterdam about seven 
times and every time I was seen by another person. Instead of one physician who would treat me. At a certain 
point you have a bond with someone and then suddenly you are seen by someone else.”
 – Patient 8 (67-year-old male)
“I really wanted the specialist to do that. (...) That it really had to be done by the specialist himself because after 
all it is my face.”
 – Patient 15 (55-year-old female)
Table 5. Illustrative quotes on need for improved collaboration between healthcare providers
“That things get mixed up now and then (...) Yes, this is not necessarily just about me… I notice this in general. 
They [dermatologist and plastic surgeon] also say that about each other. That things do not go smoothly.”
 – Patient 7 (47-year-old female)
“Well there was some confusion because the plastic surgeon said that I could go home after I had been treated, 
but the nurse on the ward said that I had to stay overnight.”
 – Partner of patient 8 (Partner of 67-year-old male)
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whereas others preferred not to see them and reported that physicians should at least 
warn patients beforehand. Patients often searched the internet for additional informa-
tion themselves, but as this was sometimes experienced as shocking, they generally 
preferred to receive clear information on hand-outs from physicians. Overall, patients 
emphasized the importance of written information besides oral information, because 
they were not able to remember all information provided during consultation. This was 
specifically the case for follow-up care.
2.2  No choice in treatment type, but a need for shared decision-making, depending 
on age
Overall, patients mentioned that they were not given a choice in treatment (Table 7). 
They did not consider this as a problem, because they fully trusted the physician in 
choosing the best treatment. Some patients stated that they were told what would hap-
pen if their tumor would not be treated, but receiving no treatment was never a real 
option for patients: they came all the way from a general hospital to have their skin 
cancer removed. Some patients appreciated that they were able to decide on type of 
reconstruction and between local or general anesthesia.
Table 6. Illustrative quotes on varying needs on improved information provision
“Yes, that they ask if you want to see pictures and that they can be shocking. That they would warn you in 
advance. But I had already seen them and that was not a disaster in itself but if I were given the choice I would 
rather not have seen them”
 – Patient 4 (65-year-old female)
“I still Googled a bit at home but not too much because it doesn’t make you feel well.”
 – Patient 4 (65-year-old female)
“Yes, you leave and that’s it. Yes, the medical world knows more than a layman. Then you could put a resume on 
a piece of paper and pass it on. So you have something tangible.”
 – Patient 1 (87-year-old male)
“You know, I have had so many things, at a certain point I just let it happen.”
 – Patient 6 (73-year-old female)
Table 7. Illustrative quotes on no choice in treatment type, but a need for shared decision-making, 
depending on age
“With me it was actually the case that there was never any choice. It had to be removed and that was it”
 – Patient 7 (47-year-old female)
“That physicians mention a few options. I can imagine that old people don’t really like this, but I do like to hear 
them. So they can include me in their thoughts and decision-making. There might also be people who will just go 
along with things, but I am not like that.”
 – Patient 11 (52-year-old male)
“Yes, they are specialists, I am no expert so I don’t know. They told me that this would be the best solution. I just 
trust them, because of their experience.”
 – Patient 10 (80-year-old male)
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Specifically younger patients expressed the need to be involved in the decision-mak-
ing process and preferred to discuss treatment choices if available. They stressed the 
importance of being informed about all treatment options including the benefits and 
disadvantages. As such, they are able to make an informed decision together with their 
physician. On the contrary, older patients generally stated to fully trust their physician 
in making the decision, as he or she is the expert.
2.3  Complete tumor resection most important outcome
Patients indicated that they considered the complete removal of the tumor to be more 
important than the cosmetic outcome (Table 8). They reported to be scared of recur-
rence and therefore found it most important that it was completely removed, regardless 
of the scar size. Still, they preferred the scars to be as small as possible. They preferred 
surgery opposed to radiotherapy, because surgery confirms complete clearance of the 
tumor. Furthermore, patients expressed a preference for the skin cancer to be removed 
as quickly as possible to prevent it from growing further. Improvement of quality of life 
was also mentioned as an important outcome.
2.4  Varying experiences regarding continuity of care and type of healthcare 
provider
Patients reported various experiences regarding continuity of care during the entire 
care process (Table 9). Some patients were seen by the same healthcare provider every 
time, whereas others reported to have seen a different physician on each occasion. See-
ing multiple physicians made them feel that the physicians were not really involved in 
their care, even if they prepared the consultation well. Overall, patients reported to be 
satisfied with the received care by medical specialists. In general, patients did not like 
to be treated by PAs or residents instead of specialists, particularly if they had not given 
permission for this.
2.5  Complications and unmet expectations
Some patients mentioned that they had experienced complications such as bleeding, 
infections and pain (Table 10). They stated that their treatment went better than expect-
ed, but the time until full recovery was disappointing. After having been shown pictures 
Table 8. Illustrative quotes on complete tumor resection most important outcome
“Even though it won’t be perfectly beautiful, and it will never be. There is not much more to improve. I don’t 
really mind that spot and that scar, as long as I look a little presentable.”
 – Patient 12 (72-year-old male)
“Although the cancer might not be completely gone (…) my quality of life has indeed improved and that is 
important to me.”
 – Patient 13 (64-year-old female)
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of the expected result and receiving explanation of the expected scar size, patients still 
reported that their scar turned out larger than expected. It also bothered patients that 
their scar sometimes frightened other people. According to patients, improved informa-
tion and explanation beforehand could facilitate being properly prepared for potential 
complications.
2.6  Perceived adequate frequency of tailored follow-up visits
Patients generally reported to be satisfied with the frequency of the follow-up checks by 
their dermatologist and plastic surgeon (Table 11). Some patients expressed the need 
for an increase or decrease of the interval time between visits. Most patients, however, 
stated they could adjust the frequency according to their needs. Patients experienced 
the hospital to be easily accessible; if they noticed new lesions in between follow-up 
visits, they could come by right away. During follow-up visits they preferred a physician 
to perform a full body skin examination as they lack the expertise to self-examine their 
skin adequately.
Table 9. Illustrative quotes on varying experiences regarding continuity of care and type of health-
care provider
“I had two people at my bedside who were both physicians, but who didn’t have a clue what kind of patient they 
had in front of them”
 – Patient 2 (71-year-old male)
“Then you get a different one every week. Even a PA once, I had not given permission for her to do the procedure 
on me. And then I immediately said that I did not want that. (…) At one point, I had the same surgery assistants 
three times in a row. That’s really great.”
 – Patient 15 (55-year-old female)
Table 10. Illustrative quotes on complications and unmet expectations
“Yes, at first I thought it wouldn’t be too bad, but it takes a long time and I hope that this will only get better. 
Applying drops and ointment every day, that is quite challenging”
 – Patient 15 (55-year-old female)
Partner of patient: “Yes, it shocks people.”
Patient: “Recently we were visiting some people and the first thing they said is what is that and what have you 
done? That is of course not very pleasant.”
 – Patient 3 (87-year-old male)
Table 11. Illustrative quotes on perceived adequate frequency of tailored follow-up visits
“If I want to come more often, I’m able to do so (…) when I call I can come by immediately”
 – Patient 7 (47-year-old female)
“She said, and I agree with her, ‘I expect an active attitude from the patient, when you see spots yourself, you 
keep an eye on them’.”
 – Patient 11 (52-year-old male)
“Obviously, as a layman you can’t see whether there are any more bad spots that have not been removed.”
 – Patient 1 (87-year-old male)
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2.7  Need for follow-up care close to home and appointments at the same day
Patients who live far away from the hospital stated that they preferred to have follow-
up visits in a hospital closer to their home to minimize their traveling time (Table 12). 
Specifically elderly patients reported the need for hospital visits to be scheduled at 
the same day to decrease the number of hospital visits. They also mentioned to be 
bothered with the high parking costs which were accompanied by the follow-up visits.
2.8  Support for emotional impact of disease is adequate, but need for recognition 
impact on partner
Patients indicated the whole process to be intense (Table 13). Some patients reported 
they became more emotional and more ashamed because of the impact of the treatment 
and disappointing recovery and scars. Despite the emotional impact of the disease, 
patients indicated not to require psychological care, although this was offered to them. 
Instead, they preferred to talk to friends or their primary care physician about it.
Patients also expressed the need for recognition and attention of the impact of the 
disease on partners, as it may be difficult for them to cope with. For example, it might 
be easier for patients to accept the risks of high-risk surgery than for their partner. Pro-
viding more attention to partners of patients in the entire care process was therefore 
suggested.
Table 13. Illustrative quotes on support for emotional impact of disease is adequate, but need for 
recognition impact on partner
“I became much more emotional after the operation. I’ve never had that before. My kids also said, ‘I don’t really 
recognize my father like that’.”
 – Patient 2 (71-year-old male)
“No. I have my own network, both friends and colleagues and privately. So no, I didn’t feel the need to talk to 
someone else about it.”
 – Patient 11 (52-year-old male)
“It’s really difficult for the partners. People often forget about this. If you want another area for improvement: 
more attention for the partner”
 – patient 5 (78-year-old male)
Table 12. Illustrative quotes on need for follow-up care close to home and appointments at the 
same day
“I was actually referred back to [name hospital], but that was also my own choice because I thought they could 
check me there just as well.”
 – Patient 9 (51-year-old female)
“I don’t know, when she says you have to come then or then, I just come again. But yesterday we also visited two 
[specialists] and now I am here again. So preferably as many consecutive visits as possible.” (…) “Yesterday 6.5 
euros [parking costs], last week again 6.5 euros. We are only old age pensioners.”
 – Patient 2 (71-year-old male)
83
Experiences and needs of complex skin cancer patients
3.3
DISCuSSION
This study focused on the experiences and needs of complex skin cancer patients, who 
had undergone surgical treatment by a dermatologist and subsequent reconstruction 
by a plastic surgeon, and revealed a range of themes which could be used as input to 
organize patient-centered care for this unique patient group.
Several needs regarding healthcare providers emerged which are reflected in pa-
tients’ experiences and needs regarding the entire care process. Consistent with various 
previous studies, both in- and outside the field of (skin)cancer, patients emphasized 
the importance of a friendly physician who provides clear and honest information.34-39 
Particularly the need for clear information seems a profound need among patients. 
Although patients in our study were generally satisfied with the provided information, 
the need for improved information (provision) reflects through all phases of the care 
process. They suggested to provide more comprehensive written information, which 
is currently being implemented in our department. Aside from receiving clear and 
honest information, the need for physicians to tailor information and communication 
to individual patients was identified. To enhance patient-centered care, it is therefore 
advocated to improve information provision and to adapt it to individual patients. This 
could be achieved by improving communication skills (e.g., increased focus on shared 
decision-making) in the medical curriculum and by using tools such as question prompt 
lists or patient-reported outcome measures.40-42
Complex skin cancer patients also expressed the need for continuity of care and 
improved collaboration between healthcare providers. A need for continuity of care, de-
fined as a continuous caring relationship with a healthcare provider, was also identified 
in qualitative studies focusing on (non-complex) skin cancer patients.27,43 According to 
patients, this strengthens the bond with their physician. Continuity of care is associated 
with various positive outcomes including decreased chance of hospitalization, costs 
reduction and improved compliance with medical regimes.44-47 The need for optimal 
collaboration between healthcare providers, may not be surprising as their care process 
is a complex step-by-step process, involving multiple healthcare providers. According to 
patients this process could be improved, as they experienced that healthcare providers 
sometimes communicate past each other. Related to this, patients indicated to prefer 
multiple follow-up visits of different medical specialties to be planned on the same day, 
which also demands effective collaboration between medical departments.
With respect to experiences and needs regarding the care process, complex skin cancer 
patients had different needs regarding shared decision-making. Especially younger pa-
tients preferred to be involved in treatment decisions. On the contrary, elderly patients 
preferred the physician to make the decision for them, as they believed the physician 
is the expert. This is consistent with previous studies indicating older patients are less 
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likely to participate in shared decision-making.48,49 Being able to adjust the frequency 
of follow-up visits to a patient’s own needs was also experienced positively by patients 
and probably contributes to their satisfaction with the frequency of follow-up visits. 
Furthermore, patients recognized the high emotional impact of the disease. Whereas 
they considered their own received support as adequate, they emphasized the need 
for recognition of the impact of the disease for their partner. It is therefore advocated 
for physicians to be sensitive to the needs for psychological support of both patients 
and their partners, as partners are known to be an essential source of social support 
for patients.50 Improved collaboration between healthcare providers of different disci-
plines, such as medical specialists, social workers and psychologists, has demonstrated 
to facilitate the identification of unmet physical and psychosocial needs.11,12,51
Although cosmetic outcome is also important, the most important aspect for complex 
skin cancer patients is that the tumor is completely removed. However, patients also 
reported complications and unmet expectations. Even after seeing pictures before the 
surgery, patients did not expect the size of the facial scars to be that large. Previous re-
search already has revealed a gap in the communication between surgeons and patients 
about the expectations of scarring due to surgery.52 Discrepancies in expectations could 
be addressed in guidelines to educate surgeons on the impact of (even minor) facial 
scars to patients.52 It also, once more, emphasizes the importance of improved informa-
tion and communication.
Results of this study imply that in order to improve patient-centered care for complex 
skin cancer patients, information, communication, as well as wider care aspects should 
be tailored to individual patients and their partner. This is in line with recent trends of 
individualizing care based on the individual needs of patients. Besides improving infor-
mation and communication skills of physicians, shared decision-making tools (decision 
aids) can be used in the care process.53,54 In addition, healthcare applications (apps) may 
be used to stimulate personalized information provision for patients. As far as these 
apps are integrated within the care pathways, they may also facilitate personalized 
(follow-up) care and improve coordination between healthcare providers.55,56 Several 
studies have shown that patient centered or personalized care improves patient experi-
ences and outcomes.57,58
A limitation of this study was that we only interviewed patients of one academic 
hospital. Although qualitative research is always context specific,59 the generalizability 
of our findings increases as we reached maximum variation in our sample of patients in 
terms of relevant characteristics (e.g. age, sex and diagnosis). A strength of our study is 
that our qualitative study, using a thorough methodology, to our knowledge is the first 
study providing an in-depth understanding of the experiences and needs of patients 
with complex skin cancer.
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In conclusion, the current study provides insight into the experiences and needs of 
complex skin cancer patients and provides suggestions to improve patient-centered 
care. Continuity of care and improved collaboration between heath care providers is 
essential for this group of patients. Furthermore, given the differences in experiences 
and needs within these patients, it is advocated for physicians to be sensitive to the 
individual needs of patients and adapt their information, communication and care ac-
cordingly. This should not be limited to the walls of the hospital, but also include the 
wider context, for instance by also focusing on interdisciplinary collaborations and by 
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Dear editor,
Basal cell carcinoma (BCC) is the most common type of (skin)cancer worldwide in Cau-
casians and its incidence is still rising.1 The high incidence of basal cell carcinoma (BCC) 
causes substantial burden on healthcare systems. This demands resources to be used 
efficiently, depending on the healthcare system, for example by de-adopting low-value 
care or substituting low-risk skin cancer care to primary care2,3 Aside from being ef-
ficient, care should be tailored to the needs and values of patients (i.e. patient-centred 
care).4 Insight into the patient perspective is therefore crucial.
Previous qualitative studies among patients with BCC revealed that they prefer a 
physician who takes them seriously and communicates well, to receive all relevant 
information including a proper explanation, and to be seen by the same physician each 
time.2,5 In addition, they value several disease-specific factors such as a short waiting 
period for the best available treatment and regular follow-up care including a full body 
skin examination in order to reduce their fear and to detect new tumours early.2,5
Although an overview of the needs of patients with BCC is informative, qualitative 
research does not allow us to draw conclusions on the relative importance of each of 
these factors to patients. For dermatologists to be able to effectively tailor their follow-
up care to the needs and preferences of patients, it is useful to assess which factors are 
considered most important to them. The aim of this study was therefore to determine 
the relative importance of factors regarding follow-up care to patients with BCC.
A ranking list questionnaire was developed (see eSupplement), based on the needs of 
patients elicited from previous qualitative studies.2,5 The list consisted of five items re-
garding the patient-physician relationship, five disease-specific items and two external 
items (Table 1). One hundred and one consecutive BCC patients from the department of 
Dermatology Erasmus Medical Center (Rotterdam, The Netherlands) were asked to par-
ticipate following their outpatient clinic visit with a physician for their BCC (diagnostic 
or follow-up visit). After providing written informed consent, participants ranked the 
items from 1 (most important) to 12 (least important). The items were subsequently 
aggregated to include patient-physician relationship factors (items 1,2,4,5,7), disease-
specific factors (items 3,6,8,9,10) and external factors (items 11,12). To test the differ-
ences between groups of factors, the Wilcoxon signed-rank test was used in SPSS v24. 
The highest ranked group of factors was compared to the second highest group and 
the second highest group was tested for statistically significant difference to the third 
group. A p-value <0.05 was considered statistically significant.
All of the 101 approached BCC patients completed the questionnaire (100% re-
sponse rate). About one-third of patients were diagnosed with BCC for the first time, the 
median age was 66 years and 56% were female. They scored patient-physician related 
factors as most important, with ‘explanation of the seriousness of the skin cancer’ as the 
most important factor regarding BCC care (Table 1). The second most important factor 
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to patients is the ‘feeling that the physician listens well to the patient’. Patients ranked 
patient-physician related factors higher than disease-specific factors (p<0.001). Of the 
disease-specific factors they ranked ‘full skin examination during follow-up appoint-
ment’ and secondly ‘early detection of skin cancer’ as most important. The external 
factors (costs and travel time) were considered least important (compared to disease-
specific factors; p<0.001).
Whereas physicians traditionally tend to focus on disease-oriented aspects and 
outcomes,6 this study highlights the importance of patient-centred aspects of care to 
BCC patients. Particularly explanation of the seriousness of the skin cancer and the 
feeling that the physician listens well were considered important to patients. This is 
consistent with previous studies showing that physicians’ interpersonal skills largely 
determine patient satisfaction.7 To facilitate physician-patient communication, training 




age (years) 68 (58-75)
Male 45%
Items*
1. Explanation of the seriousness of skin cancer 3 (2-5)
2. feeling that the physician listens well to the patient 4 (1-6)
3. full skin examination during follow-up appointment 4 (2-7)
4. being seen by the same physician 5 (2-9)
5. Explanation of the follow-up procedure and self-examination of the skin 5 (3-8)
6. Early detection of skin cancer 6 (3-10)
7. Type of care provider (DE, GP, NP) 7 (5-8)
8. Side effects of skin cancer treatment 7 (5-9)
9. frequency of follow-up screening interval 7 (5-9)
10. Duration of the follow-up appointment (5-20 minutes) 9 (6-10)
11. Costs of follow-up care 11 (9-12)
12. Travel costs and/or travel time 11 (10-12)
aggregated Items
Items regarding patient-physician relationship (1, 2, 4, 5, 7) 5 (3-6)
- Reference -
Items regarding disease-specific factors (3, 6, 8, 9, 10) 7 (5-7)
- Z-score compared to patient-physician relationship 4.5 (p<0.001)
Items regarding external factors (11, 12) 11 (9.5-11.5)
- Z-score compared to disease-specific factors 7.9 (p<0.001)
BCC, basal cell carcinoma; IQR, interquartile range; DE, dermatologists; GP, general practitioner; NP, 
nurse practitioners
*Items are ordered based on ranking score
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programmes for physicians which include active, practice-oriented strategies have been 
proven to be effective.8 Of the disease-specific factors, patients ranked a full body skin 
examination as most important followed by early detection of skin cancer. Although 
dermatologists perform routinely full body skin examinations more often than GPs and 
internists (81% versus 60% and 56% respectively), there is still room for improve-
ment.9
A limitation of the current study is that only patients from a single university medical 
centre were included. However, the patients characteristics of our sample correspond 
well to those of the average BCC patients, which Increases the generalisability of our 
results.
In conclusion, findings from this study emphasize the importance of integrating 
patient-physician relationship factors with traditional medically orientated aspects of 
BCC care. This is especially relevant because increased patient satisfaction results in 
increased compliance and subsequently improved health outcomes.10 Results of this 
study are currently used in a discrete choice experiment to determine which trade-offs 
stakeholders are willing to make to integrate these aspects in skin cancer care.
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background: Follow-up after low-risk basal cell carcinoma (BCC) is being provided 
more frequently than recommended by guidelines. To design an acceptable strategy 
to successfully reduce this ‘low-value’ care, it is important to obtain insights into the 
preferences of patients and dermatologists.
Objectives: To determine the preferences and needs of patients and dermatologists to 
reduce low-risk BCC follow-up care, and the trade-offs they are willing to make.
Methods: Eighty-four dermatologists and 266 BCC patients (21% and 72% response 
rates respectively) completed a discrete choice experiment. A panel latent class model 
was used for analysis.
Results: If the post-treatment visit was performed by the same person as treatment 
provider and a hand-out was provided to patients containing personalised information, 
the acceptance of having no additional follow-up visits (i.e. following the guidelines) 
would increase from 55% to 77% by patients. Female patients and older dermatolo-
gists, however, are less willing to accept the guidelines and prefer additional follow-up 
visits.
Limitations: The low response rate of dermatologists.
Conclusion: This discrete choice experiment revealed a feasible strategy to substan-
tially reduce costs, while maintaining quality of care, based on the preferences and 
needs of BCC patients, which is supported by dermatologists.
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INTRODuCTION
Basal cell carcinoma (BCC) is a subtype of keratinocyte cancer and the most common 
type of cancer among Caucasians.1 The probability that a BCC metastasizes or causes 
death is low, but BCCs can cause significant morbidity by local spread. Most BCCs are 
treated relatively simple by excision or even topical treatment for certain low-risk 
BCCs.2,3
The high and rising incidence of BCC puts healthcare systems under pressure.4 To 
manage finite resources, low-value care (i.e. care which provides no or little clinical 
benefit to patients) should be reduced.5 Current guidelines recommend to provide 
follow-up care to high-risk BCC patients, which implies that providing follow-up to low-
risk BCC patients (i.e. primary BCC, < 2 cm, located outside the H-zone, with a nodular 
or superficial subtype) is considered low-value care. Evidence is lacking that increased 
follow-up care leads to improved health outcomes.6,7 However, a recent study shows 
that Dutch dermatologists still provide low-value follow-up care to 83% of low-risk 
BCC patients.8
Qualitative interviews with dermatologists and focus groups with BCC patients 
revealed the factors influencing this low-value care, such as the wishes of patients 
to remain in dermatological follow-up and dermatologists complying with patients 
wishes.9,10 In order to design a successful strategy to de-adopt low-value BCC follow-up 
care, it is important to learn how important each of these factors are to the patients and 
dermatologists. Therefore, this study aimed to quantify the preferences of BCC patients 
and dermatologists, and to determine which trade-offs they are willing to make to ac-




Dutch speaking patients, 18 years or older, presenting at the dermatologists with a lesion 
that was clinically suspicious of BCC or recent biopsy confirmed BCC were approached 
by their treating dermatologist to participate. These were patients from one university 
hospital (Erasmus MC), three general hospitals (Elisabeth-TweeSteden Hospital, Amphia 
Hospital, Bravis Hospital) and two independent sector treatment centres (DermaPark, 
Mohs Klinieken) in the Netherlands. Patients received an envelope containing infor-
mation about the study, an informed consent form, a questionnaire which included a 
Discrete Choice Experiment (DCE) and a pre-paid return envelope. All patients who 
agreed to participate returned a signed informed consent form to participate in the 
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current study, which was approved by the Medical Ethical Committee of the Erasmus MC 
(MEC-2014-374). Patients were excluded afterwards if the pathologist concluded that 
the lesion was not a BCC.
Dermatologists
All dermatologists and dermatology residents in the Netherlands (from here onward 
both mentioned as dermatologists) received an email with a digital link to the ques-
tionnaire containing the same DCE as the patients. Additionally, dermatologists were 
encouraged to complete the questionnaire during a national conference.
DCE: attributes and levels
The DCE concept originates from mathematical psychology, but has increasingly found 
its way into healthcare.11 A DCE repeatedly presents varying alternative situations 
to respondents and asks them to choose their most preferred alternative.12 The DCE 
method assumes that each alternative can be described by their characteristics (“at-
tributes”), that the respondent’s valuation of the alternative depends on the levels of 
these attributes, and that the choices are based on a latent utility function.13 In a DCE, 
preferences for health outcomes and non-health outcomes can be taken into account 
simultaneously.14 This makes the DCE an ideal method to measure preferences for as-
pects of low-risk BCC follow-up visits, and to determine how to reduce this care without 
trial-and-error-implementation.
In addition to a literature review,15-21 we constructed our DCE based on focus groups 
with BCC patients and interviews with dermatologists to carefully detect and select 
relevant attributes.9,10,13 This ultimately led to the final determination of six attributes 
(Table 1).
Study design and questionnaire
Based on the six attributes and their levels, many different choice alternatives and 
choice tasks can be generated. It is not feasible to present all possible combinations 
to a respondent without creating an unreasonably long questionnaire. In order to 
achieve maximum efficiency from the minimum amount of ‘choice tasks’ needed (i.e. 
to counterbalance statistical needs and the burden for the respondent), a D-efficient 
design was created using Ngene software (http://www.choice-metrics.com).22 We took 
two-way interactions between the attributes ‘The additional follow-up visit(s) will be 
planned’ and ‘The additional follow-up visit(s) will be conducted by’ into account, based 
on the outcomes of the qualitative study. We created a set of 24 choice tasks, which was 
blocked14 in two sets of twelve for BCC patients and a full set was presented to derma-
tologists, as we expected the sample size as well as the response rate of dermatologists 
to be smaller. Each choice task contained three alternatives: two alternatives containing 
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BCC follow-up schemes and one alternative to choose ‘no additional BCC follow-up’ (i.e. 
following the guideline)
In addition, to simulate real life choices as close as possible, the corresponding 
real-life costs of each follow-up scenario were shown. Each attribute was explained 
in the survey before the choice tasks were presented. To test choice consistency, an 
extra choice task 13 was included, which was identical to choice task 4. Demographic 
questions were added to the questionnaire. The questionnaire including the DCE was 
pilot tested using think-aloud technique on a random group of 22 BCC patients and ten 
dermatologists, where they could ask for clarification when needed and to test if the 
length was acceptable. The DCE was clear to these patients and dermatologists and did 
not lead to any changes.
Sample size
The results of the pilot were used to determine that 250 BCC patients were required 
to complete the DCE.23 By taking an expected response rate of 70% into account,24-26 
we invited 371 patients. As the response rate of physicians is notoriously low,27-29 we 
invited all dermatologists and dermatology residents (n=620) in the Netherlands.
Table 1. Attributes and levels of the discrete choice experiment on low-risk BCC follow-up care.
attributes attribute Levels
Standard post-treatment visit performed: Not by same person as treatment provider (Ref)
By the same person as treatment provider






The additional follow-up visit(s) will be planned: 1 year after treatment (Ref)
6 and 12 months after treatment2
1 and 2 years after treatment
The additional follow-up visit(s) will be conducted by: Nurse practitioner (Ref)
General practitioner
Dermatologist





Part of skin to be checked during the additional 
follow-up visits
Face, upper body and treated area (Ref)
Full body
Abbreviations: Ref, Attribute of reference
1Extra information about severity of disease, prognosis, further treatment and/or follow-up and 
self-examination instructions. Which could be general information, or personalised via E-health 
or personalised letter.




The analyses were conducted by using Stata 4.2 (http://www.stata.com) and NLOGIT 5.0 
(Econometric Software Inc.30). Each choice task was considered as one observation. To 
take the sample size, the fact that one respondent completed 12-24 choice tasks, the 
model fit and our interest in preference heterogeneity into account, a panel latent class 
analysis (LCA) was conducted for the final analyses. An LCA determines whether patterns 
in preferences (i.e. latent classes of preferences) exist and provides a modelled probability 
for each respondent to belong in a certain class.31 Demographic covariates retrieved from 
the questionnaire were linked to the probability that respondents belonged to a specific 
class, in order to determine the composition of the classes. Taking the smaller sample 
size of dermatologists into account, without demographic covariates that could be linked 
to specific classes, a more simplistic model (Multinomial logit with interaction terms of 
the demographic covariates with the attribute-levels) was conducted. We performed a 
sensitivity test by excluding respondents who failed the consistency test (i.e. choosing 
different alternatives on the identical choice tasks) from the analyses. After testing for 
two-way interactions and attribute linearity, the optimal latent class utility function was:
Scenario with additional follow-up visits:
𝑉𝑉𝑉𝑉(𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎1)𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛|𝑐𝑐𝑐𝑐 =  𝛽𝛽𝛽𝛽1|c same healthcare professionalnsj|c
+ 𝛽𝛽𝛽𝛽2|𝑐𝑐𝑐𝑐 additional information by personalised letternsj|c
+ 𝛽𝛽𝛽𝛽3|𝑐𝑐𝑐𝑐 additional information by general handoutnsj|c
+  𝛽𝛽𝛽𝛽4|𝑐𝑐𝑐𝑐  additional information by general websitensj|c                             
+  𝛽𝛽𝛽𝛽5|𝑐𝑐𝑐𝑐  additional followup at 6 and 12 months after treatmentnsj|c
+  𝛽𝛽𝛽𝛽6|𝑐𝑐𝑐𝑐  additional followup at 1 and 2 years after treatmentnsj|c
+  𝛽𝛽𝛽𝛽7|𝑐𝑐𝑐𝑐  additional followup conducted by general practitioner nsj|c
+ 𝛽𝛽𝛽𝛽8|𝑐𝑐𝑐𝑐 additional followup conducted by dermatologistnsj|c
+  𝛽𝛽𝛽𝛽9|𝑐𝑐𝑐𝑐  duration of additional followup visit 10 minutesnsj|c 
+  𝛽𝛽𝛽𝛽10|𝑐𝑐𝑐𝑐  duration of additional followup visit 15 minutes nsj|c   
+  𝛽𝛽𝛽𝛽11|𝑐𝑐𝑐𝑐  inspected skin part full body  nsj|c  
 
𝑉𝑉𝑉𝑉(𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎2)𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛|𝑐𝑐𝑐𝑐 =  𝛽𝛽𝛽𝛽1|c same healthcare professionalnsj|c
+ 𝛽𝛽𝛽𝛽2|𝑐𝑐𝑐𝑐  additional information by personalised letternsj|c
+ 𝛽𝛽𝛽𝛽3|𝑐𝑐𝑐𝑐  additional information by general handoutnsj|c
+  𝛽𝛽𝛽𝛽4|𝑐𝑐𝑐𝑐  additional information by general websitensj|c                              
+  𝛽𝛽𝛽𝛽5|𝑐𝑐𝑐𝑐 additional followup at 6 and 12 months after treatmentnsj|c
+  𝛽𝛽𝛽𝛽6|𝑐𝑐𝑐𝑐 additional followup at 1 and 2 years after treatmentnsj|c
+  𝛽𝛽𝛽𝛽7|𝑐𝑐𝑐𝑐 additional followup conducted by general practitioner nsj|c
+ 𝛽𝛽𝛽𝛽8|𝑐𝑐𝑐𝑐  additional followup conducted by dermatologistnsj|c
+  𝛽𝛽𝛽𝛽9|𝑐𝑐𝑐𝑐  duration of additional followup visit 10 minutesnsj|c 
+  𝛽𝛽𝛽𝛽10|𝑐𝑐𝑐𝑐 duration of additional followup visit 15 minutes nsj|c   
+  𝛽𝛽𝛽𝛽11|𝑐𝑐𝑐𝑐 inspected skin part full body  nsj|c  
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Scenario without additional follow-up visits:
𝑉𝑉𝑉𝑉(𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎3)𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛|𝑐𝑐𝑐𝑐 = 𝛽𝛽𝛽𝛽12|c + 𝛽𝛽𝛽𝛽13|csame healthcare professional 𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛|𝑐𝑐𝑐𝑐 
+ 𝛽𝛽𝛽𝛽14|𝑐𝑐𝑐𝑐  additional information by personalised letternsj|c
+ 𝛽𝛽𝛽𝛽15|𝑐𝑐𝑐𝑐  additional information by general handoutnsj|c
+  𝛽𝛽𝛽𝛽16|𝑐𝑐𝑐𝑐additional information by  general websitensj|c 
Where
Vnsj|c represents the observable utility that respondent ‘n’ belonging to class 
segment ‘c’ has for alternative ‘j’ in choice set ‘s’;
alt represent the three alternatives in the choice set;
β 12|c represent an alternative-specific constant for the ‘no additional BCC 
follow-up scenario’ compared to the ‘additional BCC follow scenario’ for 
a certain class;
β 1-11|c are class-specific parameter weights (coefficients) associated with the 
attributes of the DCE to provide additional follow-up;
β 13-16|c are class-specific parameter weights (coefficients) associated with the 
attributes of the DCE to not provide additional follow-up.
A statistically significant coefficient of an attribute(level) shows that the attribute is 
important for the respondents in their decision to accept a certain BCC follow-up. The 
sign of the coefficient shows whether they prefer (positive sign) or disfavour (negative 
sign) the particular level of the attribute. The size of the coefficients indicates the rela-
tive importance (bigger equals more important).
Expected choice probability of bCC follow-up scenarios
To make DCE results more practical for policy makers, we calculated choice probabilities 
for several scenarios. To simulate current practice, the alternative ‘current intensive 
(and expensive) BCC follow-up practice’ was fixed at the following attribute levels: 
standard post-treatment visits performed by a different person treatment provider, 
extra information provided by a general handout, two additional follow-up visits in 
a year conducted by a dermatologist and a ten minute consultation during which the 
face, upper body and treated area is checked. The choice probabilities were calculated 
with different scenarios of ‘no BCC follow-up according to guideline’, to determine the 
optimal choice probability. The scenarios are based on previous qualitative studies.9,10 
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The expected choice probability scenarios are calculated on LCM results, by which 
the exponent of the total utility for a certain alternative was taken and divided by the 
exponent of utility of all alternatives in that scenario taking the class probabilities into 
account. The ‘current intensive BCC follow-up practice’ and ‘no BCC follow-up according 
guideline’ were chosen to resemble real life situations to determine which scenario 
without low-value follow-up visits is the most acceptable scenario by patients.
RESuLTS
Respondents’ characteristics
A total of 266 patients (72% response rate) and 131 dermatologists (21% response 
rate) completed and returned the questionnaire. Twelve dermatologists (9.1%) and 49 
BCC patients (18%) failed the consistency test), however excluding these respondents 
only aff ected the signifi cance due to lower sample size, therefore all respondents were 
included in the fi nal analysis. The characteristics of the BCC patients and dermatolo-
gists are displayed in Table 2.
 
figure 1. Choice task example of the discrete choice experiment
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age, mean years (SD) 67.2 (12.3) 42.9 (10.9)
Male 49.6% 36.6%
Type of healthcare centre
- university hospital 32.7% 21.4% 
- General hospital 35.7% 24.4% 
- ISTC 31.6% 13.7% 
- Multiple types N/A 9.9% 
- Missing 0 30.5% 
Educational level
- Low 29.3% 0% 
- Medium 39.1% 0% 
- high 28.2% 100% 
- Missing 3.4% 0% 
Income1
- Low 17.3% N/A 
- Medium 27.8% N/A 
- high 46.2% N/A 
- Missing 8.6% N/A 
history of skin cancer
- bCC 34.2% N/A 
- Other type 9.8% N/A 
- None 54.9% N/A 
- Missing 1.1% N/A 
EQ-vaS score, Mean (SD) 80.9 (13.5) N/A
Occupation
- Dermatologist N/A 76.3% 
- Dermatology resident N/A 22.9% 
- Missing N/A 0.8% 




- yes N/A 26.9% 
- No N/A 32.7% 
- Missing N/A 40.4% 
SD, standard deviation; ISTC, Independent sector treatment centre; BCC, Basal cell carcinoma; EQ-
VAS, EuroQol visual analogue scale; N/A, not applicable




Latent class analysis of patients and dermatologists
BCC patients
Three latent classes of preference patterns were identified for the BCC patients, with 
class probabilities for class 1, 2 and 3 being 13%, 46% and 41% respectively (Table 
3). The patients belonging to class 1 did not have a significant preference regarding 
receiving additional follow-up care. However, if they would receive additional follow-up 
care, they would strongly prefer this to be conducted by their general practitioner (GP). 
These were predominantly patients older than 65 years without a BCC in their medical 
history. The BCC patients belonging to class 2 had a strong preference to receive addi-
tional follow-up care. They preferred two additional follow-up visits at 6 and 12 months 
after treatment, conducted by a dermatologist and to have the standard post-treatment 
visit performed by the same person as the treatment provider. In addition, they would 
prefer to receive a personalised letter and preferred the follow up visits to include a 
total-body skin examination. The respondents with high probability to belong to this 
class were mainly women. The patients belonging to the third class strongly preferred 
no additional follow-up visits and if there would be additional follow-up, they would 
prefer the standard post-treatment visit performed by the same person as the treatment 
provider and the follow-up visit to last 15 minutes and to be conducted by their GP.
Table 3. Latent class analysis of BCC patients’ (n=266) preferences regarding BCC follow-up care








With additional follow-up visit(s)
Standard post-treatment visit performed:
Not by same person as 
treatment provider (Ref)
0.16 -0.27 -0.48
By the same person as 
treatment provider (β1)
-0.16 1.655 0.92 0.27 0.043 <0.01 0.48 0.139 <0.01
In addition to oral information, extra information will be provided by:
E-health (Ref) -0.75 0.03 -0.09
Personalised Letter (β2) 1.45 4.298 0.74 0.14 0.097 0.15 -0.13 0.343 0.71
General hand-out (β3) 0.00 1.384 >0.99 0.04 0.102 0.72 0.10 0.269 0.71
General website (β4) -0.70 3.540 0.84 -0.21 0.108 0.05 0.12 0.318 0.69
The additional follow-up visit(s) will be planned:
1 year after treatment (Ref) 1.50 -0.06 0.28
6 and 12 months after 
treatment (β5)
-0.40 2.676 0.88 0.15 0.053 <0.01 0.08 0.201 0.70
1 and 2 years after 
treatment (β6)
-1.10 1.650 0.50 -0.09 0.068 0.18 -0.36 0.190 0.06
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Table 3. Latent class analysis of BCC patients’ (n=266) preferences regarding BCC follow-up care 
(continued)








The additional follow-up visit(s) will be conducted by:
Nurse practitioner (Ref) -1.31 0.06 -0.58
General practitioner (β7) 4.23 1.540 <0.01 -0.18 0.467 <0.01 1.31 0.154 <0.01
Dermatologist (β8) -2.92 1.355 0.03 0.12 0.052 0.02 -0.73 0.240 <0.01
The duration of the additional follow-up visit(s) will be:
5 minutes (Ref) -1.16 -0.16 -0.26
10 minutes (β9) 2.28 1.243 0.07 0.05 0.079 0.56 -0.17 0.208 0.41
15 minutes (β10) -1.12 1.191 0.35 0.11 0.070 0.12 0.43 0.173 0.01
Part of skin to be checked during the additional follow-up visits:
Face, upper body and 
treated area (Ref)
0.55 -0.11 -0.01
Full body (β11) -0.55 0.472 0.24 0.11 0.029 <0.01 0.01 0.152 0.94
Without additional follow-up visit
Constant (no follow-up) 
(β12)
0.50 1.352 0.71 -2.15 0.115 <0.01 2.87 0.178 <0.01
Standard post-treatment visit performed:
Not by same person as 
treatment provider (Ref)
-0.88 -0.59 0.13
By the same person as 
treatment provider (β13)
0.88 0.770 0.25 0.59 0.148 <0.01 -0.13 0.235 0.59
In addition to oral information, extra information will be provided by:
E-health (Ref) -1.21 0.00 0.26
Personalised Letter (β14) 1.20 3.045 0.69 0.00 0.241 >0.99 -0.13 0.235 0.59
General hand-out (β15) -0.51 1.787 0.78 -0.23 0.286 0.43 -0.25 0.266 0.34
General website (β16) 0.52 3.487 0.88 0.23 0.247 0.36 0.12 0.329 0.72
Class probability model
Constant -2.23 1.405 0.11 0.77 0.340 0.02 -
Gender (male) 0.09 0.786 0.91 -1.45 0.377 <0.01 -
Older age (≥65 years) 1.82 1.074 0.09 0.04 0.372 0.91 -
Medical history of BCC (yes) -0.58 0.016 <0.01 0.00 0.000 0.79 -
Class probabilities (%)
Average 13 46 41
Log Likelihood: -1675.151
Effects coding was used to determine the effects of all attribute levels.32
BCC, Basal cell carcinoma; s.e., standard error; Ref, Reference
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Choice probabilities of BCC follow-up alternatives
The choice probability of ‘No BCC follow-up according to guideline’ was 55% if the 
standard post-treatment visit would not be performed by the same person as the treat-
ment provider and if patients would receive a general hand-out compared to ‘Current 
intensive BCC follow-up’. This choice probability of ‘No BCC follow-up according to 
guideline’ increased from 55% up to 77%, if the standard post-treatment visit would 
be performed by the same person as treatment provider and if patients were off ered a 
personalised handout as additional information. (Fig 2).
Dermatologists
Two classes could be identifi ed in the LCA regarding dermatologists (Table 4). The 
dermatologists belonging to class 1 strongly preferred no additional follow-up visits 
(i.e. according to the guideline). This contrasts with the dermatologists belonging to 
class 2, who strongly preferred additional follow-up visits, which they would prefer to 
be conducted by a dermatologist and include a total-body skin examination. The aver-
age class probabilities were 71% for class 1 and 29% for class 2. No covariates could 
signifi cantly explain the latent class probabilities for dermatologists.
Multinomial logit with interaction terms of dermatologists
To test for interaction, the covariates age over 40 years, male gender and subspe-
cialisation in oncology were multiplied with the strongest identifi er of the classes: ‘no 
 
figure 2. Expected patient choice probabilities of diff erent BCC follow-up scenarios based on la-
tent class model
*standard post-treatment visits performed by a diff erent person than treatment provider, extra 
information provided by a general handout, two additional follow-up visits in a year conducted by 
a dermatologist and a ten minute consultation in which the face, upper body and treated area are 
checked.
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Table 4. Latent class analysis of dermatologists’ (n=131) preferences regarding BCC follow-up care






With additional follow-up visit(s)
Standard post-treatment visit performed:
Not by same person as treatment provider (Ref) -0.94 -0.11
By the same person as treatment provider (β1) 0.94 0.210 <0.01 0.11 0.125 0.38
In addition to oral information, extra information will be provided by:
E-health (Ref) 0.30 0.19
Personalised Letter (β2) -0.32 0.337 0.34 -0.16 0.232 0.49
General hand-out (β3) 0.17 0.263 0.52 0.23 0.212 0.28
General website (β4) -0.15 0.269 0.57 -0.26 0.211 0.21
The additional follow-up visit(s) will be planned:
1 year after treatment (Ref) 0.75 0.48
6 and 12 months after treatment (β5) -0.59 0.292 0.04 -0.04 0.153 0.82
1 and 2 years after treatment (β6) -0.16 0.264 0.55 -0.44 0.168 <0.01
The additional follow-up visit(s) will be conducted by:
Nurse practitioner (Ref) -0.31 0.13
General practitioner (β7) 0.13 0.233 0.58 -0.91 0.184 <0.01
Dermatologist (β8) 0.18 0.253 0.47 0.78 0.184 <0.01
The duration of the additional follow-up visit(s) will be:
5 minutes (Ref) -0.12 0.18
10 minutes (β9) -0.18 0.268 0.51 -0.06 0.20 0.76
15 minutes (β10) 0.30 0.252 0.23 -0.12 0.16 0.44
Part of skin to be checked during the additional follow-up visits:
Face, upper body and treated area (Ref) 0.06 -0.37
Full body (β11) -0.06 0.167 0.70 0.37 0.106 <0.01
Without additional follow-up visit
Constant (no follow-up) (β12) 3.29 0.267 <0.01 -1.81 0.370 <0.01
Standard post-treatment visit performed:
Not by same person as treatment provider (Ref) -0.92 -0.58
By the same person as treatment provider (β13) 0.92 0.201 <0.01 0.58 0.317 0.07
In addition to oral information, extra information will be provided by:
E-health (Ref) -0.36 0.72
Personalised Letter (β14) 0.09 0.306 0.76 0.00 0.567 >0.99
General hand-out (β15) 0.22 0.294 0.46 -0.87 0.809 0.28




Effects coding was used to determine the effects of all attribute levels.32
BCC, Basal cell carcinoma; s.e., standard error; Ref, Reference.
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additional follow up’. This model demonstrated that predominantly young and male 
dermatologists preferred no additional follow-up for BCC patients (p=<0.01). Having a 
subspecialisation in oncology did not affect the preference for this attribute.
DISCuSSION
The current study quantified the preferences and needs of patients and dermatolo-
gists to accept a reduction of low-risk BCC follow-up care. We found that a reduction 
would be more acceptable if the post-treatment visit were to be performed by the same 
person as the treatment provider and additional information would be provided by a 
personalised letter for patients.
The observation of a preference for personalised letter as a feasible option to reduce 
low-value follow-up visits is supported by the preference for personalised information 
which was previously expressed in focus groups with BCC patients.9 Other studies have 
also shown that personalised information satisfies cancer patients more than general 
information, as this tells them something new and is more often relevant to them.33 A 
preference for continuity of care (e.g. same healthcare provider for treatment as post-
treatment visit) has also been well documented to have positive effects on indicators 
of quality of care, such as increased patient satisfaction, decreased hospitalisations, 
decreased emergency department visits and improved receipt of preventive services.34
Mainly female patients preferred additional low-value BCC follow-up visits, con-
ducted by a dermatologist. In contrast, predominantly male patients preferred to not 
receive additional follow-up, and should they get follow-up, they preferred the GP to 
conduct this. In contrast to studies where patients with other types of cancer preferred 
their follow-up care to be conducted by a medical specialist,15,20 overall, the patients 
in our study preferred their GP for their follow-up care. This could be explained by the 
inclusion of the out-of-pocket costs in our DCE to make our scenarios as realistic as pos-
sible, which was linked to ‘type of healthcare professional’ and ‘frequency of follow-up’. 
In addition, recent focus groups with low-risk BCC patients showed that they perceived 
their BCC as a not severe type of cancer and some patients actually preferred their GP to 
conduct follow-up care as he or she is closer to home and easier approachable.10
A limitation in this study is the low response rate of dermatologists. Although re-
sponse rates are generally low among medical specialists (27%-68%),26-29 the 21% 
in the current study was even lower. This could be explained by the facts that the DCE 
invitation was sent through a non-personal newsletter and that it encompassed a 
lengthy questionnaire. Additionally, we could not offer the physicians compensation 
and reminders could not be sent as they responded anonymously. This low participa-
tion may have led to a selection bias, as reflected in the mean age of the respondents 
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being 43 years, which is lower than the nationwide mean age of dermatologists and 
residents.35 The current study revealed that young male dermatologists preferred no 
additional follow-up care, which is in accordance with influencing factors explored in 
interviews with dermatologists.10 Inclusion of older dermatologists would probably 
shift the results to more dermatologists preferring additional follow-up care, which 
would emphasize the need for a de-adoption strategy.
In conclusion, these results form a solid foundation for a feasible strategy to reduce 
the low-value BCC follow-up care, while maintaining quality of care. This follow-up 
would consist of having one healthcare provider for the initial treatment as well as the 
standard post-treatment evaluation combined with a personalised letter for the patient 
with information about their diagnosis, received treatment and personalised follow-up 
schedule. Further research is needed to determine whether implementation of this 
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Importance The incidence of keratinocyte carcinomas is high, rapidly growing and 
shows no signs of stabilizing, making it the fifth most expensive type of cancer in the 
Netherlands. Approximately 80% of keratinocyte carcinomas consist of basal cell 
carcinomas (BCC) with 50% being considered as low-risk tumors. Nevertheless, 83% 
of the low-risk BCC patients were found to receive more follow-up care than the Dutch 
BCC guideline recommends, which is limited to one visit post-treatment. More efficient 
management could reduce unnecessary follow-up care and related costs.
Objective To study the efficacy, cost-effectiveness and budget impact of a personalized 
discharge letter for low-risk BCC patients compared with usual care (no letter).
Design Model-based cost-effectiveness and budget impact analysis using individual 
patient data gathered via surveys.
Setting Multicenter; one academic hospital, three general hospitals, and two indepen-
dent sector skin treatment centers.
Participants The study included 473 first-time BCC patients.
Intervention and control The intervention consisted of a personalized discharge letter 
in addition to usual care as defined in the Dutch BCC guideline, which consists of one 
follow-up visit post-treatment.
Main outcome measures The outcome measures were number of follow-up visits, costs 
and quality adjusted life years (QALY) per patient, incremental cost-effectiveness ratio 
and the budget impact.
Results A personalized discharge letter decreased the number of follow-up visits by 
13% in the first year. The incremental costs after five years were -€26.38 per patient. 
The QALYs were 4.12 after five years and nearly equal in both groups. Using a five-year 
time horizon, the incremental cost-effectiveness ratio was expected to be -€9,446. The 
budget impact was -€2,9 million after five years.
Conclusion and relevance The distribution of a personalized discharge letter decreases 
the number of unnecessary follow-up visits and implementing the intervention in 
a large eligible population would results in substantial cost savings, contributing to 
restraining the growing BCC costs.
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INTRODuCTION
Keratinocyte carcinoma (KC) is the most common malignancy worldwide with still 
rising incidence rates.1-5 Of these carcinomas, basal cell carcinoma (BCC) is by far the 
most common type with a prevalence of 80% in Caucasian populations. The remaining 
20% consists of cutaneous squamous cell carcinoma (cSCC).2,6In 2017, over 48,000 
individuals were newly diagnosed with a BCC in the Netherlands and this increases by 
8% annually.7 This alarming growth of new cases results in a strain on dermatological 
care and budget.8,9 Total KC costs are now 1,8 times higher compared to melanoma.1,3,10 
In addition to focusing on skin cancer prevention, interventions aimed at improving 
efficiency of care, especially in the case of high volume tumors such as the BCC, are 
equally essential to safeguard current care.
De-adoption of low-value care is a strategy that can be used to restrain costs. Low-
value care is defined as “care that is unlikely to benefit a patient given the harms, costs, 
alternatives or preferences”.11 After a low-risk BCC, follow-up visits after the initial 
check-up can be labeled as low-value, because there is no evidence that extra follow-up 
provides a health benefit.12,13 According to the Dutch BCC guideline, annual follow-up for 
BCC should therefore be limited to high-risk patients only. Dermatologists are recom-
mended to check the scar of low-risk patients just once within 6-12 months after treat-
ment and are advised to instruct patients in self-examination and provide additional 
information via brochures.14 About 50% of the BCC patients are considered low-risk, 
but research has shown that 83% of these low-risk patients receive more follow-up 
than the guidelines recommend during the first five years after treatment.3,15 There is 
currently no evidence that extra follow-up provides a health benefit. Therefore, care for 
low-risk BCC patients requires more efficient management and guideline adherence.
To avoid trial and error on de-adoption strategies, we conducted research on the 
needs and preferences of patients and dermatologists regarding current BCC manage-
ment integrated within a choosing wisely project. BCC patients expressed the need 
for more information, tailored to their situation and indicated that this information 
would lower their need for frequent follow-up visits.16 A discrete-choice experiment 
revealed that patients preferred a personalized printed discharge letter over other al-
ternatives (e-health, general brochure or website).17 These letters can contain relevant 
information on a patient’s diagnosis, treatment, complications, follow-up and lifestyle 
recommendations. These letters improve the amount of received information and the 
self-management of patients by combining educational with personalized informa-
tion.18 Providing such a letter could reduce unnecessary follow-up visits among BCC 
patients and lower the costs of BCC management compared to current practice. The 
aim of this study was to explore the efficacy, cost-effectiveness and budget impact of a 




The efficacy, cost-effectiveness and budget impact were determined for the interven-
tion consisting of the distribution of a personalized discharge letter in addition to usual 
care to first-time BCC patients, compared to usual care only. The principal outcome of 
effectiveness was the difference in the number of BCC related follow-up visits between 
both strategies. These results were used to conduct a cost-effectiveness analysis (CEA) 
and a budget impact analysis (BIA). A CEA compares the health outcomes with the costs 
of the intervention and control strategy per patient.19 However, the decision to imple-
ment the intervention on a large scale also depends on the total budgetary impact. A 
CEA, followed by a BIA, allows decision-makers to foresee the entire expected impact of 
adopting the innovation in their local setting.20,21 The analyses were performed accord-
ing to the (inter)national guidelines of CEAs and BIAs as well as the CHEERS checklist 
for reporting.22-26
Study population and design
The study population consisted of patients with a first BCC who were included after 
treatment but prior to follow-up. Patients needed to be at least 18 years old and had to 
be able to speak Dutch. Patients with skin cancer prior to their first BCC were excluded. 
Patients were included in six healthcare centers in the Netherlands; one academic 
hospital, three general hospitals, and two independent skin sector treatment centers. 
All participants were asked to complete a survey at baseline and after three, six, and 
twelve months. Each survey consisted of general questions regarding demographics, 
their quality of life (based on the EQ-5D-3L questionnaire), the number of BCC related 
visits to the general practitioner (GP) and medical specialist, whether they received any 
subsequent skin cancer diagnosis and the SF-HLQ questionnaire to monitor the effects 
of a BCC on labor activities.25,27
First, the control patients were included in 2014 and their data were collected via 
surveys. These patients received usual care and could be offered general dermatologi-
cal brochures, whichever the dermatologists considered appropriate. A discrete choice 
experiment was conducted in the control group, which showed that a printed personal-
ized discharge letter could be a potential helpful intervention to reduce the need for 
unnecessary follow-up.28,29 This personalized discharge letter contained information 
on the patient’s diagnosis, treatment, chance of having a subsequent BCC, lifestyle 
recommendations, information on self-examination and advice for actions when new 
suspicious lesions would appear. An example of this letter can be found in appendix 1.
In 2016, new BCC patients were included in the study in the same health care centers 
after implementing the intervention, forming the intervention group. They received 
usual care with the personalized discharge letter post-treatment.
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Efficacy
The efficacy of the intervention was expressed as the percentage reduction in BCC-
related visits to a specialist during a period of one year between the control and 
intervention group.
Due to logistic errors in the distribution of the surveys in the intervention group, up 
to 47% and 45% of the participants did not respond at t=3 and t=6 months, respec-
tively. This mainly resulted in missing data on the number of GP and specialist visits. 
The missing data were only correlated with age and therefore considered to be missing 
at random (MAR). The missing data were imputed with multiple imputation (MI) and 
pooled using SPSS® 26. With MAR data, MI increases the precision and reduces the level 
of bias compared to a complete case analysis.30-32 The missing data were imputed and 
used for further modelling.
Cost-effectiveness analysis
The cost-effectiveness was estimated through decision modeling using a patient level 
health state transition model with a societal perspective. This decision model simulates 
potential effects on health outcomes and the costs that patients would have made over 
time to estimate the effect of the intervention.19,22 The model consisted of several health 
states between which patients can transition once per cycle. The following health states 
were included: full recovery from first BCC, new BCC, new cSCC, new melanoma, death 
due to skin cancer and death due to other causes. Each cycle represented one year and 
allowed one transition from one state to another, except for death.
A schematic overview of the model structure can be found in Figure 1.
The patient characteristics of the survey were used to simulate a cohort of 10,000 
hypothetical patients in the model. BCC is a condition with very low mortality rates; 
therefore, the incremental effects and costs were expected to stabilize after five years. 
To assess the stability of these incremental outcomes the model-based analysis was 
performed for a five- and ten-year time horizon. Each health state comes with certain 
costs and health utilities. Using a societal perspective, costs were accrued in different 
categories; medical costs, costs for patients and the costs of productivity losses. All 
costs were presented in euros (€) and converted to price level 2019 using the Dutch 
derived consumer price indices.33 Costs were discounted by 4% and health outcomes 
by 1.5% according to the Dutch guideline for economic evaluations in healthcare.25,34 
Disaggregated total deterministic costs were used to express the impact on each cost 
category. The measured health outcomes were expressed in QALYs and calculated via 
the scores resulting from the EQ-5D-3L questionnaire. Full descriptions of the included 
costs, probabilities, utilities and their sources are provided in appendices 2 and 3. The 
efficacy results were used to model the number of appointments that were made. For 
the remaining four years, previous trial data were used.35 The primary outcomes of 
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the model were the total and incremental costs and eff ects and the incremental cost-
eff ectiveness ratio (ICER), which indicates the cost per QALY gained.19
To investigate the impact of the joint parameter uncertainty on the results, a probabi-
listic analysis (PA) was carried out. The PA shows how variation in the input of parameter 
values aff ected the outcomes of the model.36 The PA was performed with 5,000 Monte 
Carlo simulations. The Monte Carlo simulation calculated the outcomes of the model by 
simultaneously drawing random parameter values from previously determined prob-
ability distributions. The health utilities were defi ned using a beta distribution, whereas 
the costs were defi ned using a gamma distribution. Variation in the number of appoint-
ments made was simulated using a Dirichlet distribution.37 Prices were obtained from 
the Dutch Costing Manual or aggregated from national data and were therefore free 
of uncertainty.38 As a result they were fi xed (i.e., without distribution). The software 
related costs to facilitate the generation of the personalized discharge letter were esti-
mated at €5,000 for the fi rst hospital by an IT-specialist. Any additional hospital would 
have to pay an estimated €1,000 for implementation of the software. To address the 
uncertainty surrounding this estimate, a scenario analysis was conducted which consid-
ered implementation in a single hospital and national implementation. The model was 
re-run to monitor its eff ect on the outcomes. The parameter inputs are listed in Table 1. 
 
figure 1. Schematic overview of the model
This model focuses on the eff ects of a personalized discharge letter on fi rst-time BCC patients. Once 
patients receive a new diagnosis, they no longer meet the criteria of the fi rst group. Expert consensus 
was reached over the fact that any new diagnosis might infl uence the eff ect of the letter, both posi-
tively and negatively. To solely model the eff ect of the letter, patients within the model cannot return 
to the fi rst state once they have left it.
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Table 1. Parameter inputs
Parameter Value Standard error Distribution Source
General practitioner appointments
Intervention 
0 0.986 - Beta Trial 
1 0.014 - Beta Trial 
Control 
0 0.978 - Beta Trial 
1 0.021 - Beta Trial 
Specialist appointments
Intervention year 1     
0 0.209 - Dirichlet Trial 
1 0.380 - Dirichlet Trial 
2 0.266 - Dirichlet Trial 
3 0.114 - Dirichlet Trial 
4 0.023 - Dirichlet Trial 
5 0.006 - Dirichlet Trial 
6 0.002 - Dirichlet Trial 
7-10 0.000 - Dirichlet Trial 
>10 0.000 - Dirichlet Trial 
Control year 1     
0 0.138 - Dirichlet Trial 
1 0.325 - Dirichlet Trial 
2 0.375 - Dirichlet Trial 
3 0.136 - Dirichlet Trial 
4 0.018 - Dirichlet Trial 
5 0.006 - Dirichlet Trial 
6 0.002 - Dirichlet Trial 
7-10 0.000 - Dirichlet Trial 
>10 0.000 -  Trial 
Control year 2   Dirichlet  
0 0.700 - Dirichlet 39 
1 0.210 - Dirichlet 39 
2 0.040 - Dirichlet 39 
3-5 0.040 - Dirichlet 39 
6-10 0.010 - Dirichlet 39 
>10 0.000 -  39 
Control year 3   Dirichlet  
0 0.820 - Dirichlet 39 
1 0.120 - Dirichlet 39 
2 0.050 - Dirichlet 39 
3-5 0.010 - Dirichlet 39 
6-10 0.000 - Dirichlet 39 
>10 0.000 -  39 
Chapter 5
124
Table 1. Parameter inputs (continued)
Parameter Value Standard error Distribution Source
Control year 4   Dirichlet  
0 0.780 - Dirichlet 39 
1 0.160 - Dirichlet 39 
2 0.050 - Dirichlet 39 
3-5 0.000 - Dirichlet 39 
6-10 0.000 - Dirichlet 39 
>10 0.000 -  39 
Control year 5   Dirichlet  
0 0.940 - Dirichlet 39 
1 0.030 - Dirichlet 39 
2 0.030 - Dirichlet 39 
3-5 0.000 - Dirichlet 39 
6-10 0.000 - Dirichlet 39 
>10 0.000 - 39 
Recurrence quality of life
No recurrence 0.910 0.010 Beta Trial 
bCC after bCC 0.910 0.025 Beta Trial 
cSCC after bCC 0.910 0.025 Beta Trial 
Melanoma after bCC 0.719 0.011 Beta 40 
Recurrence after first BCC
bCC 0.258 0.052a Beta 41 
cSCC 0.045 0.009a Beta 41 
Melanoma 0.004 0.001a Beta 41 
Mortality
bCC 0.001 0.000a Beta 42 
cSCC 0.021 0.004a Beta 43 
Melanoma 0.071 0.014a Beta 44 
General Appendix 3 - Fixed 45 
average productivity loss in hours
Intervention 0.795 0.159a Gamma Trial 
Control 1.606 0.321a Gamma Trial 
Costs
follow-up at SP €117.92 - Fixed 38 
follow-up at GP €34.95 - Fixed 46 
Intervention €1.61 0.322a Gamma 47 
Software €5,000.00 - Fixed Expert estimate 
Travel expenses €2.78 - Fixed 38 
Productivity loss male €39.56 - Fixed 38 
Productivity loss female €32.98 - Fixed 38 
Abbreviations: BCC, basal cell carcinoma; cSCC, cutaneous squamous cell carcinoma; SP, medical 
specialist; GP, general practitioner.
a ±20% of the deterministic value
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The results of the PA were visualized in the incremental cost-effectiveness plane. Both 
the model and the PA were performed using Microsoft Excel 2019 for Mac.
budget impact analysis
A BIA was performed to calculate the budgetary impact of implementing the interven-
tion in the Netherlands for a time horizon of five years. The BIA has a societal perspec-
tive equal to the CEA and shows the impact for the involved parties.26 The eligible 
population for this BIA were low-risk BCC patients diagnosed with skin cancer for the 
first time. About 48,000 individuals were diagnosed with a BCC in the Netherlands in 
2017.7 Half of them were considered to be low-risk.15 With an annual growth of 8% 
in new cases, the eligible population was calculated for five years.4 The intervention 
uptake was defined as 40% in 2021, 50% in 2022, 60% in 2023, 75% in 2024, and 
75% in 2025, based on estimates made by dermatologists, an implementation expert, 
and the results of focus group sessions held with dermatologists.12 To address the un-
certainty surrounding this estimate, scenario analyses with a lower and higher uptake 
were conducted. The lower uptake was defined as 20%-30%-40%-50%-50% and the 
higher uptake was 50%-60%-80%-80%-80%. These scenarios were also run for local 
(single hospital) and national implementation.
RESuLTS
Efficacy
The results of 473 first-time BCC patients were used for this analysis; 278 patients 
were included as controls and thereafter 195 patients received the intervention. Their 
characteristics are listed in Table 2.
The number of visits to a specialist in the first year was 1.38 and 1.59 per patient in 
the intervention group and control group respectively. The distribution of a personal-
ized discharge letter reduced the number of visits by 13% (0.21 visits; 95% CI 0.129 
– 0.289; P<0.001) after imputation.
Cost-effectiveness
The costs per patient after the first five years were €328.24 for the intervention and 
€354.63 for the control group. This resulted in a cost saving of €26.38 per patient. A 
time horizon of ten years resulted in total costs of €367.76 for the intervention group 
and €394.13 for the control group. After ten years the expected cost saving would be 
€26.37 per patient, confirming that effects stabilized after five years. After a period 
of five years and ten years, the QALYs were 4.123 and 7.250 respectively. The QALYs 
in both groups were very similar with differences between the groups being smaller 
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than 0.003 for five years and 0.009 for ten years in favor of the intervention group. 
The ICER was -€9,446 per QALY gained after five years and -€3,138 after ten years. The 
deterministic results of the intervention showed that the cost category medical costs 
accounted to 80.7% of the total costs. The costs for patients made up 2.4% and the 
remaining 16.9% was made up of productivity losses.
The outcomes of the PA showed that 97% of the simulations were in the southern 
quadrants (Figure 2). This means that the intervention is very likely to be cost saving. 
Of all the simulations, 37% indicated health loss (left side of the y-axis) and 63% 
indicated health benefits (right side of y-axis), meaning that improvement of the health 
outcomes was more likely than deterioration.
A scenario analysis was conducted to measure the effect of uncertainty surrounding 
the costs of the software during implementation. When the software costs were divided 
over a local setting (one hospital) of 1,000 patients, the cost savings were €26.69 per 
patient, as mentioned before. If the software costs were divided over the national 
eligible population of about 31,000 patients, the cost saving was €26.38 per patient (a 
decrease of 1.2%). An overview of the analysis can be found in appendix 4.
budget impact analysis
The budget impact of implementing the intervention in the Netherlands would be 
-€2,876,844 over a five-year period. Implementing the intervention in a single hospital 







Male 94 (48.2) 145 (52.2) 0.75 
Age (in years)
Mean (SD) 64.8 (12.7) 66.4 (11.8) 0.15 
Range 31-94 31-100 
Education [n (%)]
Low 53 (27.1) 90 (32.4)  
Medium 84 (43.1) 104 (37.4) 0.38 
High 62 (26.7) 74 (26.7) 
Self-reported previous actinic keratosis [n (%)]
Actinic Keratosis 7 (3.6) 4 (1.4) 0.16 
None 169 (86.7) 250 (89.9)  
VAS score at t = 0
Mean (SD) 81.45 (11.8) 79.65 (14.5) 0.56 
Range 30-100 19-100 
Abbreviations: SD, standard deviation; VAS, visual analogue scale.
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resulted in a budget impact of -€121,230. The cost savings for each year and scenario 
are specifi ed in Table 3.
After fi ve years the intervention would result in cost savings on a national scale in the 
medical category of €2,101,780. The costs for all patients would drop by €60,763. The 
productivity loss would lower by €714,300. In the local setting the cost savings for the 
medical category would be €97,832, for the patients €2,909 and for productivity loss 
€20,488.
A scenario analysis was conducted to determine the impact of a lower and higher 
uptake. The total national savings on a lower estimate were €1,835,966. The total sav-
ings on a high estimate were €3,333,541. Locally, the lower estimate was -€77,367 and 
the high estimate was -€140,475. The full analysis can be found in appendix 5.
 
figure 2. Incremental cost-eff ectiveness plane
Most simulations were in the southern quadrant, right side of the y-axis, indicating that intervention 





To our knowledge, this is the first study evaluating both the efficacy, cost-effectiveness 
and budget impact of a personalized discharge letter in dermatology. The introduction 
of a personalized discharge letter resulted in 13% less follow-up in one year compared 
to usual care. This would save €26.38 per patient in five years, while the national budget 
impact would be saving almost €3 million in the same period with an annual saving of 
approximately €575,000. The expected QALYs remained nearly equal in both groups.
The cost category that experienced the highest cost saving were the medical costs, 
followed by productivity losses and finally the costs for patients. Insurance companies 
who pay for the medical costs will therefore experience the most (financial) benefits 
from implementation. The employers of patients, who will have lower productivity 
losses, are the second largest party who will benefit. Finally, the patients themselves 
will experience lowered costs.
To implement this intervention, an investment has to be made to develop the required 
software. After its development, other hospitals could participate as well. When more 
hospitals join, the number of patients who participate will be higher, resulting in lower 
intervention costs and an even greater benefit for all involved parties.
There were no data available on the uptake of such an intervention among derma-
tologists, although the dermatologists who participated in the current trial are eager to 
implement the letter into their routine care. To improve the chances of success, a well-
defined implementation plan could increase the uptake.48 Making the letter available 
in multiple languages or adding more graphical features can help to include harder to 
Table 3. Budget Impact Analysis of the implementation of the personalized discharge letter
Year 2021 2022 2023 2024 2025 Total
Local implementation (Erasmus MC, Academic Hospital)
Eligible population 1,260 1,361 1,470 1,587 1,714 7,392
Expected uptake 40% 50% 60% 75% 75% 75%
Patients receiving the intervention 504 680 882 1,190 1286 4,542
budget impact -€13,451 -€18,159 -€23,534 -€31,772 -€34,313 -€121,230
Lower estimate -€6,726 -€10,896 -€15,690 -€21,181 -€22,875 -€77,367
Higher estimate -€16,814 -€21,791 -€31,379 -€33,890 -€36,601 -€140,475
National implementation
Eligible population 30,247 32,667 35,280 38,103 41,151 177,448
Expected uptake 40% 50% 60% 75% 75% 75%
Patients receiving the intervention 12,099 16,333 21,168 28,577 30,863 109,040
budget impact -€319,207 -€430,929 -€558,484 -€753,954 -€814,270 -€2,876,844
Lower estimate -€159,603 -€258,558 -€372,323 -€502,636 -€542,847 -€1,835,966
Higher estimate -€399,009 -€517,115 -€744,646 -€804,217 -€868,555 -€3,333,541
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reach populations.49,50 It is also important that the letter is easy to create. The less hassle 
it is to create the letter, the more likely that it will be used in practice. This could be 
achieved through software that automatically creates the letters and does not require 
manual adaptations.51 Prior research has emphasized this; personalized information is 
rated positively by both patients and professionals and the uptake of the innovation 
improves when the letter is added to the electronic patient files.18 Apart from this, 
personalized information in general has proven to be cost-effective in the long run.52
During the COVID-19 pandemic, there is an increased need for efficient capacity 
management. Personalized discharge letters provide a solution to decrease the number 
of follow-up visits. In addition, personalized discharge letters could also be created for 
other (skin) conditions to reduce low-value follow-up, such as melanoma. The Dutch 
melanoma guideline states that patients with stage 1A melanoma should receive a 
single follow-up visit one month after treatment to answer remaining questions, iden-
tify potential psychosocial problems and to provide instructions for self-examination.53 
As this is very similar to low-risk BCC follow-up, a personalized discharge letter could 
provide a solution in this situation as well.
A barrier in the implementation of this intervention is the effect on dermatologists, 
as follow-up visits provide revenue. A financial incentive was already identified as bar-
rier for de-adoption in previous research.12 On the other hand, the reduction of visits 
lowers the strain on dermatological care and the available time creates space for other, 
more pressing, consults. Barriers such as these should be considered and taken into the 
implementation plan, such as increased compensation for complex skin cancer patients.
Limitations and strengths
One of the limitations of this study was that patients in the control and intervention 
group were included in different time periods. During the study period, a new skin 
cancer guideline was published for GPs which might have altered the clinical practice 
and therefore the outcome of the intervention.54 The guideline was published in 2017 
and the inclusion period of the intervention group started shortly after its publication. 
Adoption of guidelines among clinicians is often slow making it unlikely that it had 
an effect on the outcomes.55 In addition, the patient characteristics were very similar 
in both groups, suggesting that the effect of time on the outcomes caused by charac-
teristics would be limited. Another limitation was that the effect of the letter has only 
been monitored for one year. Since patients usually make about one or two follow-up 
appointments, it is possible that the effect of the letter continued beyond the twelve 
months of monitoring, which would cause an underestimation of the efficacy. A strength 
of the design was that the trial was conducted at different types of dermatological 
departments (i.e., university medical center, general hospital, independent sector treat-
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ment center), which each have their specific target population creating a representative 
study population, making the results more generalizable to all Dutch BCC patients.
Conclusions
In conclusion, the personalized discharge letter decreases the amount of low-value 
follow-up visits among first-time BCC patients. It is a cost-effective strategy and has a 
positive impact on the healthcare budget in the Netherlands. The letter also provides 
a solution for the patients’ need for more and tailored information, which is valuable 
in itself. Incorporating this intervention in routine BCC care can improve patients’ sat-
isfaction with care, helps to decrease the number of unnecessary follow-up visits, and 
subsequently lowers the costs.
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Basal cell carcinoma (BCC) is the most common type of (skin) cancer in the Netherlands 
and its incidence is still rising.1 According to Dutch BCC guidelines, periodical follow-up 
care should be restricted to high-risk BCC patients. This implies that providing follow-
up to low-risk BCC patients is considered low-value care. Low-value care is defined as 
care which has no or little benefit to the patient, wastes limited resources and may 
even cause harm to patients.2 Nevertheless observational studies and analyses of clini-
cal routine data demonstrate that low-risk BCC patients do often have follow up visits 
despite the recommendation in the national guideline.3,4
The main aim of this thesis was to develop and test a strategy to de-adopt low-value 
BCC follow-up care. This was done by following the steps of the implementation of 
change model by Grol and Wensing.5 We started with a proposal for change (Chapter 
1). Thereafter, performance was determined made by analysing claims data (Chapter 2). 
Qualitative research was conducted, including both patients and physicians, to uncover 
the factors influencing low-value follow-up care (Chapter 3). These factors were quanti-
fied to find which trade-offs BCC patients and dermatologists were willing to make to 
accept fewer follow-up visits (Chapter 4). This resulted in the development of the actual 
de-adoption strategy: a personalised letter for BCC patients. The personalised letter 
was tested in multiple healthcare centres resulting in a decrease in follow-up visits 
and it was evaluated that implementation in the eligible population would result in 
considerable cost savings (Chapter 5).
This final chapter reflects on the main conclusions of this thesis by defining its place 
in current BCC care, among other suggestions for improvement. In addition, light is shed 
on the involvement of patients in different sections of research. It closes with final 
conclusions and prospects.
IMPROvING baSaL CELL CaRCINOMa CaRE
A care pathway for any disease mainly consists of prevention, diagnosis, treatment and 
follow-up. Some parts of the pathway may be more prominent for one disease than 
another. In the case of BCC, prevention could play a larger role than it currently is in 
the Netherlands. Regarding diagnosis, the gold standard is the clinical inspection by a 
dermatologist and/or by means of a skin biopsy to confirm the diagnosis and to identify 
the histological subtype. A sheer amount of research has been conducted on treatment 
of BCCs. The type of treatment is based on location, size and subtype of the BCC, but 
also patient characteristics and preferences. On the contrary, research regarding the 
added value of BCC follow-up and its different regimens is lacking. Chapter 1 provides 
an overview of current practice in primary and secondary care. figure 1 provides an 
overview of the BCC care pathway and suggested instruments to adjust components of 
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care with. In the following sections, suggestions for improvement of each step of the 
pathway are discussed.
Prevention
Prevention is usually categorised into primary (i.e. preventing the onset of disease), 
secondary (i.e. detecting disease as soon as possible) and tertiary (i.e. reducing symp-
toms of a disease) prevention. Tertiary prevention is relevant for incurable and chronic 
diseases, which is not typically the case for BCC. Primary and secondary prevention are 
more relevant for BCC, as elaborated hereafter.
The most signifi cant preventable risk factor for skin cancer is ultraviolet (UV) exposure 
from the sun and sunbeds.6-8 For BCC, intermittent (recreational) UV exposure seems 
more important than chronic exposure, in particular UV exposure at a young age.9,10 
Last year the Dutch Cancer Society launched a campaign at primary schools to educate 






























gists as guest speakers,11 but there is no active sun prevention programme aimed at 
adolescents in the Netherlands. A Canadian study revealed that 8.4 percent of the 
population aged 18-34 use tanning equipment, opposed to 1.7 percent aged 12-17.12 
The use of sunbeds at a younger age is correlated with earlier onset of BCC.13
This calls for prevention programmes aimed at this teenage population. Even though 
it is generally known that UV-radiation is the most important factor in developing skin 
cancer,14 a tanned skin is currently still associated with beauty and positive health.15 It 
seems difficult to change this behaviour in this important, but hard to reach age group. 
An opportunity to reach this teenage population is by means of Entertainment-Educa-
tion (EE). EE is a communication strategy that uses popular media formats to engage 
with audiences on prosocial topics such as health, sustainability and social tolerance. 
A recent meta-analysis has found that EE has a significant effect on the persuasion of 
people, which consists of change in people’s knowledge, attitude, behavioural intention 
and behaviour.16 By using this method, the issue of skin cancer prevention could be 
dealt with properly and not too preachy, as the teenagers can be turned off by preachy 
messages.17 EE can overcome this by the creation of a compelling storyline with positive 
and negative role models, with realistic consequences, which allows the audience to 
draw their own conclusions.17 This might be an opportunity to change tanning behav-
iour early in life in order to prevent skin cancer later on.
Another form of primary prevention has already been initiated. The UV-index action 
plan (“Zonkrachtactieplan”) was set up in 2019 by the Dutch Ministry of Health.18 This 
is a group consisting of National Institute for Health and the Environment (“RIVM”) 
together with other parties involved in efforts to prevent skin cancer. Their aim is to 
agree with all involved parties on clear and consistent communications regarding UV 
exposure in order to contribute to the awareness of people concerning UV-radiation. 
They will also increase knowledge of UV radiation by drafting a joint knowledge agenda 
in order to identify gaps and prioritise topics for research purposes.
Regarding secondary prevention, skin cancer screening of the general population 
has been a point of discussion for several years.19 The main issue is that the evidence 
is currently inadequate to determine whether screening in asymptomatic individuals 
leads to a reduction in mortality, while evidence exists that screening may have adverse 
consequences.20 The US Preventive Services Taskforce therefore concluded in 2016 
that the current evidence is insufficient to assess the balance of benefits and harms of 
skin cancer screening.21 One of their statements was that visual skin examination by a 
clinician has modest sensitivity and specificity for detecting melanoma, which in turn 
may lead to cosmetic and (more rarely) functional adverse effects resulting from biopsy 
and overtreatment.
In the near future, skin cancer screening might be possible with smartphone apps based 
on algorithms to detect skin cancer. A recent review stated that the current algorithm 
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based smartphone apps cannot be relied on yet.21 They found that the SkinVision app 
produced the highest estimates of accuracy, but in a hypothetical population of 1,000 
adults in which 3% has a melanoma, four out of 30 melanomas would not be picked 
up as high risk, and more than 200 people would be given false positive results.21,22 
However, the technology is constantly improving and it might soon be accurate enough 
to be used as screening tool in the general population. Skin cancer screening might be 
implemented in the near future in the Netherlands, as the Dutch government recently 
analysed the costs and benefits of multiple screening scenarios, which implies their 
interest of actually executing it.23 In addition, screening also implies a form of primary 
prevention, as participants are implicitly educated about skin cancer risk factors.24
Diagnosis
The Dutch BCC guideline for dermatologists states that, in principle, all lesions suspi-
cious for BCC should be histologically confirmed by a skin biopsy before treatment.25 
However, exceptions are made for BCCs with a strong clinical suspicion on a low-risk 
location or for patients with many BCCs. The positive predictive value (PPV) of der-
matologists regarding a clinical BCC diagnosis varies from 79% to 86%.26-28 By using 
dermatoscopy, the PPV increases up to 96%.29 However, dermatoscopy does not replace 
the gold standard, which is histological confirmation by a skin biopsy. This is not just 
needed to confirm the diagnosis, but also to determine the histological subtype, which 
affects therapeutic options. The disadvantages of histopathology are the processing 
time, chance of sampling error in case of biopsies and the related costs.
To improve the accuracy and efficiency of diagnosing skin cancer, the use of artificial 
intelligence (AI) might be a promising solution. At the moment, there is a lot of dis-
cussion regarding the use of mobile apps integrated with AI to diagnose skin cancer.30 
This is mostly due to missing of regulation, suboptimal diagnostic accuracy (especially 
false positives) and absence of evidence of the positive impact on health care (costs) of 
automated smartphone medical apps.30,31 These obstacles do not seem insurmountable. 
The authors of a recent systematic review plead for a shift from a human-computer 
competition to human–computer collaboration.31 They concluded that AI-based support 
improves diagnostic accuracy over either AI or physicians alone. Given the potential, it 
seems inevitable that AI will make its way into skin cancer diagnostics in one way or 
another.
Not all skin cancer patients have to be diagnosed and treated by a dermatologist. 
GPs might have a bigger role to play in the management of skin cancer (i.e. shift of 
care). However, the current dermatological expertise of GPs still has great room for 
improvement. It is astonishing that, although one out of every six primary care con-
sultations concerns skin problems, it is possible to become a GP without any clinical 




GPs regarding skin cancer expertise. In 2017, the GP guideline ‘suspicious skin lesions’ 
was published.33 It is known that merely publishing a guideline does not change care.34 
Barriers to adhere to guidelines by GPs are, among others, lack of agreement with the 
recommendations, organisational constraints and lack of knowledge regarding the 
guideline recommendations.35 A recent study found that a tailored 2-day educational 
program regarding skin cancer management, including hands-on training, improved the 
GPs’ diagnostic accuracy for skin tumours.36 In addition, their approach and awareness 
towards suspicious skin tumours improved. Although long-term effects are still to be 
determined, it shows promising results.
Only after the basic dermatological expertise of GPs has been increased, GPs with 
special interests (GPSIs) could be introduced in the Netherlands to further increase 
efficiency of care. This concept entails that GPs refer patients with lesions suspicious 
for skin cancer to GPSIs instead of a dermatologist, in order to reduce excessive waiting 
lists, to improve the accessibility and convenience of care.37 GPSIs are currently well 
integrated in the healthcare systems of UK and Australia.38 This model has shown to be 
successful as GPSI care shows superior patient satisfaction and comparable outcomes 
to medical specialists.38 In addition, waiting times are reduced and it is cost-effective.39 
The major disadvantage of GPSIs is that GPs are expected to be knowledgeable and 
skilled in a broad range of aspects of medicine and be able to integrate their knowledge 
and expertise to provide holistic, comprehensive care to their patients.40 When GPs 
become too specialised, they might lose their generalist skills.
Treatment
A lot of research has been conducted regarding treatment of BCCs, including many 
randomised controlled trials.41-43 Conventional excision is the golden standard for most 
BCC, except the superficial BCC subtypes that should be treated by topical therapies such 
as 5-fluorouracil cream.44 Mohs’ micrographic surgery is increasingly being performed, 
but also further developed by using digital imaging.45,46 For patients with inoperable 
(locally advanced) or metastatic BCCs sonic hedgehog inhibitors are the first choice and 
the first clinical studies of immunotherapy show a positive response in these tumours.47
The question remains, what is the best treatment? Ideally, treatment choices are made 
in agreement after information exchange between physician and patient and on the 
involvement of both parties (i.e. shared decision making).48 Type of treatment is partly 
physician dependent, which is confirmed by the practice variation displayed in Chapter 
2. However, progress has been made over the past decade to also include patients’ pref-
erences. Although recurrence chance is usually considered the most important aspect 
of treatment by patients, this is not the case for all BCC patients. Patients also value the 
cosmetic result as an important factor in choosing a treatment (Chapter 3).49 In order to 
find the best treatment for each patient, decision aids could provide a solution. Deci-
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sion aids can also improve patients’ knowledge of the options and help them to feel 
better informed and more clear about what matters most to them.50 By helping patients 
decide which treatment aligns best with their preferences, patient-centred care will be 
improved.
Currently, BCC guidelines are very focused on curative rates. In contrast, palliative 
care (with less focus on complete excision) such as curettage and electrodesiccation 
or even watchful-waiting receives much less attention. A significant portion of BCC pa-
tients consists of elderly patients with a short life expectancy. For them, the side-effects 
of treatment may outweigh the burden of leaving their BCC untreated as they might not 
have lived long enough to develop symptoms such as itch or bleeding.51,52 BCCs causing 
symptoms or located close to vital structures such as eyelids or ears should certainly be 
treated. Many BCCs, however, are detected during yearly screening by a dermatologist 
and may have remained undetected by patients and might never have been a problem 
for these patients. During a prospective population-based cohort study of people aged 
≥ 45 years, about one in 25 participants was diagnosed with at least one cutaneous 
malignancy. Currently, life expectancy is not routinely taken into consideration in the 
selection of the most appropriate treatment.53,54 The rationale to treat BCCs in fragile 
patients is that they may cause symptoms later, and then may require more extensive 
treatment. Although BCCs are slow-growing tumours, it is not yet clear how fast they 
actually grow and when they will cause symptoms. More research should be conducted 
concerning the natural course of BCCs in order to integrate watchful waiting into BCC 
guidelines, especially in case of frail elderly, and avoid unnecessary harm.52
Another suggestion for improvement is substitution of low-risk BCC treatments from 
secondary to primary care. The previously mentioned GP guideline recommends GPs to 
treat low-risk BCCs.33 A recent randomised clinical trial aimed to assess whether low-
risk BCCs can be surgically treated by GPs without loss of quality of care.36 GPs included 
in the study received extensive training, but the study failed due to low inclusion and 
excision rates of these GPs. A process evaluation was conducted alongside the trial, 
which revealed administrative challenges, lack of time, high workload and low volume 
of BCC patients as barriers to success. Qualitative interviews showed that GPs and, to 
a lesser extent, dermatologists are positive regarding the substitution of low-risk BCC 
care. Aside from essential strategies such as improving GPs’ skin cancer education, rear-
rangement of (financial) organisational structures in primary and secondary care are 
needed in order to successfully substitute treatments of low-risk BCCs to primary care.55
follow-up care
Although it seems logical that more intensive follow-up schedules after any type of 
cancer will result in earlier detection of recurrence or new primary tumours, which 




dence supporting this assumption.56 On the contrary, evidence exists that less intensive 
follow-up schedules for certain types of cancer do not differ in effectiveness, are ac-
cepted by patients and do not have adverse effects on survival outcomes, while saving 
healthcare costs and reduce patients anxiety before follow up visits.56 Recently, 3-year 
results of the Dutch MELFO study were reported.57 This is a prospective randomised 
controlled trial on the effects of a reduced stage-adjusted follow-up schedule on cuta-
neous melanoma IB–IIC. Patients in the reduced follow-up group did not differ from the 
conventional follow-up group regarding quality of life, recurrence or survival. However, 
costs were 39% lower in the reduced follow-up group, while patients in this group 
reported lower stress symptoms than patients in the conventional follow-up group.
Unfortunately, the research conducted regarding BCC follow-up is scarce. The health 
benefit in BCC follow up is not mortality or disease progression because the rate of 
advanced disease is extremely rare. There is no evidence that earlier detection of BCC 
leads to improved health outcomes (i.e. cosmetic and functional morbidity or improved 
quality of life), while evidence exists that significant delay to treatment (up to 12 
months) is not relevant to the outcome of the intended operation.58 This led to the 
Dutch BCC guidelines stating to consider providing regular follow-up only to high-risk 
BCC patients.25 Regarding the frequency and length of follow-up, the Dutch guideline 
states that in most cases annual monitoring will be sufficient, or more often if necessary, 
depending on the patient and if the attending physician deems this necessary. Chapter 
2 reveals large practice variation in terms of skin cancer follow-up care, of which BCC 
constitutes a large part. This variation in routine care emphasises the need for a ran-
domised controlled trial on different BCC follow-up schedules, in order to provide an 
evidence-based guideline which finds the best balance between health outcomes, pa-
tient preferences and healthcare costs. The current thesis provides a solution to reduce 
the number of follow-up visits for BCC patients: In Chapter 5 it was demonstrated that 
a personalised discharge letter for BCC patients, as was suggested in the focus groups 
with patients, is a relatively simple strategy to decrease low-value BCC follow-up visits.
After patients are discharged from follow-up or in-between follow-up visits, patients 
may require more medical information and reassurance (Chapter 3). In addition, some 
BCC (and other types of skin cancer) patients may want to connect with other skin cancer 
patients to share information and experiences. In response to these needs, a skin cancer 
patient organisation was founded in November 2019 called ‘De Huidkanker Stichting’.59 
This organisation’s goal is to represent the interests of all Dutch non-melanoma skin 
cancer patients. Patient organisations have a responsibility to connect peers and pro-
vide understandable and high-quality information, as this may drive patients to carry 
out treatment and motivate them to make lifestyle changes (e.g. use sunscreen) in 
everyday life.60 This is important as the chance of being diagnosed with a subsequent 
skin cancer is high.61
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INTEGRaTING ThE PaTIENT PERSPECTIvE IN ThE RESEaRCh PROCESS
The position of patients is shifting in healthcare. Where the physician used to be in 
the lead, the voice of the patient is becoming increasingly important. Formerly, physi-
cians informed patients about risks, benefits and alternative treatments based on what 
the physicians deemed important, but today physicians are obliged to inform patients 
based on what a reasonable patient deems important.62 Shared decision making, a 
collaborative communication process between physicians and patients that integrates 
the best evidence available with the patients’ values and preferences, is becoming the 
new standard in healthcare in most countries.62,63 In order to facilitate shared decision-
making, patients’ needs and preferences must be known. This led to increased qualita-
tive research to understand patients’ values and believes and, in extent, incorporation 
of shared decision making in daily practice.64
However, the position of patients could be taken a step further: into the research 
process. In 1995 it was already argued in the BMJ that “patients should help to decide 
which research is conducted, help to plan the research and interpret the data, and hear 
the results before anybody else”.65 However, patient participation in research has not yet 
made the same progress as in clinical healthcare.66 In order to increase patient involve-
ment in research, it requires researchers to respect and recognize patients’ unique, 
diverse and complementary experiential expertise.67
Commonly, patients are involved after research has failed (e.g. in a process evaluation 
to understand why sample size was not reached). However, failure this late in the pro-
cess may be prevented if patients are involved sooner. figure 2 provides an overview of 
the research process from research prioritisation to implementation into daily practice. 
Patients could be more involved in any step of the process.
Including the patient perspective in the conduction of research
For most studies, patients are usually the ‘subject’ and their thoughts and believes are 
not relevant for the outcomes. This is, for example, the case when testing which type of 
treatment for skin cancer has the lowest recurrence chance. However, if the treatment 
with the lowest recurrence chance has too many side effects or is too time consuming 
for patients to receive, it will fail to be successfully implemented. This illustrates that 
the perspective of patients should be taken into account in trials.
The perspective of patients already have a central place in the field of implementa-
tion science, as the main goal is usually to identify factors that affect the uptake of 
implementation strategies.68 Therefore barriers and facilitators across multiple levels 
of context, including the patient perspective, have to be identified. In the current thesis, 
patients were also involved as stakeholders in the development of the de-adoption 




in the development of a strategy to reduce low-value BCC follow-up visits (Chapter 3). 
Thereafter, a discrete choice analysis was conducted in order to learn which trade-offs 
they are willing to make in order to increase the chance of success of the developed 
strategy (Chapter 4).
Including the patient perspective in the grant proposal
Even though the patients involved in the qualitative studies in Chapter 3 had a voice, they 
were still ‘subjects’, as the study protocol was already written before they participated. 
It should be advocated to involve patients in identifying clinically relevant research 
questions and drafting the study design including defining outcomes in the grant pro-
posal. Patients could assist in the review of consent procedures and patient information 
sheets, refine research questions, suggestion of additional outcome measurements, 
review of trial data collection procedures and recommendations on the timing and loca-
tion of trial follow-up data collection.69 Fortunately, it is increasingly more common to 
involve patients in the design of clinical trials, as this increases the participation rate of 

















figure 2. Overview of the research process
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Involving patients in research prioritization
The last step up the ladder would be for patients to be involved in the prioritisation of 
research. There seems to be a mismatch between the research that gets done and the 
research that patients would like to see done, which is caused by the fact that what is 
scientifically relevant does not necessarily mean that it is relevant from the patient’s 
perspective.66,72 For example, a review of interventions for the treatment of osteoarthri-
tis of the knee joint revealed that 59% of the studies were based on pharmaceutical- and 
26% on surgical interventions, while 36% of surveyed patients ranked knee replace-
ment as highest priority for research and 21% chose education as first choice and only 
8% of patients ranked pharmaceutical interventions highest.73 It was suggested that 
this mismatched was caused by commercial funding bias, vested researcher interests, 
professional dominance of research (i.e. medical and surgical professions directing 
research funding), publication and a lack of patient involvement in research. Several 
methods have been described to involve patients in research prioritisation, such as 
online crowd-voting, focus groups and modified Delphi method.74 Organisations such as 
the James Lind Alliance facilitate patients, carers and clinicians to come together in ‘Pri-
ority Setting Partnerships’ to identify and prioritise the top 10 unanswered questions 
or evidence uncertainties that they agree are the most important.75 Fortunately, patient 
organisations were involved in the establishment of the most recent prioritisation of 
research in dermatology in the Netherlands.76
Concerns of involving patients in research
Aside from the extra time and costs to include the patient perspective in research, 
another major concern is how to select representatives of the general population. 
The problem is that representatives of marginalised patient groups (e.g. with a lower 
level of education) may be the ones who are not able to bear the required work, which 
leads to excluding patients who are deemed “not able” to contribute.77 This may lead 
to healthcare interventions that are tailored to those with the strongest voice, instead 
of the marginalised.78 It is not uncommon for patients to receive training before con-
tribution to research, however, this may result in the creation of ‘professionalised’ lay 
experts who do not longer represent the general population anymore.79
CONCLuSIONS aND PROSPECTS
This thesis provides the foundation for a strategy to reduce low-value BCC follow-up 
visits. By following the steps of the implementation of change model by Grol and 
Wensing, the chance of developing a successful strategy that would be accepted by all 




However, the implementation model presented in Chapter 1 was not yet complete. As 
displayed in figure 3, the next step is to integrate the personalised letter in routine care. 
The letter is currently in the process of being professionalised (i.e. print it directly from 
electronic patient files with as few clicks as possible) in order to increase the uptake of 
the strategy by dermatologists in the Netherlands. After it is integrated in routine care, 
(continuous) evaluation will take place and processed will be adapted where neces-
Development of proposal for 
changeChapter 1
Analysis of actual performance, 
targets for changeChapter 2
Problem analysis of target 
group and settingChapter 3
Development and selection of 
strategies and measures to 
change practice
Chapter 4
Development, testing and 
execution of implementation 
plan
Chapter 5
Integration of changes in 
routine care






figure 3. Implementation of change model by Grol and Wensing5, which was used as guiding prin-
ciple for the de-adoption of low-value basal cell carcinoma follow-up care
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sary. The claims data analysis (Chapter 2) will be repeated to monitor the effects and to 
detect any possible unwarranted practice variation.
After successfully implementing the personalised letter in routine care for BCC, this 
intervention could also be adapted to other diseases. Squamous cell carcinoma patients 
will be the easiest to adapt the letter to first, as it they show many similarities with BCC 
patients (Chapter 3). For now, patients preferred to have the letter on paper (Chapter 4), 
but as new generations will be diagnosed with skin cancer, at a certain point the letter 
will be digitalised. I believe that in the future, all patient information for any disease 
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Chapter 1 is a general introduction based on skin cancer practices of general practitio-
ners (GPs) and dermatologists. It exposes opportunities for improvement of care and 
provides the main objectives of this thesis.
Skin cancer is the most common type of cancer in the Netherlands and its incidence 
is still rising. The two most common subtypes of skin cancer are basal cell carcinoma 
(BCC) and squamous cell carcinoma (SCC), both commonly referred to as keratinocyte 
carcinoma (KC). About 48,000 inhabitants being diagnosed for the first time with BCC 
and 12,000 with SCC in 2017. Although KC is usually not deadly, it could cause consider-
able functional and cosmetic morbidity, as it is typically found on sun-exposed areas 
such as the face. More than one-third of KC patients develops at least one subsequent 
KC. These high incidence rates put pressure on healthcare systems.
In order to identify areas for improvement, clinical practices of GPs and dermatolo-
gists were described by using the Integrated Primary Care Information database and the 
Netherlands Cancer Registry (secondary care). A random selection was made of patients 
who consulted their GP for suspicious or confirmed KC (n = 1597) and for secondary care 
1569 patients were randomly selected with a histologically confirmed KC. All patients 
were diagnosed between 2009 and 2013 and followed up until 2016. Details on diag-
nosis, treatment and follow-up care were described. The descriptive analyses revealed 
that one-third of lesions suspected for KC by GPs were indeed skin malignancies, lead-
ing to unnecessary referrals. GPs treated almost a third of all suspected KC lesions, but 
one-third of those treatments were not primarily directed at KC (e.g. antibacterial and/
or antimycotic ointments). In the analyses regarding secondary care, it was noted that 
low-risk BCC patients received more follow-up than recommended in the guidelines. 
Strengthening the diagnostic pathway for KC in primary care and reduction of low-risk 
BCC follow-up visits were suggested as potential areas for improvement in KC care. As 
initiatives focussing on primary care seemed unfeasible at the moment, the focus of this 
thesis was placed on the low-value BCC follow-up visits.
Therefore the main aim of this thesis was to develop a strategy to reduce the number 
of low-value BCC follow-up visits, while maintaining quality of care. This was done by 
following the Grol and Wensing Implementation of Change Model. The first step was to 
develop a proposal for change, which was done in this chapter.
In Chapter 2 we measured performance of the target for change, which was the 
second step in the implementation of change model. In order to measure performance, 
first quality indicators have to be defined. Therefore, all skin cancer related claims were 
extracted from the nationwide Vektis claims database. For over 220,000 patients a skin 
cancer claim was reimbursed in 124 healthcare centres. It showed large practice varia-
tion in both treatments and follow-up visits. On average, skin cancer patients received 
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1.8 follow-up visits in 2016. The analysis demonstrated that claims data may be a valid 
and feasible dataset to extract quality indicators for skin cancer. It is still to be investi-
gated whether the detected practice variation is unwarranted.
In Chapter 3 the target groups were analysed by obtaining the views of stakehold-
ers. In Chapter 3.1 we identified the needs and preferences of BCC and SCC patients 
regarding their care by the means of six focus groups with 42 patients in total. Both 
BCC and SCC patients expressed the following needs and preferences: (I) the need to 
receive all relevant, tailored information; (II) a physician who takes you seriously and 
communicates well; (III) a short waiting period and the best treatment with direct 
results; (IV) to be seen by the same physician; a preference for a dermatologist dur-
ing (V) treatment and (VI) follow-up; (VII) a general need for structured follow-up care 
and (VIII) a full-body skin examination during follow-up. Patients with BCC additionally 
expressed the need for openness and transparency and wanting to participate in shared 
decision making. These results could be used to tailor skin cancer care to the needs of 
KC patients. It is advocated to add the patient’s perspective to guidelines.
In Chapter 3.2 the factors that influenced low-value BCC follow-up practices were 
identified among dermatologists and suggestions were made to de-adopt this care. In 
addition, the views of low-risk BCC patients were explored. A qualitative study was con-
ducted consisting of 18 semistructured interviews with dermatologists and three focus 
groups with in total 17 low-risk BCC patients. Factors influencing current follow-up care 
practices among dermatologists included complying with patients’ preferences, lack of 
trust in GPs, financial incentives and force of habit. Patients reported varying needs re-
garding periodic follow-up visits, preferred to be seen by a dermatologist and indicated 
a need for improved information provision. Suggested strategies by dermatologists to 
de-adopt the low-value care encompassed educating patients with improved informa-
tion, educating GPs to increase trust of dermatologists, realising appropriate financial 
reimbursement and informing dermatologists about the low value of care. This mixture 
of factors contributing to low-value BCC follow-up practices indicate that in order to 
de-adopt this care strategies should be aimed at all stakeholders.
In Chapter 3.3 the other side of the spectrum was investigated: the experiences and 
needs of complex skin cancer patients. These are patients who had undergone surgical 
treatment for skin cancer by a dermatologist with a subsequent reconstruction by a 
plastic surgeon. Their care process is often more complicated and psychological and 
social problems may play a larger role. Sixteen complex skin cancer patients were 
interviewed on their experiences and needs regarding care using a predefined topic 
list. They reported a need for a skilled and friendly physician who tailors information 
and communication to their individual situation. A need for continuity of care and im-
proved collaboration between healthcare providers was also emphasised. Furthermore, 




shared decision-making at various steps throughout the treatment process (depending 
on age). Patients also considered completeness of tumour removal, follow-up visits with 
multiple specialists to be planned the same day and recognition of the psychological 
impact of the disease on the partner important. These results advocate for efforts to 
be undertaken to improve continuity of care and collaboration for this patient group. 
Furthermore, physicians should take the individual needs of patients and their partner 
into account and adjust information, communication and (supportive) care accordingly.
In Chapter 4 the qualitative results from the previous chapters were quantified. 
First, in Chapter 4.1 a ranking list was developed, based on the results of the focus 
groups. The list consisted of five items regarding the patient-physician relationship, five 
disease-specific items and two external items (costs and travel time). The items were 
ranked by 101 BCC patients from 1 (most important) to 12 (least important). They scored 
patient-physician related factors as most important, with ‘explanation of the serious-
ness of the skin cancer’ as the most important factor regarding BCC care. The second 
most important factor to patients is the ‘feeling that the physician listens well to the 
patient’. Patients ranked patient-physician related factors higher than disease-specific 
factors. The external factors were considered least important. This study emphasises 
the importance of integrating patient-physician relationship factors with traditional 
medically orientated aspects of BCC care.
Subsequently, in Chapter 4.2, the most important items were used in a discrete 
choice experiment in order to learn which trade-offs BCC patients and dermatologists 
are willing to make to accept fewer low-value follow-up visits. Eighty-four dermatolo-
gists and 266 BCC patients completed the discrete choice experiment. A panel latent 
class model was used for analysis. The results showed that the acceptance of having 
no additional follow-up visits (i.e. following the guidelines) would increase from 55% 
to 77% by patients if the post-treatment visit was performed by the same person as 
treatment provider and a printed hand-out was provided to patients containing per-
sonalised information. Female patients and older dermatologists are less willing to 
accept the guidelines and prefer additional follow-up visits. This study revealed that a 
personalised hand-out would be a feasible strategy to substantially reduce costs, while 
maintaining quality of care.
In Chapter 5 the strategy, a personalised discharge letter for patients based on all 
the previous research, was tested in one academic hospital, three general hospitals, 
and two independent sector treatment centres. The efficacy, the cost-effectiveness 
and the budget impact of the personalised letter on the number of follow-up visits for 
patients following a low-risk BCC compared with usual care were studied by the means 
of a model-based cost-effectiveness analysis using individual patient data gathered via 
surveys. The study included 473 first-time BCC patients. The personalised discharge 
letter decreased the number of follow-up visits at the dermatologist by 13% in one 
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year. The incremental costs after five years were -€26.04 per patient. The budget impact 
was -€2,9 million after five years in the Netherlands. These results show that distribu-
tion of a personalised discharge letter decreases the number of follow-up visits and 
implementing the intervention in the eligible population results in large cost savings 
and contributes to restrain the growing skin cancer costs.
Chapter 6 is the general discussion of the thesis, in which an overview of the main 
findings is provided and placed into perspective of existing literature. In the first part 
of the general discussion the care pathway of BCC is evaluated from prevention until 
follow-up, with suggestions for improvements in each step of the pathway. This deter-
mines the place of the personalised letter in current BCC care. The second part of the 
discussion reflects on the position of patients in research. It advocates to make benefit 
of patients’ unique, diverse and complementary experiential expertise in all the steps 
of the research process, from prioritisation of research until implementation of care. 





hoofdstuk 1 is een algemene inleiding, gebaseerd op de dagelijkse praktijk van huis-
artsen en dermatologen op het gebied van huidkankerzorg. In dit hoofdstuk worden 
de mogelijkheden voor verbetering van de huidkankerzorg blootgelegd en worden de 
belangrijkste doelstellingen van dit proefschrift beschreven.
Huidkanker is de meest voorkomende vorm van kanker in Nederland en de incidentie 
neemt nog steeds toe. De twee meest voorkomende subtypen van huidkanker zijn 
basaalcelcarcinoom (BCC) en plaveiselcelcarcinoom (PCC), beiden worden algemeen 
aangeduid als keratinocyt carcinoom (KC). Ongeveer 48.000 Nederlanders werden in 
2017 voor het eerst gediagnosticeerd met BCC en 12.000 met PCC. Hoewel KC meestal 
niet dodelijk is, kan het wel aanzienlijke functionele en cosmetische schade veroorza-
ken, omdat het meestal wordt aangetroffen op aan de zon blootgestelde gebieden zoals 
het aangezicht. Meer dan een derde van de KC-patiënten ontwikkelt ten minste nóg een 
KC. Deze hoge incidentiecijfers zetten de gezondheidszorg onder druk.
Om verbeterpunten te identificeren is de dagelijkse praktijk van huisartsen en derma-
tologen beschreven met behulp van de ‘Integrated Primary Care Information’ database 
en de Nederlandse Kankerregistratie. Er werd een willekeurige selectie gemaakt van 
patiënten die hun huisarts hebben geraadpleegd voor een voor maligniteit verdachte 
huidafwijking of bevestigde KC (n = 1597) en voor de dermatologische zorg zijn 1569 
patiënten willekeurig geselecteerd met een histologisch bevestigde KC. Alle patiënten 
werden gediagnosticeerd tussen 2009 en 2013 en opgevolgd tot 2016. Details over de 
diagnose, de behandeling en de zorg tijdens de nacontroles werden beschreven. Uit de 
analyses bleek dat een derde van de door de huisartsen voor KC verdachte huidafwij-
kingen daadwerkelijk huidkanker was, wat leidde tot onnodige verwijzingen. Daarnaast 
behandelden huisartsen bijna een derde van alle verdachte KC, maar een derde van die 
behandelingen was niet primair gericht op KC (bijv. antibacteriële en/of antimycotische 
zalven). In de analyses van de dermatologische zorg werd opgemerkt dat laag-risico 
BCC-patiënten meer nacontroles kregen dan in de richtlijnen werd aanbevolen. Op 
basis van de resultaten werden versterking van het diagnostische zorgtraject voor KC 
in de eerstelijnszorg en vermindering van laag-risico BCC nacontroles gesuggereerd als 
mogelijke verbeterpunten in de KC-zorg. Omdat initiatieven gericht op de eerstelijns-
zorg op dit moment onhaalbaar leken, lag de focus voor dit proefschrift op de onnodige 
BCC nacontroles.
Het hoofddoel van dit proefschrift was het ontwikkelen van een strategie om de 
hoeveelheid onnodige laag-risico BCC nacontroles te verminderen, met behoud van de 
kwaliteit van de zorg. Dit werd gedaan aan de hand van het model van Grol en Wensing 
voor implementatie en verandering. De eerste stap was het ontwikkelen van een voor-
stel voor verandering, wat in dit hoofdstuk is gedaan.
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In hoofdstuk 2 werd de feitelijke zorg van het veranderingsdoel gemeten, dit was de 
tweede stap in het model. Om deze zorg te meten moeten eerst kwaliteitsindicatoren 
worden gedefinieerd. Daarom zijn alle zorgdeclaraties met betrekking tot huidkanker uit 
de Vektis-declaratie-database geëxtraheerd en geanalyseerd. Voor meer dan 220.000 
patiënten werd in 124 zorgcentra een declaratie voor huidkanker vergoed. Het toonde 
een grote praktijkvariatie in zowel de behandelingen als de nacontroles. In 2016 kregen 
huidkankerpatiënten gemiddeld 1,8 nacontroles. De analyse toonde aan dat de Vektis-
declaratie-database een valide en bruikbare dataset kan zijn om kwaliteitsindicatoren 
voor huidkanker te meten. Er moet nog worden onderzocht of de gedetecteerde prak-
tijkvariatie ongewenst is.
In hoofdstuk 3 zijn de standpunten van de belanghebbende doelgroepen ge-
analyseerd. In hoofdstuk 3.1 hebben we de behoeften en voorkeuren van BCC- en 
PCC-patiënten met betrekking tot hun zorg in kaart gebracht aan de hand van zes 
focusgroepen met in totaal 42 patiënten. Zowel BCC- als PCC-patiënten hebben de 
volgende behoeften en voorkeuren kenbaar gemaakt: (I) de noodzaak om alle relevante 
informatie op maat te ontvangen; (II) een arts die hen serieus neemt en goed communi-
ceert; (III) een korte wachttijd en de beste behandeling met direct resultaat; (IV) gezien 
worden door dezelfde arts; een voorkeur voor de dermatoloog tijdens (V) behandeling 
en (VI) nazorg; (VII) een algemene behoefte aan gestructureerde nazorg en (VIII) een 
volledig huidonderzoek tijdens de nacontrole. Patiënten met BCC gaven bovendien aan 
dat er behoefte is aan openheid en transparantie en dat zij willen deelnemen aan de 
gezamenlijke besluitvorming. Deze resultaten kunnen worden gebruikt om de huid-
kankerzorg af te stemmen op de behoeften van KC-patiënten. Er wordt gepleit om het 
patiëntperspectief in de huidige richtlijnen te integreren.
In hoofdstuk 3.2 werden de factoren die van invloed waren op de onnodige BCC 
nacontroles onder dermatologen geïdentificeerd en werden suggesties gedaan om 
deze zorg te verminderen. Daarnaast werd het perspectief van laag-risico BCC pati-
enten onderzocht. Er werd een kwalitatief onderzoek uitgevoerd bestaande uit 18 
semigestructureerde interviews met dermatologen en drie focusgroepen met in totaal 
17 laag-risico BCC patiënten. Factoren die van invloed waren op de BCC nacontroles 
genoemd door dermatologen waren onder andere het voldoen aan de behoefte van 
patiënten, gebrek aan vertrouwen in de huisarts, financiële prikkels en de macht der 
gewoonte. Patiënten meldden uiteenlopende behoeften met betrekking tot periodieke 
nacontroles, ze gaven een voorkeur aan om gezien te worden door een dermatoloog 
en gaven aan dat er behoefte was aan betere informatievoorziening. De voorgestelde 
strategieën van de dermatologen om de laag-risico BCC nacontroles te verminderen 
waren het opleiden van patiënten met betere informatie, het opleiden van de huis-
artsen om het vertrouwen van de dermatologen te vergroten, het realiseren van een 




waarde van de laag-risico BCC nacontroles. Deze mix van factoren die bijdragen aan de 
laagwaardige BCC nacontroles geeft aan dat een strategie om deze zorg te verminderen 
gericht moeten zijn op alle belanghebbenden.
In hoofdstuk 3.3 werd de andere kant van het spectrum onderzocht: de ervaringen 
en behoeften van complexe huidkankerpatiënten. Dit zijn patiënten die chirurgisch zijn 
behandeld voor huidkanker door een dermatoloog met daaropvolgend een reconstruc-
tie door een plastisch chirurg. Hun zorgproces is vaak ingewikkelder en psychologische 
en sociale problemen kunnen een grotere rol spelen. Zestien complexe huidkanker-
patiënten werden geïnterviewd over hun ervaringen en behoeften op het gebied van 
zorg aan de hand van een vooraf gedefinieerde onderwerpenlijst. Zij meldden behoefte 
te hebben aan een bekwame en vriendelijke arts die de informatie en communicatie 
op hun individuele situatie afstemt. Ook werd de behoefte aan continuïteit van zorg 
en een betere samenwerking tussen zorgverleners benadrukt. Verder ervoeren patiën-
ten complicaties en onvervulde verwachtingen en gaven ze aan behoefte te hebben 
aan gedeelde besluitvorming in verschillende stappen van het behandelingsproces 
(afhankelijk van de leeftijd). De patiënten vonden ook het volledig verwijderen van 
de tumor, meerdere nacontrolebezoeken van verschillende specialisten op dezelfde 
dag plannen en de erkenning van de psychologische impact op de partner belangrijk. 
Deze resultaten pleiten ervoor om de continuïteit van de zorg en de samenwerking 
tussen specialisten voor deze patiëntengroep te verbeteren. Bovendien moeten artsen 
rekening houden met de individuele behoeften van patiënten en hun partner en de 
informatie, communicatie en (ondersteunende) zorg daarop afstemmen.
In hoofdstuk 4 werden de kwalitatieve resultaten van de vorige hoofdstukken ge-
kwantificeerd. Allereerst is in hoofdstuk 4.1 een ranglijst ontwikkeld, gebaseerd op de 
resultaten van de focusgroepen. De lijst bestond uit vijf items met betrekking tot de 
patiënt-arts relatie, vijf ziektespecifieke items en twee externe items (kosten en reis-
tijd). De items werden vervolgens gerangschikt door 101 BCC-patiënten van 1 (belang-
rijkste) tot 12 (minst belangrijke). Zij scoorden patiënt-arts gerelateerde factoren als 
belangrijkste, met ‘uitleg over de ernst van de huidkanker’ als belangrijkste factor met 
betrekking tot de BCC-zorg. De tweede belangrijkste factor voor patiënten is het ‘gevoel 
dat de arts goed naar de patiënt luistert’. Patiënten hebben patiënt-arts gerelateerde 
factoren hoger ingeschat dan ziektespecifieke factoren. De externe factoren werden 
het minst belangrijk geacht. Deze studie benadrukt het belang van het integreren van 
patiënt-arts relatiefactoren in de huidige BCC-zorg.
Ten tweede werden in hoofdstuk 4.2 de belangrijkste items gebruikt in een ‘Discrete 
choice experiment’ (DCE) om te leren welke afwegingen BCC-patiënten en dermato-
logen bereid zijn te maken om minder laagwaardige nacontroles te accepteren. Vie-
rentachtig dermatologen en 266 BCC-patiënten hebben de DCE ingevuld. De resultaten 
laten zien dat de acceptatie van geen extra follow-up bezoeken (d.w.z. het volgen van 
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de richtlijnen) door patiënten zou toenemen van 55% tot 77% als de nacontrole werd 
uitgevoerd door dezelfde persoon als de behandelaar en er een hand-out werd gegeven 
aan patiënten met gepersonaliseerde informatie. Vrouwelijke patiënten en oudere 
dermatologen zijn minder bereid de richtlijnen te accepteren en geven de voorkeur aan 
extra vervolgbezoeken. Uit dit onderzoek bleek dat een gepersonaliseerde hand-out 
een realiseerbare strategie zou zijn om de kosten aanzienlijk te verlagen met behoud 
van de kwaliteit van de zorg.
In hoofdstuk 5 werd de strategie, een gepersonaliseerde ontslagbrief voor patiënten 
gebaseerd op al het voorgaande onderzoek, getest in één academisch ziekenhuis, drie 
algemene ziekenhuizen en twee zelfstandig behandelcentra. De effectiviteit, de kos-
teneffectiviteit en de budgettaire impact van de gepersonaliseerde brief op het aantal 
nacontroles voor laag-risico BCC patiënten werd vergeleken met de standaard zorg. 
Dit werd gedaan aan de hand van een modelgebaseerde kosteneffectiviteitsanalyse 
met behulp van individuele patiëntgegevens die via enquêtes werden verzameld. De 
studie omvatte 473 patiënten bij wie voor het eerst BCC werden gediagnosticeerd. 
De gepersonaliseerde brief verminderde het aantal nacontroles bij de dermatoloog 
met 13% in één jaar. De vermindering in kosten na vijf jaar bedroegen € 26,04 per 
patiënt. De budgettaire impact in Nederland bedroeg -€ 2,9 miljoen na vijf jaar. Uit deze 
resultaten blijkt dat de verspreiding van een gepersonaliseerde ontslagbrief het aantal 
nacontroles vermindert en dat de interventie bij implementatie in Nederland leidt tot 
een aanzienlijke kostenbesparing.
hoofdstuk 6 is de algemene discussie, waarin een overzicht gegeven wordt van de 
belangrijkste bevindingen. Deze werden in het perspectief van de bestaande literatuur 
geplaatst. In het eerste deel van de algemene discussie wordt het zorgpad van BCC ge-
evalueerd vanaf de preventie tot en met de nazorg, met suggesties om elke stap van het 
traject te verbeteren. Dit toont de plaats van de gepersonaliseerde brief in de huidige 
BCC-zorg. Het tweede deel van de discussie reflecteert op de positie van patiënten in 
het onderzoeksproces. Er wordt gepleit om gebruik te maken van de unieke, diverse 
en complementaire ervaringsdeskundigheid van patiënten in alle stappen van het 
onderzoeksproces, vanaf de prioritering van onderzoek tot en met de implementatie in 
de zorg. Tot slot wordt het model van Grol en Wensing afgerond door de perspectieven 


























BCC Basal cell carcinoma
BIA Budget impact analysis
CEA Cost-effectiveness analysis
DCE Discrete Choice Experiment
DRG Diagnosis-related group
FBSE Full body skin examination
GP General practitioner
ICER Incremental cost-effectiveness ratio
ISTC Independent sector treatment centre
KC Keratinocyte carcinoma
LCA Latent class analysis
LM Lentigo maligna
MAR Missing at random
MI Multiple imputation
MMS Mohs micrographic surgery
NMSC Non-melanoma skin cancer
NP Nurse practitioner
PA Physician assistant or Probabilistic analysis
PDL Personalized discharge letter
PDT  Photodynamic therapy
QALY Quality-adjusted life year
QI Quality-indicator
SCC Squamous cell carcinoma
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mijn eerste werken bijna geheel in het rood terugstuurde. Naast dat je mij bekwaam 
hebt gemaakt in het kwalitatieve onderzoek, heb je mij opnieuw leren schrijven. Zelfs 
voor het schrijven van mijn dankwoord gaf je mij nog advies. Daarnaast was het altijd 
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erg gezellig om samen te werken, aangezien we altijd eerst begonnen met de (gedetail-
leerde) weekendbespreking, die we er nog steeds in hebben gehouden.
Mijn kleine promotiecommissie. Beste prof. dr. E.P. Prens, prof. dr. C.A. Uyl – de Groot en 
prof. dr. G.P. Westert, bedankt voor jullie bereidheid om mijn proefschrift te beoordelen 
en met mij van gedachten te wisselen tijdens de verdediging van mijn proefschrift.
Lieve Selma, één van de mooiste dingen die ontstaan is tijdens mijn promotieonderzoek 
is onze vriendschap. Ik ben heel erg blij dat wij tegelijk en in dezelfde onderzoekskamer 
zijn gestart in het GK gebouw. Met jou kan ik altijd alles delen en ik kan bij jou altijd 
terecht met al mijn problemen, van statistiek tot relatieadvies. Het is ongelofelijk dat 
we nog maar één keer onenigheid hebben gehad: omdat we allebei de deur niet open 
wilden doen. En dit was na 2 uur niet tegen elkaar praten alweer opgelost. We hebben 
al veel avonturen beleefd en het kan niet anders dan dat wij (samen met Bram en Laura) 
tot het einde der tijden blijven borrelen en kaasfonduen. Ik ben enorm blij dat jij straks 
achter mij staat als paranimf en ik zal niet veel later trots achter jou staan.
Lars, mijn grote broer. Ik ben blij dat we de afgelopen jaren meer naar elkaar toe ge-
groeid zijn. Ik bewonder hoe je, samen met Judith, je zonen Levi en Benja groot aan het 
brengen bent zonder dat het je enige moeite lijkt te kosten en dat naast je drukke baan. 
Ik realiseer mij nu weer dat ik vaker langs zou moeten komen en ik beloof bij dezen dat 
ik dat ga doen. Ik ben erg vereerd dat je achter mij zal staan als paranimf.
Lieve Eline, mijn sister from another mister, mijn mede-smurf. Het was mooi om te zien 
hoe je tijdens je promotieonderzoek steeds meer jezelf werd, waarbij je aanstekelijke 
lach steeds vaker door de muren te horen was. Ik ben heel erg dankbaar dat ik veel 
met jou samen heb mogen werken en dat je mijn oneindige geblaat, flauwe grappen en 
ongevraagde taalcorrecties tolereerde. Behalve dat het altijd erg gezellig was, ben je 
echt een powervrouw, het verbaast mij dan ook niet dat je nu al de directrice bent van 
de NVDV. En wat was ik trots op je toen ik achter jou stond bij je verdediging. Helaas 
mogen er maar twee, maar ik had jou erg graag als mijn derde paranimf gehad. Ik wil je 
nogmaals heel erg bedanken, en wens jou en Rik veel geluk en het allerbeste met alles 
en hopelijk kunnen we weer snel naar een wijnbar.
Alle (arts-)onderzoekers wil ik graag bedanken voor de leuke tijd inclusief wine-tastings 
en nuttige gedachtewisselingen over het werk, maar ook vaak over het leven. In het 
bijzonder wil ik Eline, Kirtie, Martijn, Merel, Minke, Selin, Selma en Sterre bedanken 




thuis. Daarnaast ben ik ook de uit-zijn-voegen-groeiende onco-groep onder leiding van 
Marlies en Loes zeer dankbaar voor de oneindige wekelijkse adviezen.
Ook alle A(N)IOS wil ik bedanken. Tijdens mijn ANIOS-jaar werd ik warm ontvangen als 
onderdeel van de groep. Dank ook aan alle dermatologen voor alle uitleg waardoor 
mijn dermatologische kennis een boost heeft gekregen. The Amsterdam Crew heeft er 
daarbij voor gezorgd dat zelfs het vele reizen leuk (en voedzaam) was.
Mijn onderzoek was niet mogelijk geweest zonder de deelname van patiënten aan mijn 
studies. Deze wil ik dan ook hartelijk hiervoor bedanken. Daarbij ook de (dermatologen 
van de) deelnemende ziekenhuizen voor het verlenen van de toegang tot hun patiënten.
Mijn dank gaat ook uit naar de ondersteuning, tijdens mijn klinische werkzaamheden 
en het onderzoek. In het bijzonder Barbera en Natasja, bedankt voor jullie hulp en de 
gezellige gesprekken tijdens het afwassen van de kopjes.
Prof. dr. E. Linos, dear Eleni, I would like to thank you for providing me the opportunity to 
conduct further research in your group. I hope that Covid-19 will allow us soon to work 
together in person.
Ik wil ook graag iedereen bedanken die geholpen heeft bij de oprichting van De Huid-
kanker Stichting (HUKAs). Ik wil hier in het bijzonder Jaap Touw bedanken voor zijn 
tomeloze inzet voor de stichting.
Lieve Vrienden en (Schoon)familie, allen heel erg bedankt voor jullie steun en afleiding. 
Jullie hadden vaak geen idee wat ik doe, maar misschien was daardoor de afleiding 
extra fijn. Thomas en Marco, jullie nog extra dank voor de gezellige samenwoontijd in 
Leiden. Schoonfamilie, ik ben blij dat ik jullie erbij heb gekregen. 
Mama en papa, ondanks dat jullie niet meer samen zijn, noem ik jullie in één zin. Ik ben 
dankbaar voor de manier waarop jullie mij hebben gevormd tot waar ik nu ben. Mama, 
hartelijk dank voor de wekelijkse ‘hoe gaat het?’ en interesse. Papa, ik ben erg blij dat 
onze band het laatste jaar aan het versterken is en we elkaar weer vaker zien.
Liefste Laura, ik ben onbeschrijflijk blij dat ik jou tegen ben gekomen. Ondanks dat we 
totaal verschillend zijn, blijven we nog elke dag meer en meer naar elkaar toe groeien. 
Ik weet zeker dat ik met jou oud wil gaan worden en ik kijk er al naar uit om samen voor 
Gizzy te gaan zorgen (maar nu nog niet). Ik weet het, ik zeg het niet vaak genoeg, maar 
ik hou heel veel van je.
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